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Abstract 
 
Development of Asymmetric Alkylation Chemistry Using Chiral Lithium Amides and 




Jeffrey James Jackson 
 
Asymmetric alkylation of enolates has been the subject of vigorous investigation for 
several decades as researchers are constantly aiming to increase the efficiency of 
stereoselective C−C bond constructions, a cornerstone in asymmetric synthesis. 
Furthermore, Michael addition is a premier synthetic method for carbon−carbon and 
carbon−heteroatom bond formation. Our group has recently developed a procedure 
utilizing the chiral reactive enediolate−dilithium amide aggregate of aryl- and hetereo-
aryl acetic acids in enantioselective Michael additions to α,β-unsaturated esters for 
asymmetric carbon-carbon bond formation, mediated by a dimeric chiral tetramine. A 
free carboxyl group in the product provides versatility for further functionalization, and 
the chiral reagent can be readily recovered by extraction with aqueous acid. The method 
has been applied in the enantioselective total synthesis of the purported structure of 
pulveraven B. In addition, our preliminary studies also reveal the potential expansion of 
alkylation scope towards the synthesis of quaternary stereocenters.  
Dragmacidin D is a member of a family of heterocyclic bis-indolyl alkaloids isolated 
from deep-water Caribbean sponges of Dragmacidon and Spongosorites sp. Although 
  x 
the initially isolated sample displayed no optical activity, subsequent reisolation 
provided a sample with an [α]D of +12° (c 0.95, EtOH). These observations indicate a 
certain measure of ambiguity for the stereochemical identity and configurational 
stability of its sole stereogenic center. The asymmetric synthesis of (+)-dragmacidin D 
was completed in 10 steps. Its sole stereocenter was set by a direct asymmetric 
alkylation enabled by a C2-symmetric tetramine and lithium N-(trimethylsilyl)-tert-
butylamide as the key enolization reagent. A central Larock indole synthesis was 
employed in a convergent assembly of the heterocyclic subunits. The 2-aminoimidazole 
heterocycle was installed in a concise manner via a copper mediated acyl cross coupling 
reaction. The stereochemical evidence from this work strongly supports the predicted S 
configuration at the 6ʹ′ʹ′ʹ′ position, which is consistent with other members of the 
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1.1 Introduction 
Lithium enolates, and their subsequent reactions with electrophiles, have been the 
subject of rigorous investigation for many decades.1 Researchers are constantly aiming 
to increase the efficiency of stereoselective C−C bond constructions, a cornerstone in 
asymmetric synthesis. Of the classic methods for α-functionalization of carboxylic acids, 
the traditional chiral auxiliary approach2 has dominated the field. Evans’ oxazolidinone3 
and Myers’ pseudoephedrine4 auxiliaries have gained widespread acceptance as premier 
methods for stereoselective enolate alkylation, finding utility from academic total 
synthesis project to industrial production of pharmaceuticals. These methods have set 
the benchmark for utility and truly broad generality in the field. Nevertheless, while 
commercially available, enantiopure auxiliaries are still relatively expensive. In addition, 
alkylation involves a three-step process: 1) attachment of the appropriate auxiliary, 2) 
diastereoselective alkylation, and 3) cleavage and recovery of the chiral auxiliary. These 
extra steps lower overall yields and generate additional waste. Furthermore, removal of 
the auxiliary must be achieved using conditions compatible with existing functionalities, 
a feat which becomes increasingly difficult when handling more complex molecules.  
Current research has focused on accomplishing these transformations in the most 
efficient manner possible. The use of chiral lithium amides5 as traceless auxiliaries to 
stereoselectively alkylate enediolates is a relatively uninvestigated area. Shiori and Koga 
were among of the first to utilize monomeric chiral diamine bases in stereoselective 
alkylations of enediolates (Scheme 1).6,7 While their substrate scopes were limited, and 
yields and selectivities were generally poor to modest, these seminal publications 
demonstrated a proof of concept for this powerful approach.  
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Scheme 1. Shiori and Koga Precedents for Traceless Asymmetric Alkylation 
 
Our group has recently developed a procedure utilizing the chiral reactive 
enediolate−dilithium amide aggregate of aryl- and hetereo-aryl acetic acids in 
enantioselective Michael additions to α,β-unsaturated esters for asymmetric carbon-
carbon bond formation, using a dimeric C2-symmetrical chiral tetramine (Scheme 2). 
Our preliminary studies also reveal the potential expansion of alkylation scope towards 
the synthesis of all-carbon quaternary stereocenters.  
Scheme 2. Asymmetric Michael Addition and Quaternary Stereocenters 
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1.2 Traditional Auxiliary-Based Methods 
The use of chiral auxiliaries for the asymmetric construction of carbon stereocenters 
is an extremely important method in chemical synthesis. Although significant advances 
in the fields of asymmetric catalysis,8 biocatalysis,9 and chiral reagents have been made 
in recent years, chiral auxiliaries have remained the workhorses in asymmetric synthesis. 
The massive amount of research in the field has yielded a wealth of expertise providing 
a high level of predictability. Often, this knowledge can be utilized to install 
stereocenters in an incredibly time efficient manner because of this predictive power. 
Early examples involved diastereoselective alkylation and Diels-Alder reactions using 
menthol10 and camphor11 derived directing groups. While many different chiral 
auxiliaries have been developed and demonstrated as chiral enolate synthons, Evans’ 
oxazolidinone and Myers’ pseudoephedrine, in particular, are among the most popular 
options. High diastereoselectivities from these methods stem from exceptionally 
selective enolization and the stereochemical properties of the auxiliary, which directs 
approach of the electrophile preferentially to one face of the nucleophilic enolate. Their 
outstanding versatility is demonstrated by their control in regards to both relative and 
absolute stereochemistry in asymmetric alkylation, aldol, and Diels-Alder reactions. For 
example, both methods generally provide access to α-alkylated products in good to 
excellent yield and excellent diastereoselectivities (Scheme 3). Additionally, the 
covalently bound auxiliaries can be cleaved using a variety of mild conditions without 
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Scheme 3. Evans’ and Myers’ Auxiliaries for Diastereoselective Alkylation 
 
As mentioned earlier, there is significant exposure to chiral auxiliaries for industrial 
purposes. For example, the oxazolidinone auxiliary has been used in the asymmetric 
synthesis of Trocade (Scheme 4), a potential candidate for the treatment of rheumatoid 
and osteoarthritis.12  
Scheme 4. Asymmetric Synthesis of Trocade 
 
1.3 Enantioselective Alkylations Using Traceless Auxiliary  
Our group has recently shown that C2-symmetrical dimeric Koga-type chiral 
tetramine (R)-1TA, readily accessible on a multi-kilogram scale from commercially 
  6 
available styrene oxide (Scheme 5),13 can be used to stereoselectively alkylate aryl- and 
heteroarylacetic acids with a variety of alkyl halide electrophiles in high yields, 
diastereo- and enantioselectivities in a one-step process (Scheme 6).14 Direct alkylation 
of enediolates offers several convenient advantages compared to functionalization with 
covalently bound auxiliaries.15 Firstly, they benefit from geometrical symmetry, 
eliminating the need for selective formation of E/Z enolates. Secondly, they are 
particularly nucleophilic, showing good reactivities with inactivated and sterically 
hindered electrophiles. Additionally, this one-pot method effectively eliminates two 
steps from the alkylation process, thus contributing to more efficient chemistry. Finally, 
the chiral amine is recovered in nearly quantitative yield (>95%) by simple acidic 
aqueous extraction during work up.  
Scheme 5. Multikilogram-Scale Synthesis of (R)-1TA 
 
Scheme 6. Asymmetric Alkylation with (R)-1TA 
 
The substrate scope includes several primary and secondary alkyl bromides and 
iodides, both activated and inactivated, providing products in good to excellent 
enantiomeric excess (Table 1). Numerous electron rich and electron deficient aryl- and 
heteroaryl acetic acids were also compatible with the reaction conditions (Table 2).  
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Table 1. Asymmetric Alkylation: Alkylating Agent Scope Summary 
 
Table 2. Asymmetric Alkylation: Carboxylic Acid Scope Summary 
 
This method is amenable to large-scale applications, illustrated by direct alkylation 
of 10 g of phenyl acetic acid with 2-iodopropane in 89% yield and 98% ee. Additionally, 
the technique was applied to the synthesis of the known γ-secretase modulator 1 
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Scheme 7. Synthesis of γ-Secretase Inhibitor 1 by Enantioselective Alkylation 
 
1.3.1 Mechanistic Studies 
Evidence from mechanistic studies of enantioselective organolithium reactions has 
shown that high stereo control is sometimes correlated with high structural control of the 
reactive aggregates. Through a collaborative effort, the crystal structures of n-BuLi with 
the bis(lithium)amide of (R)-1TA (2) and of (R)-1TALi2 bound to the (bis)lithium 
enediolate of phenylacetic acid (3, Figure 1) have been elucidated.17 Both structures 
crystallize as dimers but are shown in monomeric form for simplification purposes. 
Bis(lithium)amide 2 crystallizes in the orthorhombic space group P212121 with each 
piperidine-derived nitrogen atom coordinated to a single lithium cation, whereas each 
amide nitrogen atom is coordinated to two lithium cations. This orientation places both 
phenyl groups in the amine backbones pseudoequatorially. The enediolate−dilithiated 
amide mixed aggregate 3 crystallizes in the orthorhombic space group P212121 as the 
THF solvate containing two chiral dilithiated amides and two enediolates. The most 
interesting feature of 3 is the incorporation of the enediolate, whose atoms are all 
  9 
coplanar, suggesting strong π conjugation. Additionally, each oxygen atom is 
coordinated to three lithium cations.  
Figure 1. Aggregate Structures of (R)-1TALi2  and (R)-1TALi2−Enediolate 
 
In solution, these reagents assume distinct aggregation states, which are supported 
by multinuclear solution NMR and in silico computations. The synthesis of a 15N-
labeled (R)-1TA from isotopically enriched ammonia, followed by 6Li and 15N two-
dimensional NMR (2D-NMR) have allowed for systematic study of the active reagent 
aggregates in relation to structure, size, solvation, sterics, and reactivity. The assignment 
of trilithiated monomer 2 rather than the hexalithio dimer was established from 13C 
NMR spectrum splitting patterns. Similarly, tetralithio monomeric endiolate−dilithium 
amide mixed aggregate 3 is preferentially supported by observations via NMR and 
computational models, in comparison to its theoretical octalithio dimeric structure. A 
mechanistic model for the origin of, and in certain cases loss of, stereoselectivity has 
been established through the elucidation of these crystal structures, 2D-NMR data, and 
computations. The aggregate exhibits an immensely strong conformational preference 
for phenyl orientation to expose the si face of the enediolate derived from phenylacetic 
acid, resulting in exceedingly high selectivities (Figure 2). We believe the orientation of 
the phenyl ring of the enediolate is the variable that is most critical to enantioselectivity. 
It is noteworthy to mention that the level of enantioselectivity was dependent on the 
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quality of n-butyl lithium. Aged reagent bottles, likely contaminated with ionic lithium 
salts, resulted in drastically lower, inconsistent stereoinduction.  
Figure 2. Conformational Preferences of the Enediolate 
 
1.4 Enantioselective Michael Addition 
1.4.1 Introduction 
Enantioselective Michael addition of lithium enolates is a process of significant 
utility. From simple precursors, this reaction has the potential to generate multiple 
consecutive stereocenters that are difficult to access by other methods. There has been 
considerable progress in methodology that has tapped into this potential,18,19 including 
several methods based on covalent chiral auxiliaries.20,21 Asymmetric transformations 
with lithium enolates derived from carboxylic acids are performed predominantly with 
covalently attached chiral auxiliaries. These reactions provide a broad arsenal of 
methods for enantioselective synthesis and are indispensable in the synthesis of many 
complex natural products and pharmaceuticals.22 We recently reported that high 
enantioselectivities could be achieved in the direct one-step alkylation of arylacetic acids 
using chiral lithium amides.14 In this process, the chiral C2-symmetric dilithium amide 
  11 
functions as a chiral auxiliary within a mixed enediolate−dilithium amide aggregate 
formed in situ, thus bypassing the additional steps required to attach and remove 
covalently bound chiral auxiliaries. X-ray crystallography, 6Li, 13C, and 15N NMR 
spectroscopy, and DFT calculations pointed to the structure of the aggregate.17,23  
A direct enantioselective Michael addition of carboxylic acids via enediolates 
mediated by chiral lithium amides is described (Scheme 8).24,25,26 The reaction occurs 
with high stereocontrol in both the relative and absolute sense, further highlighting the 
utility of chiral lithium amides as traceless auxiliaries for asymmetric synthesis.  
Scheme 8. Asymmetric Michael Addition with Enediolate−Dilithium Amides 
 
1.4.2 Reaction Optimization 
The addition of phenylacetic acid to alkyl cinnamates and methyl (E)-3-
cyclohexylacrylate in the presence of dilithium amides from chiral C2-symmetric 
tetramines 1TA−6TA was investigated first (Table 3).27  From the onset, the reactions 
were characterized by facile, highly anti-selective 1,4-additions with high conversions at 
-78 °C.28 Piperidine-based tetramine (R)-1TA,13,29 which was previously shown to be 
highly effective in asymmetric alkylations of arylacetic acids, again proved to be 
optimal (88% yield, >30:1 dr, 83% ee; entry 1). One of the most striking observations is 
that a seemingly minor adjustment in the structure of the base, i.e., replacing the 
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piperidine unit with pyrrolidine as in (R)-2TA, resulted in reversal of the enantiomeric 
preference, giving the opposite enantiomer ent-6 as the major product with 84% ee and 
17:1 dr (entry 2). The previously reported alkylation reaction showed the same sense of 
enantiofacial preferences for these two bases. The azepine base also displayed a reversal 
of selectivity, although at a lower level (46% ee; entry 3). Introduction of the gem–
dimethyl substitution on the propylene bridge in (R)-4TA gave a diminished yield of the 
product with lower diastereoselectivity (entry 4). Replacing the phenyl group with 2-
naphthyl ((R)-5TA) had a minor impact on the course of the reaction.  
Variations in the ester group revealed that the enantioselectivity was higher for 
methyl cinnamate (4, R = Me) than for ethyl and tert-butyl cinnamate. Under optimal 
conditions, the addition product was formed in 88% yield with 93% ee as a single 
diastereomer (Table 3, entry 8). A larger-scale experiment was performed at -78 °C on 
26 mmol scale, affording 5.97 g of 6 (R = CH3) in 78% yield with 90% ee (entry 13). 
The product was isolated as a single diastereomer by recrystallization, and the reagent 
(R)-1TA was recovered by extraction in 99% yield.  
Similar selectivity trends were observed with methyl (E)-3-cyclohexylacrylate (5) 
(Table 3, entries 9−12). In this case, the pyrrolidine base (R)-2TA proved to be 
significantly more effective, giving adduct 7 in 74% isolated yield with 96% ee as a 
single anti diastereomer (cf. entries 9 and 10). The absolute and relative configurations 
of addition products 6 and 7 were established using X-ray crystallographic analysis as 
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Table 3. Chiral Lithium Amides for the Enantioselective Conjugate Addition of 
PhCH2CO2H to Ester 4 and 5a 
 
1.4.3 Substrate Scope 
Guided by the initial experiments, we selected the piperidine base (R)-1TA and the 
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pyrrolidine base (R)-2TA for further investigations. The scope of Michael acceptors was 
examined first (Table 4). In all of the examples, ∼1:1 stoichiometry between the Michael 
donor and acceptor was applied. Many aryl and heteroaryl substituents were suitable for 
the reaction using the piperidine base (R)-1TA. The diastereoselectivity was uniformly 
high for all of the α,β-unsaturated esters (>20:1), and the enantioselectivity was in the 
range of 69−97% ee, with the highest value observed for products 8a and 8f bearing 2-
methoxyphenyl and 3-indolyl groups, respectively. The 3-nitroaryl substituent (8c) 
afforded a much lower yield of the addition product, likely because of the high reactivity 
of the substrate; however, high enantioselectivity was maintained. In our screening 
efforts, we placed an emphasis on heteroaryl substituents because of their relevance to 
medicinal chemistry (8d−i). Although the enantioselectivity was somewhat reduced, it 
was in the practical range of 70−97% ee for a variety of groups, including N-methyl-2-
pyrrolyl (8d, 86% ee), 2-benzofuryl (8e, 73% ee), N-Boc-3-indolyl (8f, 97% ee), 2-furyl 
(8g, 85% ee), 3,5-dimethyl-4-isoxazolyl (8h, 86% ee), and 2-thiazolyl (8i), which gave 
the lowest ee of 69%. Notably, the potentially sensitive N-Boc group in 8f was 
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Table 4. Conjugate Addition: Scope of α,β-Unsaturated Estersc 
 
On the basis of the preliminary studies, aliphatic α,β-unsaturated esters were studied 
with both chiral bases,  (R)-1TA and (R)-2TA (Table 5). With crotonates (8j, 8k), we 
found that the best enantioselectivity of 78% was obtained with the tert-butyl ester using 
the original piperidine base (R)-1TA. For all of the other substrates except for methyl 
4,4,4-trifluorocrotonate (8p, 58% ee), the enantioselectivity was superior with (R)-2TA. 
Ethyl (8l), isopropyl (8m), isobutyl (8n), cyclopropyl (8o), and (4-
methoxyphenyloxy)methyl (8q) substituents were effectively introduced. The 
enantioselectivities were in the range of 85−90%, except for 8q, which was isolated with 
66% ee. Under the conditions studied, no reactivity was observed with sterically 
demanding methyl (E)-4,4-dimethylpent-2-enoate (cf. 8r in Table 5). 
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Table 5. Conjugate Addition: Aliphatic α,β-Unsaturated Estersc 
 
The scope of carboxylic acids investigated as Michael donors with the piperidine 
base (R)-1TA is summarized in Table 6. Initially, variation of the position of the chlorine 
on the phenyl ring revealed that ortho substitution resulted in a drastic reduction of 
enantioselectivity. While 4- and 3-chlorophenylacetic acid afforded addition products 
with 93 and 86% ee, respectively, 33% ee was observed with 2-chlorophenylacetic acid. 
The selectivity could be substantially improved to 70% ee by using the alternative base 
(R)-2TA (9c). Again, the enantiomeric product was favored. Similar trends were 
observed for 2- and 3-naphthylacetic acid (9e, 9f). The former afforded the addition 
product with 87% ee, while the selectivity with the latter was 33% ee, which could be 
enhanced to −79% ee using (R)-2TA. 2-(Benzo[d]dioxol-5-yl)acetic acid afforded 9d 
with 89% ee.  
The heteroarylacetic acids 2-thiophene- and 3-furanacetic acid afforded 9g and 9h 
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with high enantioselectivity (Table 6). Although N-Boc-3-indoleacetic acid proved to be 
a poor substrate in the addition reaction, N-benzyl-3-indoleacetic acid afforded 9i in a 
very high yield with 76% ee. Improved selectivity was observed with (R)-2TA as the 
base, which again afforded the product with the opposite sense of enantioinduction. 
Table 6. Conjugate Addition: Scope of Carboxylic Acidsc 
 
Although a systematic study of aliphatic carboxylic acids as Michael donors was 
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beyond the scope of this contribution, addition of 4-phenylbutyric acid was an important 
initial advance in this direction (9j; Table 6). In contrast to our previous work on 
alkylation reactions, a rather high ee of 80% (dr 4:1) was observed with (R)-1TA as the 
base. Studies of enediolates from aliphatic acids continue and will be reported in due 
course. Variation in both coupling partners using more functionalized substrates is 
tolerated (9k). 
1.4.4 Applications 
The versatility of the Michael addition methodology is illustrated by the applications 
depicted in Scheme 9. The first application capitalized on the reactivity of the initially 
formed enolate by exploiting it in a secondary alkylation reaction with iodomethane in 
one pot. This process enabled the formation of three consecutive tertiary stereocenters 
with excellent stereocontrol in 74% yield (Scheme 9a). The free carboxyl group is an 
exceptionally convenient surrogate for an amino group via the Curtius rearrangement 
transform. In the event, treatment of acid 10 with diphenylphosphoryl azide followed by 
benzyl alcohol delivered γ-amino acid derivative 11 in 53% unoptimized yield.  
The second application was the enantioselective synthesis of the purported structure 
of pulveraven B (12) (Scheme 9b), reported as a constituent of the edible mushroom 
Pulveroboletus ravenelii in 2003.30 It displayed selective inhibition of carcinogen-
induced pre-neoplastic lesion formation in mouse mammary organ culture with IC50 = 
0.8 µM. The potency was reduced 10-fold for its epimer pulveraven A. 
In the synthesis described herein, the initial Michael adduct was subjected in situ to 
aldol coupling with 3-phenyl-2-propynal, affording a 2:1 mixture of aldol products 14 
with 86% ee for both diastereomers (83% yield). After cleavage of the 
trimethylsilylethyl ester with n-Bu4NF, a Ag-catalyzed cyclization afforded γ-lactone 
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15.31 Oxidation delivered the tetronic acid with a structure proposed for pulveraven B. 
However, the optical rotation and NMR spectral data did not match those reported for 
the natural product.ref 




In conclusion, we have developed a method for direct enantio- and diastereoselective 
conjugate addition of carboxylic acids to α,β-unsaturated esters. The stereoselectivity is 
imparted by a chiral lithium amide−enediolate aggregate formed from chiral C2-
symmetric Koga-type tetramines. The study revealed intriguing and unexpected patterns 
of stereoselectivity that are the subject of current mechanistic investigations.32 Multiple 
selective bond formations were illustrated (1) by a highly stereoselective one-pot 
alkylation with iodomethane and (2) by an aldol coupling within the context of the 
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enantioselective total synthesis of pulveraven B, which revealed that its structure 
appears to be misassigned. 
1.5 Asymmetric Alkylation for the Construction of Quaternary Stereocenters 
1.5.1 Introduction 
While countless methods have been developed in order to solve numerous obstacles 
in chemical synthesis, one problem that continues to elude organic chemists is the 
asymmetric synthesis of all-carbon quaternary stereocenters. Preparation of these centers 
is problematic due to the steric repulsions between the four carbon substituents. Despite 
this fact, many creative and elegant solutions have appeared in the literature making 
great strides towards this lofty goal, including, but not limited to: asymmetric Diels-
Alder reactions, allylic substitution, chiral allylmetal electrophiles, intramolecular Heck 
reactions, conjugate additions, and desymmetrization reactions.33 Once again, chiral 
auxiliaries have also been effectively utilized to overcome this challenge.  
Esumi and Fukuyama prepared the C11 quaternary stereocenter of (+)-Neovibsanin 
by employing a 1,4-conjugate addition with the higher order organocuprate 
(H2C=CH)2Cu(CN)Li2 to a trisubstituted α,β-unsaturated carboxylic acid derivative of 
(R)-4-phenyl-2-oxazolidinone (16, Scheme 10).34 In the course of their total synthesis of 
madindolines, Kobayashi and co-workers developed a regio- and stereoselective α-
alkylation of α,β-unsaturated chiral imides (Scheme 11).35 Their alkylation is also 
compatible for the introduction of allyl and acetate fragments with excellent 
diastereoselectivities. Similarly, Myers and co-workers developed a one-pot conjugate 
addition, alkylation of α,β-unsaturated pseudoephedrine amides providing a variety of 
differentially substituted quaternary stereocenters in good yields and selectivities 
(Scheme 12).36  
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Scheme 10. Esumi’s Formal Synthesis of (+)-neovibsanin B 
 
Scheme 11. Kobayishi’s Alkylation 
 
Scheme 12. Myers’ Conjugate Addition−Alkylation  
 
1.5.2 Preliminary Results 
We have developed an alternative alkylation procedure to form quaternary 
stereocenters in high conversion and enantiomeric excess. The reaction was optimized 
by the alkylation of 2-pheylpropanoic acid (17) using excess iodoethane to produce 2-
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methyl-2-phenylbutanoic acid (18, Table 7). Under the standard alkylation conditions, 
aggregation at 0 °C for 10 minutes, a modest yield was observed along with a modest 
stereoselectivity (Table 7, entry 1). An insightful publication from Amgen regarding 
their development of a diastereoselective alkylation to prepare the quaternary 
stereocenter of AMG-221 (19), a 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 
led to a revelation in our procedure.29c Their aggregation conditions consisted of aging 
the reaction mixture, prior to alkylation, at 15 °C for 30 minutes (Scheme 13). We 
postulated it would be beneficial to the selectivity by extending the aggregation time and 
to increase the aggregation temperature. Consequently, increasing the aggregation time 
to 1 hr at 0 °C drastically improved enantioselectivity but, surprisingly, actually lowered 
conversion (Table 7, entry 2). We were delighted to find that by increasing aggregation 
temperature and time, an optimized 76% conversion and 90% ee was achieved (entry 3). 
Gentle heating of the aggregate mixture had a detrimental impact on the reaction (entry 
4). We believe the rate of formation of the highly structured aggregate is more difficult, 
and therefore slower, due to the increased sterics from a disubstituted enediolate.  
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Scheme 13. Amgen Diastereoselective Alkylation Towards AMG-221 
 
Using the piperidine base (R)-1TA, ethylation (18), allylation (20), and benzylation 
(21) generate quaternary products in good yields and good enantioselectivities (Scheme 
14). Allylation with pyrrolidine base (R)-2TA gave a slightly lower yield and modest 
enantioselectivity. Regrettably, conjugate addition to methyl cinnamate only provides 22 
with modest stereoselectivity and yield.  
Scheme 14. Alkylation Scope 
 
Extension of this procedure is currently limited to 2-phenylpropanoic acid. Attempts 
to extend the protocol to 2-phenylbutanoic acid (23) results in good conversion but low 
enantioselectivity (Scheme 15). This outcome likely originates from lower energy 
differences (ΔG° calculated for mono-substituted substrates, R1 = Ph, Me, i-Pr, 
cyclohexyl; R2 = H) between stereo-conformations of the reactive aggregate (Figure 
3).17 When disubstituted, the phenyl substituent of 2-phenylbutanoic acid is much closer 
in energy to an ethyl group, 7.7 kcal/mol and 1.3 − 4.2 kcal/mol, respectively, compared 
  24 
to a methyl group, 1.3 kcal/mol. This leads to a higher probability for a conformational 
change exposing the re face, resulting in an erosion of enantioselectivity as a 
consequence. Another result of this structural change is a conformational flip of the 
piperidine ring, which may affect electrophilic approach.  
Scheme 15. Asymmetric Alkylation of 2-Phenylbutanoic Acid (23) 
 
Figure 3. Calculated Conformation Energy Differences 
 
1.5.3 Conclusions 
The development of asymmetric alkylation of enediolate—dilithium amide mixed 
aggregates with chiral tetramine (R)-1TA continues to yield fruitful results. The growth 
and expansion of this direct enantioselective alkylation methodology has the potential to 
continue to contribute to the chemical and scientific communities.  
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2.1 Introduction 
Dragmacidin D (26) is a member of a family of heterocyclic bis(indole) natural products 
isolated from deep-water Caribbean sponges of Dragmacidon and Spongosorites sp. (Figure 
4).37 Although the initially isolated sample displayed no optical activity,38 subsequent 
reisolation from a sponge specimen collected at 90 m depth along the coast of South 
Australia provided a sample of dragmacidin D with an [α]D of +12° (c 0.95, EtOH).39 These 
observations indicate a certain measure of ambiguity for the stereochemical identity of 
dragmacidin D and configurational stability of its sole stereogenic center.37 Dragmacidin D, 
along with dragmacidin E (27), was found to be a potent inhibitor of serine-threonine 
phosphatases PP1 and PP2A (PP1, IC50 = 21.0 nM; PP2A1, IC50 = 3.0 µM; PP2A2, IC50 = 3.0 
µM). Other biological activity reported for dragmacidins include antiviral, antibacterial, 
antifungal, and in vitro cytotoxicity against P388 murine leukemia, A549 human lung, HCT-
8 human colon, and MDAMB human mammary cancer cell lines, in addition to selective 
inhibition of neural nitric oxide synthase (bNOS) with EC50 = ~2.9 µM. The distinctive 
structure of dragmacidin D combines a reactive central pyrazinone core with flanking indole 
substituents, one of which is further elaborated with an aminoimidazole unit bound by a 
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Figure 4. Pyrazinone Dragmacidins 
 
2.2 Previous Syntheses of Dragmacidin D 
2.2.1 Stoltz’ Synthesis of (±)-Dragmacidin D 
In 2002, Stoltz and co-workers completed the first total synthesis of racemic 
dragmacidin D by effectively utilizing a series of sequential, temperature-controlled Suzuki 
cross-coupling reactions between organoboron reagents 29, 30 and dihalopyrazine 31 
(Scheme 16).40 The synthesis was completed in 17 steps, which reflect many intricacies at 
the late-stage installation of the polar aminoimidazole substituent.  
Scheme 16. Stoltz’ Synthetic Plan 
 
Although the Suzuki cross-coupling approach lead to the successful synthetic route to 
dragmacidin D, Stoltz originally studied a cyclocondensative pyrazinone synthesis to 
assemble the bis-indolyl pyrazinone core structure, (Scheme 17). After identifying keto 
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aldehyde 32 and aminoamide 33 as simple model substrates, the authors were encouraged by 
facile condensation under basic conditions to form bis-indolyl pyrazinone 34. Unfortunately, 
this approach was ineffective for producing the desired dragmacidin framework 37 with 
more functionalized ketoaldehyde 35 and aminoamide 36, likely due to the steric component 
of C4 substitution of the 3,4,7-trisubstituted indole.  
Scheme 17. Stoltz’ Cyclocondensative Approach 
 
Focusing on the Suzuki coupling approach, preparation of the 3,4,7-trifunctionalized 
indole boronate 29 began with a Bartoli indole synthesis from 1-(benzyloxy)-4-bromo-2-
nitrobenzene (38) in a modest 33% yield (Scheme 18a). Initial protection of the indole 
nitrogen with a 2-(trimethylsilyl)ethoxymethyl (SEM) group was followed by lithium-
halogen exchange and trapping as the pinacol ester. Suzuki coupling between indole 39 and 
vinyl bromide 40 provided silyl ether 41. Synthesis of the fragment was accomplished via 
hydrogenation of the alkene, bromination of the indole at the C3 position, and finally 
lithium-halogen with subsequent trapping as the pinacol ester. Dihalopyrazine 31 was 
prepared via a Sandmeyer reaction from known amino pyrazine 42,41 synthesized from 2-
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aminopyrazine in two steps (Scheme 18b). The bromoindole boronic acid 30 was prepared 
in 4 steps from 6-bromoindole through the organomercury indole 43 (Scheme 18c).42 
Scheme 18. Synthesis of Suzuki Precursors  
 
Next they turned their attention to the key sequential Suzuki couplings. After gaining 
insight regarding the reactivity of dihalopyrazines gathered from a model study, selective 
coupling between boronic acid 30 to the iodide of dihalopyrazine 31 was accomplished at 
room temperature in good yield (Scheme 19). The subsequent Suzuki coupling could be 
accomplished under carefully controlled reaction conditions, specifically restricting the 
reaction temperature at 50 °C, effectively coupling with the other indole boronate 29 to 
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Scheme 19. Temperature Controlled Sequential Suzuki Coupling 
 
With the bis-indolylpyrazine core in hand, the authors attempted to convert 45 into 
dragmacidin D (Scheme 20). Silyl ether cleavage and two-step oxidation to carboxylic acid 
46 was accomplished in good yield. An Arndt-Eistart homologation to α-bromo ketone was 
initially problematic, but after careful drying of the diazomethane, the transformation was 
accomplished in a good 58% yield. Treatment of bromoketone 47 with acetylguanidine did 
not produce the desired N-acetylaminoimidizale, but instead formed acetoxyketone 48 in 
nearly quantitative yield. Alternatively, condensation of the α-aminoketone with cyanamide 
in ethanol generated the desired aminoimidazole 49. Sadly, all attempts to remove the 









  31 
Scheme 20. Stoltz’ Endgame Strategy 1 
 
The authors decided to alter their final endgame strategy (Scheme 21). After silyl 
deprotection, Dess-Martin oxidation gave aldehyde 50.  Nitromethane addition followed by 
another Dess-Martin oxidation resulted in nitro ketone 51. After deprotection, tin(II) 
promoted nitro reduction and dealkylation with TMSI gave amino ketone 52. Finally, 
condensation of 52 with cyanamide in EtOH provided (±)-26, isolated as the trifluoroacetate 
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Scheme 21. Completion of (±)-Dragmacidin D 
 
The key Suzuki coupling strategy was also utilized in the exceptional total synthesis of 
both enantiomers of dragmacidin F43 as well as formal syntheses of dragmacidins A, B, and 
C.37  
Scheme 22. Stoltz’ Synthetic Plan for (+)-Dragmacidin F 
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Scheme 23. Stoltz’ Formal Syntheses of Dragmacidin A, B, and C 
 
After completing the total synthesis of (−)-dragmacidin F (28) and thereby assigning its 
absolute configuration (Scheme 24),43 the Stoltz group proposed the configuration of natural 
(+)-dragmacidin D (26) and (−)-dragmacidin E (27) to be 6ʹ′ʹ′ʹ′S and 5ʹ′ʹ′ʹ′R, 6ʹ′ʹ′ʹ′S, respectively, 
postulating a common biogenesis (Scheme 25).37  
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Scheme 25. Stoltz’ Biosynthetic Proposal 
 
2.2.2 Itami-Yamaguchi Synthesis of (±)-Dragmacidin D 
In 2011, Yamaguchi and Itami et al. reported the second total synthesis of (±)-26, which 
was completed in 12 steps by using a series of C−H cross-coupling reactions.44 This concise 
synthesis highlights the utility of C−H functionalization technology in complex total 
synthesis45 and was accomplished by taking advantage of three sequential C−H coupling 
reactions and a tautomeric switch between pyrazinone and pyrazine N-oxide (Scheme 26).  
Scheme 26. Itami-Yamaguchi’s Synthetic Plan 
 
Utilizing methodology developed in their lab, Itami and co-workers employed a 
regioselective coupling at the C4 position of silyloxy thiophene 54 to 4-iodoindole 55 
(Scheme 27).46 The steric bulk of the silyloxy group was critical to achieve good 
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regioselectivity through directed palladium complexation to the C4/C5 double bond of 54. 
Removal of the silyl ether, parallel thiophene and benzyl ether reduction, followed by 
protecting group exchange provided methyl ketone 57. This substrate was used in a 
C−H/C−H coupling at the C3 indole position with pyrazine N-oxide catalyzed by Pd(OAc)2 
and stoichiometric AgOAc.47 By recycling recovered starting material and resubmitting it to 
the reaction conditions, they were able to isolate coupled pyrazine N-oxide 58 in 50% yield. 
Tautomeric switch of the N-oxide 58 was induced by trifluoroacetic anhydride, affording 
pyrazinone 59 as a 5:1 mixture of regioisomers. It was reasoned that the steric bulk of the 
methyl ketone at the C4 position of the left-hand indole unit influenced the increase in 
regioselectivity favoring the desired regioisomer. Attachment of the 6-bromoindole unit was 
achieved through an oxidative C−H/C−H coupling reaction with pyrazinone 59 mediated by 
F3CSO3H with simultaneous MOM deprotection.48 The synthesis of 26 was completed via 
α-bromination of 60 followed by nucleophilic attack and cyclocondensation of 61 with Boc-
protected guanidine. Notably, the aminoimidazole installation was accomplished in a 
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Scheme 27. Itami-Yamaguchi Synthesis 
 
2.2.3 Jia-Capon Synthesis of (+)-Dragmacidin D 
Recently, a collaborative effort by the Jia and Capon groups culminated in the 
asymmetric total synthesis of (+)-26 in 26 steps.49 This effort suggested a curious divergence 
in stereochemistry between dragmacidins D and F, and revises the stereochemistry of (+)-26 
to 6ʹ′ʹ′ʹ′R. The authors noted that 26 has never been co-isolated with dragmacidin F (28) but 
has been co-isolated with dragmacidin E (27), thus providing a plausible basis for this 
divergence, and reported that samples of 26 isolated by Capon and co-workers were either 
racemic or enantioenriched at 39% ee.  
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Retrosynthetically the authors opted, like the previous two syntheses, to install the 
aminoimidazole heterocycle at the end of the synthesis. They chose to use a modification of 
Chen’s method.50 The central pyrazinone ring would be constructed using a strategy similar 
to Stoltz’ original approach via intermolecular cyclocondensation. The key 3,4,7-
trisubstituted indole fragment, preinstalled with the stereogenic methyl group, would be 
prepared by an asymmetric conjugate addition directed by Evans’ chiral oxazolidinone 
auxiliary. The indole heterocycle would be synthesized using a palladium-catalyzed 
heteroannulation reaction.  
Scheme 28. Jia-Capon Synthetic Plan 
 
The synthesis began with a palladium-catalyzed heteroannulation reaction from iodo-
aniline 62 and butyraldehyde 63 to prepare the tryptophol derivative (Scheme 29). 
Following N-Boc protection, chemoselective iodination at the C4 position with N-
iodosuccinimide in the presence of acetic acid afforded iodide 64. An intermolecular Heck 
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reaction with N-acyl oxazolidinone 65 gave indole 66 as a 7:2 ratio of E:Z isomers. 
Conjugate addition of methyl cuprate followed by methanolysis of Evan’s auxiliary gave 
methyl ester 67 in 70% yield and a 7:2 ratio of diastereomers. After separation of the 
isomers via column chromatography, silyl ether deprotection, azide installation, Staudinger 
reduction, Boc deprotection, and Boc protection gave N-Boc tryptamine 69. Treatment of 69 
with a mixture of DDQ and TMSN3 followed by azide reduction with NaBH4 and NiCl2 
provided the amine 70 as a mixture of diastereomers.  
Scheme 29. Installation of Stereocenter and Synthesis of Left-Hand Fragment 
 
The cyclocondensation strategy was completed in three-steps involving acylation of 
amine 70 with 6-bromoindole oxalyl chloride 71, cyclization, and subsequent DDQ induced 
oxidative aromatization to pyrazinone 72 (Scheme 30). Protection of both indoles and 
pyrazinone provided methyl ester 73 in preparation for α-bromination. Azide substitution 
and Staudinger reduction generated α-amino ester 74, which, after guanidine formation, 
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gave di-Boc guanidinyl methyl ester 76. Reduction with iBu2AlH and TFA induced 
deprotection/cyclization gave aminoimidazole 77. Finally, dealkylation with boron 
tribromide provided a synthetic sample of dragmacidin D with an [α]D of +18.8° (c 0.10, 
EtOH).  
Scheme 30. Cyclocondensation and Completion of Synthesis 
 
Chiral HPLCs of both synthetic and natural dragmacidin D, isolated by Capon and co-
workers, are represented in Figure 5. Synthetic dragmacidin D was without a doubt 
enantioenriched (ee unreported), while natural dragmacidin D possessed either a low 
enantiopurity of 39% ee or racemic.  
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Figure 5. Chiral HPLC Analysis. a) Synthetic (+)-Dragmacidin D. b) (+)-Dragmacidin 
D (39% ee) from RJC-91-011. and c) (±)-Dragmacidin D from RJC-98-305 
 
The 6ʹ′ʹ′ʹ′R stereochemistry, installed from the asymmetric organocuprate conjugate 
addition, was confirmed through derivitization of methyl ester 67 to known succinic benzyl 
ester 7951,52 (Scheme 31) and chiral HPLC analysis (Figure 6).  
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2.3 Zakarian Synthesis of (+)-Dragmacidin D 
2.3.1 Early Strategies Towards the Total Synthesis of Dragmacidin D  
Our early synthetic strategy originally focused on employing a tri-substituted benzene 
ring, such as 80 or 81, to manufacture the left-hand indole fragment 82, avoiding the need to 
prepare a 1,2,3,4-tetrasubstituted benzene 83, which would be much more difficult to 
synthesize efficiently (Scheme 32).  
Scheme 32. Early Synthetic Strategy 
 
One initial strategy involved synthesis of alkenyl azide 84 through a ceric ammonium 
nitrate (CAN) mediated process followed by base promoted elimination (Scheme 33).53 
Subsequent thermal heating provided cyclized indole 85 with 100% conversion.54 However, 
the need to remove the ethyl ester in the C2 position of the indole as well as the need to 
attach the pyrazinone heterocycle at the C3 position drastically reduced our enthusiasm 
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Scheme 33. Azide Cyclization 
 
Another early strategy involved a Bartoli indole synthesis from nitro arene 86,55 
followed by a palladium-catalyzed Hartwig enolate coupling to provide indolylacetate 87 
(Scheme 34).56 However, yields above 15% were never achieved and the issue of attaching 
the pyrazinone heterocycle regioselectively remained unsolved.  
Scheme 34. Bartoli Synthsis−Hartwig Coupling Strategy 
 
Adjusting our strategy, we wanted to form our left-hand indole 88 with simultaneous 
attachment of the pyrazinone and 6-bromoindole moieties (Scheme 35).  
Scheme 35. Revised Left-Hand Indole Strategy 
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Using precedents by Inamoto and Queiroz, we attempted an intramolecular C−N 
cyclization of protected enamines (Scheme 36).57 A model study showed the feasibility of 
this route using enamine 89 to provide 3-phenylindole 90 in modest yield.  Unfortunately, 
the differentially substituted pyridine model 91 showed that the reaction was not 
regioselective. In addition, products were isolated in very poor yields.  
Scheme 36. Intramolecular C−N Cyclization Strategy 
 
Inspired by the work of Glorius and Yoshikai (Scheme 37), we sought to oxidatively 
cyclize an N-aryl imine or enamine intermediate such as 92 or 93, to form 3-arylindole 94 
(Scheme 38).58 An attempt to form imine 95 revealed that aryl acetaldehydes simply 
undergo a base catalyzed aldol polymerization so we decided to synthesize a carbamate 
protected N-aryl enamine (Scheme 39). Copper catalyzed Buchwald-Hartwig coupling to 
aryl iodide 96 provided Cbz-enamine 97 in modest yield.59 Unfortunately, all cyclization 
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Scheme 37. Glorius’ and Yoshikai’s Oxidative Cyclization 
 
Scheme 38. Cyclization Strategy 
 
Scheme 39. Cyclization Attempts 
 
Conceding the option to pursue a route utilizing a tri-substituted benzene ring, we 
attempted to form our left hand indole 98, with simultaneous pyrazine ring attachment, 
through a Larock heteroannulation from tetra-substituted bromoaniline 99 (Scheme 40).  
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Scheme 40. Larock Indole Synthesis Strategy 
 
The most attractive feature of this method is the ability to regioselectively position aryl 
substituents in the C3 indole position through the use of silyl protected aryl alkynes. 
Heteroannulation between bromoanilide 100 and trimethylsilylphenyl acetylene confirmed 
our optimism by producing 3-phenyl indole 101 in moderate yield with acceptable 
selectivity (Scheme 41). We adjusted our strategy and decided to pursue this route. The 
reaction worked well between bromoaniline 102 and pyrazinyl alkyne 103 with complete 
regioselectivity. A quick optimization study revealed that 2 equivalents of alkyne 103 could 
produce indole 104 in 80% yield. Additionally, hydrodesilylation could be accomplished in 
good yield after treatment with TBAF providing indole 105 (Scheme 42).  
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Scheme 42. Hydrodesilylation 
 
2.3.2 Protecting Group Selection 
At this stage in the study, we began to investigate potential deprotection of the methyl 
ether and methyl ester protecting groups to expose pyrazinone 106 (Scheme 43). We were 
surprised to find that treatment of 3-pyrazinyl indole 105 with either BBr3 or TMSI did not 
efficiently induce bis-demethylation. Additionally, we were unable to remove the methyl 
ester of 107 under a variety of the hydrolytic conditions.  
Scheme 43. Protecting Group Issues 
 
We attempted to switch the pyrazinyl methyl ether to a para-methoxybenzyl ether-
protecting group (Scheme 44). After exposing 108 to boron tribromide, clean dealkylation 
was not observed; instead a very efficient Friedel−Crafts arylation took place yielding indole 
109, even in the presence of thiolane as a cation trap. After careful consideration, we 
decided to install a TBS ether and (2-trimethylsilyl)ethyl ester as protecting groups in 110, 
which eventually led to the successful route.  
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Scheme 44. PMB Issues and Successful Protecting Groups 
 
2.3.3 10-Step Asymmetric Synthesis and Stereochemistry of (+)-Dragmacidin D 
Detailed herein is a 10-step asymmetric total synthesis of (+)-dragmacidin D and what 
appears to be compelling evidence that its absolute configuration is indeed 6ʹ′ʹ′ʹ′S, as 
originally forecasted by Stoltz, and is thus uniform with that of (−)-dragmacidin F. This 
short 10-step synthesis is enabled by direct early-stage enantioselective alkylation of 
commercially available 4-methoxy-2-bromophenylacetic acid, in an extension of the 
methodology recently developed in our laboratory.14,17 The final synthesis plan that 
unlocked the path to success is outlined in Scheme 45. A concise elaboration of the thioester 
to the aminoimidazole was projected for the final operations of the synthesis.60 In contrast to 
all previous efforts that engaged a preassembled 7ʹ′ʹ′-hydroxyindole found in 26, we opted for 
the construction of the indole ring system by a Larock indole synthesis,61 thereby 
introducing a point of convergence in the synthesis plan. This transformation was to be 
followed by a Friedel–Crafts-type direct arylation with 6-bromoindole under acidic 
conditions, which was also utilized in the Itami/Yamaguchi synthesis. Bromoaniline 111 for 
the Larock indole synthesis was to be produced from precursor 112, with 4-methoxy-2-
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bromoacetic acid 113 identified as a straightforward starting material for its preparation by 
our direct alkylation method with the readily available tetramine (R)-1TA as the 
stereodirecting reagent (Scheme 45). One of the challenging objectives was preservation of 
the stereogenic center in 112 through the remaining operations of the synthesis.  
Scheme 45. Synthesis Plan for Dragmacidin D (26) 
 
Direct α-alkylation of carboxylic acids occurs via dianionic enediolates as reactive 
intermediates. Our initial studies showed that 113 is a challenging substrate for this reaction. 
Attempts to obtain the α-methylation product with CH3I and lithium diisopropylamide 
(LDA) or n-BuLi as the enolization reagents only led to decomposition of the starting 
material (Table 8, entries 1 and 2). Clean methylation was observed with LiN(SiMe3)2 (entry 
3). We postulated that decomposition with the more basic reagents was due to competitive 
lithiation of the arene C−H bond of 113 at the C3 position to form benzyne species. This 
problem could be solved through careful choice of a base that would prevent the arene 
lithiation and yet be potent enough to be compatible with the asymmetric alkylation 
protocol. To our dismay, after enolization with LiN(SiMe3)2, alkylation with (R)-1TALi2 
resulted in racemic 114 (entry 4). It is likely that, after enolization, the higher acidity of 
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(Me3Si)2NH (pKa=26) led to protonation of (R)-1TALi2 to give (R)-1TA (Scheme 46). Intact 
lithium amide (R)-1TALi2 is a critical part of the chiral aggregate for stereoselective 
alkylation. Investigation of various readily available amines drew our attention to t-
Bu(Me3Si)NH, which in our assessment struck the right balance between steric bulk to 
prevent C3 lithiation, and basicity (pKa=33 for t-BuNHSiMe3; pKa=37 for iPr2NH).62 A 
preliminary experiment supported this assessment (entry 5). We were delighted to discover 
that LiN(tBu)SiMe3 was an excellent choice, affording product 114 in 65% yield and 81% 
ee (entry 6).  
Table 8. Development of the Direct Stereoselective α-Methylation of 113 
 
Scheme 46. Postulation for Racemic Alkylation with LiHMDS 
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The synthesis of (+)-26 began with direct asymmetric alkylation of 113 with 0.9 equiv of 
iodomethane mediated by (R)-1TA on scales up to 4.7 g, which afforded (S)-114 in 65% 
yield and 81% ee (Scheme 47). We found that excess iodomethane was detrimental to 
enantioselectivity. Esterification of (S)-114 with 2-(trimethylsilyl)ethanol was accomplished 
under Yamaguchi conditions in high yield with no racemization. Nitration of 115 was best 
achieved with Cu(NO3)2 ! 5 H2O in Ac2O at -10 °C63 to provide a mixture of nitration 
products 116 and 117 in 67% and 30% yield, respectively. The temperature of the reaction 
mixture had to be maintained at or below -10 °C to avoid racemization. At this junction, we 
opted against further optimization of regioselectivity in favor of advancing the synthesis, 
given that multigram quantities of 117 could be produced in a concise fashion from 113 in 
81% ee. Reduction of the nitro group to aniline was accomplished by treating 117 with N2H4 
! H2O and Pd/C in CH3OH at 50 °C. Careful control of temperature and N2H4 stoichiometry 
was necessary to minimize over-reduction. In this manner, 118 was obtained in 67% yield, 
along with its over-reduced product in 27% yield.64 Metal mediated nitro reductions in 
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Scheme 47. Synthesis of Precursor 118 
 
Scheme 48. Racemization Observed during Reduction with Fe 
 
The alkynyl pyrazine precursor 119 was prepared in 4 steps from 2,6-dichloropyrazine 
(Scheme 49).65 The central heteroannulation between 118 and 119 with the [1,1ʹ′-bis(di-
tertbutylphosphino)ferrocene]PdCl2 catalyst 120[11] afforded the requisite 2,3,4,7-
tetrasubstituted indole 121 in good yields and with no erosion of enantiomeric excess 
(Scheme 50). Yields were variable but the best results were obtained with freshly prepared 
substrates and freshly purified solvents. A dramatic improvement in reaction yield and 
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reproducibility was observed upon the addition of tetra-n-butylammonium bromide (TBAB) 
to prevent the formation of Pd black. A variant of the indole synthesis with an alkyne 
reagent analogous to 119 but bearing a preinstalled 6-bromoindole substituent (122) was 
unproductive (Scheme 50).  
Scheme 49. Synthesis of Alkyne Precursor 119 
 
Scheme 50. Larock Indole Synthesis 
 
The indole synthesis was followed by simultaneous cleavage of the 2-
(trimethylsilyl)ethyl ester, indole C2 trimethylsilane, phenolic methyl ether, and pyrazine 
silyl ether upon exposure to BBr3 in dichloromethane at -10 °C for 1 h (Scheme 51). The 
  54 
resulting carboxylic acid 124 was isolated by reverse-phase column chromatography in a 
nearly quantitative yield. Since we could not identify a procedure to determine its 
enantiomeric excess, the material was advanced further. Friedel–Crafts-type arylation with 
6-bromoindole was achieved in the presence of CF3SO3H in DMF at 100 °C under an 
atmosphere of oxygen to deliver bis(indole) carboxylic acid 125 in 42% yield. Thioester 126 
was produced in high yield with carbonyldiimidazole and 4-methylphenylthiol in 
tetrahydrofuran (THF). Again, we were unable to determine conditions to measure the ee of 
this compound. Therefore, the total synthesis was completed with two additional steps: 1) 
CuOAc-mediated acyl cross-coupling of thioester 126 with stannane 127, which bears a 
guanidinyl substituent, and 2) cyclocondensation of the resulting guanidinylmethyl ketone 
under acidic conditions with CF3CO2H in CH2Cl2 at 23 °C for 3 h. After purification by 
reverse-phase preparative HPLC, 15 mg of the trifluoroacetic acid (TFA) salt of synthetic 
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Scheme 51. Completion of the Total Synthesis of (+)-Dragmacidin D 
 
2.3.4 Stereochemistry of (+)-Dragmacidin D 
With 26 now available in sufficient supply (as well as the racemic sample prepared 
analogously), we were able to identify an effective chiral-phase HPLC method to measure 
its enantiomeric excess, which turned out to be 61% (Figure 7). Clearly there had been some 
erosion of ee between pyrazine-indole intermediate 121 and 26. The most likely origins of 
the erosion in our assessment are either the multiple-group cleavage reaction with BBr3, the 
Friedel–Crafts indolization, or, less likely, the final aminoimidazole formation with 
CF3CO2H. The potential instability of (+)-26 to racemization could also be an issue (see 
below).   
In light of uncertainties regarding the stereochemistry of 26, as discussed in the 
literature, we measured the rate of racemization of a solution of (+)-dragmacidin D in water 
(Fisher Scientific W5-4, HPLC grade, pH 6.8, 1 mg mL −1). The results reveal that 26 (61% 
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ee) undergoes slow but steady epimerization, reaching 33% ee after 4 days and 4% ee in 
approximately 16 days (Figure 7). Notably, the (+)-dragmacidin D TFA salt is 
configurationally stable upon storage at -20 °C as a mixture with benzene for at least 40 
days with no change in enantiomeric excess. When aqueous 26 was exposed to light at 23 
°C, rapid decomposition occurred. 
Figure 7. Enantiomeric excess of (+)-dragmacidin D trifluoroacetate solution in water at 
pH 6.8, as measured by chiral-phase HPLC. a) freshly prepared synthetic (+)-26, 61% ee. b) 
after 4 days at 23 °C, 33% ee. c) after 16 days, 4% ee.  
 
 
  57 
 
Perhaps more intriguingly, our work provides evidence for the absolute configuration of 
(+)-dragmacidin D that appears to contradict the recent results of Jia, Capon, and co-
workers.[8] First, the specific rotation of our sample at 61% ee ([α]D +106 (c 0.95, EtOH); 
[α]D +95 (c 0.10, EtOH) is notably higher at both concentrations than reported previously 
([α]D +12 (c 0.95, EtOH) at 39% ee; ([α]D +18 (c 0.10, EtOH), ee not reported). Importantly, 
the precision of our enantiomeric excess measurement is supported by clear baseline 
separation in the HPLC traces (Figure 7). Second, the absolute configuration of (+)-26 has 
been recently reassigned based on total synthesis to 6ʹ′ʹ′ʹ′R, in contrast to the biosynthetic 
prediction by Stoltz and co-workers. The present work, however, clearly supports the 6ʹ′ʹ′ʹ′S 
configuration, which is consistent with the known configuration of natural dragmacidin F. 
The evidence comes from correlation of the reduction product of carboxylic acid (+)-114, 
which was used as an intermediate in the total synthesis of (+)-26 reported herein, to the 
well-characterized alcohol (−)-128 (Scheme 52).66 
Scheme 52. Confirmation of the Absolute Stereochemistry of (+)-114 
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2.4 Conclusions 
In summary, we have completed a 10-step asymmetric total synthesis of the marine 
alkaloid dragmacidin D (26). Key transformations include: 1) a direct asymmetric 
methylation of carboxylic acid 113 with CH3I mediated by the reagent (R)-1TA; 2) a Larock 
indole assembly at the convergence point of the total synthesis; and 3) a concise conversion 
of a thioester into an aminoimidazole at the concluding stage of the synthesis. As a result, 15 
mg of (+)-dragmacidin D were produced in 61% ee, thus supporting the assignment of its 
sole stereogenic center at carbon 6ʹ′ʹ′ʹ′ as S. This result is in line with the original prediction 
by Stoltz and consistent with the absolute stereochemistry of dragmacidin F but contrasts 
with recent results by Jia, Capon, and co-workers. Additional studies revealed that 
dragmacidin D in solution in water at room temperature undergoes racemization within 
about 16 days and decomposes rapidly when exposed to light at room temperature. 
However, (+)-26 is chemically and configurationally stable at -20 °C in the dark. 
Collectively, these observations provide an interesting context for the existence of this 
natural product in oceanic environments at high depth.  
Experimental Procedures 
General Information. All reactions were carried out under an inert atmosphere of dry 
argon in oven or flame-dried glassware, unless the reaction procedure states otherwise. 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from sodium-benzophenone 
in a continuous still under an atmosphere of argon. Dichloromethane, di-iso-propylamine, 
triethylamine, and acetonitrile were distilled from calcium hydride in a continuous still 
under an atmosphere of argon. Chlorotrimethylsilane was distilled from calcium hydride and 
stored over calcium hydride. Reaction temperature was controlled by IKA ETS-D4 fuzzy 
thermo couples. Room temperature reactions were carried out between 22-24 °C. Analytical 
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normal-phase thin-layer chromatography (TLC) was performed using pre-coated TLC plates 
with Silica Gel 60 F254 (EMD no. 5715-7) and visualized using combinations of UV, 
anisaldehyde, ceric ammonium molybdate (CAM), potassium permanganate, and iodine 
staining.  Normal-phase flash column chromatography was performed using 40-63 mm 
silica gel (EMD, Geduran, no. 1.11567.9026) as the stationary phase. Analytical reverse-
phase thin-layer chromatography was performed using pre-coated TLC plates with Silica gel 
60 RP-18 F254s (Merck, no. 1.15685.0001). Reverse-phase flash column chromatography 
was performed using C18-Reversed phase silica gel, fully end-capped (Fluka, no. 60756). 
Proton nuclear magnetic resonance spectra were recorded at 400, 500, and 600 MHz on 
Varian Unity Inova. Carbon nuclear magnetic resonance spectra were recorded at 101 MHz, 
126 MHz, and 151 MHz on Varian Unity Inova, and Varian Unity Inova spectrometers.  All 
chemical shifts were reported in δ units relative to tetramethylsilane. Optical rotations were 
measured on a Rudolph Autopol III polarimeter. High-resolution mass spectral data were 







n-BuLi, THF, -90 oC, 0.5 h
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General Procedure I:  
(2S,3R)-5-Methoxy-5-oxo-2,3-diphenylpentanoic acid. A solution of n-BuLi (0.81 
mL, 2.46 M in hexanes, 1.99 mmol, 4.0 equiv) was added dropwise to a solution of 
phenylacetic acid (68.1 mg, 0.500 mmol) and (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv) in 
THF (5.0 mL) at 0 °C and the reaction mixture was stirred at this temperature for 30 min. 
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The reaction mixture was then cooled to -90 °C and stirred for an additional 5 min. A 
solution of (E)-methyl cinnamate (81.1 mg, 0.500 mmol, 1.0 equiv) in THF (0.30 mL + 2 × 
0.10 mL rinses) was added to the reaction mixture dropwise over 10 min. The resultant 
mixture was stirred for additional 20 min before a quench with a mixture of THF-MeOH 
(3:1, 0.64 mL) at -90 °C. After 5 min, the reaction mixture was acidified with 1 M aqueous 
solution of HCl and extracted with ethyl acetate. The combined organic phase was 
sequentially washed with 1 M aqueous solution of HCl and brine, dried over Na2SO4, 
concentrated, and the residue was purified by column chromatography on silica gel (2-4% 
methanol in dichloromethane) to afford the pure product (0.132 g, 0.442 mmol, 88% yield). 
[α]D
23 +25.8° (c 1.2, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.43-7.39 (m, 2H), 7.37-
7.29 (m, 3H), 7.27-7.21 (m, 4H), 7.20-7.16 (m, 1H), 3.87-3.78 (m, 2H), 3.37 (s, 3H), 2.42 -
2.33 (m, 2H). 13C NMR (125 MHz, CDCl3) δ (ppm): 177.1, 171.9, 140.8, 135.9, 128.9, 
128.7, 128.4, 128.2, 127.9, 127.2, 57.4, 51.4, 44.7, 38.5. HRMS-ESI (m/z): [M+Na]+ calcd 
for C18H18O4Na, 321.1103; found, 321.1091. 
Note: In most cases, ee values for the product were measured using the corresponding 
methyl ester due to low solubility of the free carboxylic acid in the HPLC eluent system 













(2S,3R)-Dimethyl 2,3-diphenylpentanedioate. A solution of TMSCHN2 in hexane 
(0.10 mL, 1.76 M, 0.176 mmol) was added dropwise to a solution of carboxylic acid (9.3 
mg, 31.2 µmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C. The resultant mixture 
was stirred at the same temperature for 0.5 h. The solvent was removed on a rotary 
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evaporator and the residue was purified by column chromatography on silica gel (8% ethyl 
acetate in hexanes) to afford the product (7.4 mg, 23.7 µmol, 76% yield). Ee: 93% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=15.0 min; t2=18.5 min). [α]D
23 +15.9o (c 0.57, CHCl3). 1H NMR (600 MHz, CDCl3) δ 
(ppm): 7.47 (d, J=7.4 Hz, 2H), 7.37 (t, J=7.4 Hz, 2H), 7.34-7.27 (m, 5H), 7.25-7.19 (m, 1H), 
3.91-3.83 (m, 2H), 3.39 (s, 3 H), 3.37 (s, 3 H), 2.47-2.35 (m, 2H). 13C NMR (125 MHz, 
CDCl3) δ (ppm): 172.6, 172.0, 141.2, 136.5, 128.9, 128.7, 128.4, 128.0, 127.9, 127.1, 57.7, 
51.8, 51.4, 45.2, 38.6. LRMS-ESI (m/z): [M+Na]+ calcd for C19H20O4Na, 335; found 335. 
Practical preparation at gram scale with recovery of the tetramine (R)-1TA.  
To a 3-neck round-bottom flask was attached a gas-inlet adapter, glass-stopper, and 
thermometer adapter fitted with a low-temperature thermometer. After flame drying under 
vacuum and back filling with argon, the flask was charged with phenylacetic acid (3.50 g, 
25.7 mmol), (R)-1TA (11.8 g, 26.4 mmol, 1.03 equiv), and THF (220 mL) under a positive 
pressure of argon gas. The reaction mixture was cooled in an ice-water bath to 0 °C and a 
solution of n-BuLi (39.0 mL, 2.65 M in hexanes, 103 mmol, 4.0 equiv) was added dropwise, 
keeping the internal reaction temperature below 15 °C. The mixture was stirred at 0 °C for 
additional 15 min. The reaction mixture was then cooled to -78 °C and stirred for an 
additional 10 min. A solution of (E)-methyl cinnamate (4.59 g, 28.3 mmol, 1.1 equiv) in 
THF (50 mL + 15 mL rinse) was added to the reaction mixture dropwise over 30 min, 
maintaining the internal reaction temperature below -70 °C. The resultant mixture was 
stirred for additional 30 min before a quench with a mixture of THF-MeOH (3:1, 32 mL) at 
-78 °C. After 5 min, the reaction mixture was acidified to pH = 1 with a 1 M aqueous 
solution of HCl and extracted with ethyl acetate (400 mL X 3). The combined organic phase 
was sequentially washed with 1 M aqueous solution of HCl (300 mL) and brine, dried over 
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Na2SO4, concentrated. The crude product was obtained as a light yellow solid (8.09 g, 89% 
ee). The crude product was dissolved in a minimal amount of EtOAc (~30 mL) using heat 
and sonication to aid dissolution. The solution was cooled to room temperature and then to 0 
°C in an ice-water bath. The formed precipitate was filtered through a medium-porosity 
sintered glass funnel and washed with ice-cold EtOAc to yield the pure product as a white 
solid (4.02 g, 13.5 mmol, 52% yield, 95% ee). A second recrystallization of the material 
recovered from the mother liquor of the first crystallization provided a second batch of pure 
product (1.95 g, 6.54 mmol, 25% yield, 80% ee). The two batches provided a total of 5.97 g 
(20.0 mmol, 78% yield, 90% ee).  
Recovery of (R)-1TA: The combined acidic aqueous layers were washed with diethyl 
ether then basified with sodium hydroxide to pH >12 at room temperature, and extracted 
with diethyl ether (400 mL X 3). The combined organic layers were washed with brine, 
dried over MgSO4, filtered, and concentrated to recover pure (1H NMR analysis) (R)-1TA 
(11.8 g, 26.3 mmol, 99%).  
OH
O
n-BuLi, THF, -90 oC, 0.5 h
+












(2S,3R)-5-Ethoxy-5-oxo-2,3-diphenylpentanoic acid. The title compound was 
prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 mmol), 
(R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.81 mL, 2.46 M in hexanes, 1.99 
mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-ethyl cinnamate 
(85 µL, 89.2 mg, 0.506 mmol, 1.0 equiv) in THF (0.50 mL) at -90 °C. The reaction was 
quenched after 0.5 h and the product (0.126 g, 0.403 mmol, 81%) was obtained after 
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purification by column chromatography on silica gel (4% methanol in dichloromethane). 
[α]D
23 +28.2° (c 0.54, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.45-7.39 (m, 2H), 7.39-
7.28 (m, 3H), 7.28-7.20 (m, 4H), 7.20-7.15 (m, 1H), 3.86-3.76 (m, 4H), 2.42-2.31 (m, 2H), 
0.97 (t, J=7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ (ppm): 177.0, 171.5, 140.8, 136.0, 
128.9, 128.7, 128.6, 128.4, 128.1, 128.0, 127.1, 60.2, 57.5, 44.7, 38.7, 13.9. HRMS-ESI 













(2S,3R)-5-Ethyl-1-methyl 2,3-diphenylpentanedioate. The title compound was 
prepared using carboxylic acid (14.2 mg, 45.5 µmol), TMSCHN2 in hexane (0.12 mL, 1.76 
M, 0.211 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford the product (12.4 mg, 38.0 µmol, 84% yield). Ee: 90% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=13.3 min; t2=16.6 min). [α]D
23 +22.6o (c 0.62, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.50-7.45 (m, 2H), 7.39-7.34 (m, 2H), 7.34-7.27 (m, 5H), 7.24-7.19 (m, 1H), 3.93-
3.78 (m, 4H), 3.37 (s, 3H), 2.46-2.33 (m, 2H), 0.99 (t, J=7.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ (ppm): 172.6, 171.5, 141.2, 136.5, 128.9, 128.7, 128.4, 128.01, 127.95, 127.0, 
60.2, 57.9, 51.8, 45.2, 38.8, 13.9. LRMS-ESI (m/z): [M+Na]+ calcd for C20H22O4Na, 349; 
found 349. 
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(2S,3R)-5-tert-Butoxy-5-oxo-2,3-diphenylpentanoic acid. The title compound was 
prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 mmol), 
(R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.81 mL, 2.46 M in hexanes, 1.99 
mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-tert-butyl 
cinnamate (102 mg, 0.500 mmol, 1.0 equiv) in THF (0.50 mL) at -90 °C. The reaction was 
quenched after 1 h and the product (0.121 g, 0.355 mmol, 71%) was obtained after 
purification by column chromatography on silica gel (4% methanol in dichloromethane). 
[α]D
23 +24.6o (c 0.50, MeOH). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.42 (d, J=6.7 Hz, 2H), 
7.35 (t, J=7.2 Hz, 2H), 7.34-7.27 (m, 1H), 7.27 (d, J=7.2 Hz, 2H), 7.22 (d, J=7.9 Hz, 2H), 
7.18 (t, J=6.8 Hz, 1H), 3.81-3.70 (m, 2H), 2.27 (d, J = 6.8 Hz, 2H), 1.12 (s, 9H). 13C NMR 
(125 MHz, CDCl3) δ (ppm):  177.2, 170.8, 140.7, 136.1, 128.9, 128.7, 128.22, 128.18, 
128.0, 127.0, 80.3, 57.8, 45.0, 39.8, 27.7. HRMS-ESI (m/z): [M+Na]+ calcd for C21H24O4Na, 













(2S,3R)-5-tert-Butyl-1-methyl 2,3-diphenylpentanedioate. The title compound was 
prepared using carboxylic acid (10.3 mg, 30.3 µmol), TMSCHN2 in hexane (0.10 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
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was removed and the residue was purified by column chromatography on silica gel (6% 
ethyl acetate in hexanes) to afford the product (9.1 mg, 25.7 µmol, 85% yield). Ee: 83% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=6.0 min; t2=7.2 min). [α]D
23 +17.1o (c 0.48, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.50-7.44 (m, 2H), 7.40-7.33 (m, 2H), 7.35-7.24 (m, 5H), 7.24-7.17 (m, 1H), 3.84-3.76 (m, 
2H), 3.37 (s, 3H), 2.36-2.23 (m, 2H), 1.13 (s, 9H). 13C NMR (125 MHz, CDCl3) δ (ppm):  
172.7, 170.8, 141.1, 136.6, 128.9, 128.6, 128.2, 127.9, 126.9, 80.3, 58.2, 51.7, 45.6, 39.9, 






n-BuLi, THF, -78 oC, 1 h
+









(2R,3R)-3-Cyclohexyl-5-methoxy-5-oxo-2-phenylpentanoic acid. The title compound 
was prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 
mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in hexanes, 
2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-methyl 3-
cyclohexylacrylate (84.1 mg, 0.500 mmol, 1.0 equiv) in THF (0.50 mL) at -78 °C. The 
reaction was quenched after 1 h and the product (0.113 g, 0.370 mmol, 74%) was obtained 
after purification by column chromatography on silica gel (4% methanol in 
dichloromethane). [α]D
23 +5.6o (c 1.4, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.37 (d, 
J=6.7 Hz, 2H), 7.33-7.21 (m, 3H), 3.60 (d, J=11.7 Hz, 1H), 3.38 (s, 3H), 2.81 (virt. dtd, 
J=11.7, 6.0, 2.9 Hz, 1H), 2.16 (dd, J=16.0, 6.2 Hz, 1H), 1.92 (dd, J=16.0, 5.7 Hz, 1H), 1.80-
1.71 (m, 3H), 1.70-1.62 (m, 2H), 1.58-1.48 (m, 1H), 1.32-1.05 (m, 4H), 1.02-0.92 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ (ppm): 179.1, 173.6, 136.4, 129.3, 128.6, 127.9, 54.7, 51.4, 
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42.8, 40.8, 33.0, 31.6, 27.1, 26.8, 26.6, 26.5. HRMS-ESI (m/z): [M+Na]+ calcd for 














(2R,3R)-Dimethyl 3-cyclohexyl-2,3-diphenylpentanedioate. The title compound was 
prepared using carboxylic acid (28.7 mg, 94.3 µmol), TMSCHN2 in hexane (0.20 mL, 1.76 
M, 0.352 mmol) in a mixture of benzene-MeOH (4:1, 2.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford the product (27.9 mg, 87.6 µmol, 93% yield). Ee: 96% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=6.7 min; t2=7.5 min). [α]D
23 +9.9o (c 1.3, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.39-7.33 (m, 2H), 7.31-7.27 (m, 2H), 7.6-7.20 (m, 1H), 3.65 (s, 3H), 3.60 (d, J=11.6 Hz, 
1H), 3.38 (s, 3H), 2.82 (virt. dtd, J=11.6, 6.0, 3.0 Hz, 1H), 2.15 (dd, J=16.0, 6.4 Hz, 1H), 
1.93 (dd, J=16.0, 5.7 Hz, 1H), 1.81-1.71 (m, 3H), 1.70-1.63 (m, 2H), 1.44 (virt. td, J=12.0, 
3.0 Hz, 1H), 1.32-1.04 (m, 4H), 1.01-0.91 (m, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
174.0, 173.6, 137.0, 129.2, 128.5, 127.6, 54.7, 51.9, 51.3, 43.1, 40.9, 33.1, 31.5, 27.2, 26.8, 
26.7, 26.5. LRMS-ESI (m/z): [M+Na]+ calcd for C19H26O4Na, 341; found 341. 
OH
O
n-BuLi, THF, -78 oC, 5 h
+
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(2S,3R)-5-Methoxy-3-(2-methoxyphenyl)-5-oxo-2-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl-3-(2-methoxyphenyl)acrylate (101 mg, 0.525 mmol, 1.05 equiv) in THF 
(0.50 mL) at -78 °C. The reaction was quenched after 5 h and the product (0.136 g, 0.413 
mmol, 83%) was obtained after purification by column chromatography on silica gel (25% 
ethyl acetate in hexanes then 4% methanol in dichloromethane). [α]D
23 +34.5o (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.43-7.37 (m, 2H), 7.36-7.26 (m, 3H), 7.16 (d, J=7.4 
Hz, 2H), 6.81 (d, J=7.4 Hz, 2H), 4.21 (d, J=11.2 Hz, 1H), 4.01 (ddd, J=11.2, 9.5, 4.6 Hz, 
1H), 3.80 (s, 3H), 3.36 (s, 3H), 2.59 (dd, J=15.6, 9.5 Hz, 1H), 2.36 (dd, J=15.5, 4.6 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ (ppm):  178.2, 172.5, 157.4, 136.4, 130.2, 128.9, 128.6, 
128.3, 128.2, 127.8, 120.4, 111.0, 55.3, 54.6, 51.2, 41.3, 36.1. HRMS-ESI (m/z): [M+Na]+ 












(2R,3R)-Dimethyl 3-(2-methoxyphenyl)-2-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (16.4 mg, 49.9 µmol), TMSCHN2 in hexane (0.10 mL, 
1.76 M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(9% ethyl acetate in hexanes) to afford the product (12.1 mg, 35.3 µmol, 71% yield). Ee: 
97% (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 
nm; t1=12.3 min; t2=30.9 min). [α]D
23 +32.2o (c 0.61, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
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(ppm): 7.49-7.44 (m, 2H), 7.39-7.33 (m, 2H), 7.31-7.27 (m, 1H), 7.23 (dd, J=7.9, 1.7 Hz, 
1H), 7.22-7.17 (m, 1H), 6.91-6.84 (m, 2H), 4.29 (d, J=11.4 Hz, 1H), 4.10-4.01 (m, 1H), 3.89 
(s, 3H), 3.37 (s, 3H), 3.37 (s, 3H), 2.64 (dd, J = 15.5, 9.5 Hz, 1H), 2.37 (dd, J = 15.5, 4.6 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ (ppm):  178.2, 172.5, 157.4, 136.4, 128.9, 128.7, 128.2, 
127.8, 120.4, 111.0, 55.3, 54.6, 51.2, 36.1. LRMS-ESI (m/z): [M+Na]+ calcd for 






n-BuLi, THF, -78 oC, 5 h
+











(2S,3R)-5-Methoxy-3-(4-methoxyphenyl)-5-oxo-2-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl 3-(4-methoxyphenyl)acrylate (101 mg, 0.525 mmol, 1.05 equiv) in THF 
(0.50 mL) at -78 °C. The reaction was quenched after 5 h and the product (0.121 g, 0.369 
mmol, 74%) was obtained after purification by column chromatography on silica gel (25% 
ethyl acetate in hexanes then 4% methanol in dichloromethane). [α]D
23 +24.4o (c 0.30, 
CHCl3). 1H NMR (600 MHz, DMSO-d6) δ (ppm): 7.47 (d, J=7.3 Hz, 2H), 7.39 (t, J=7.3 Hz, 
2H), 7.31 (t, J=7.3 Hz, 1H), 7.28 (d, J=8.5 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 3.89 (d, J=11.7 
Hz, 1H), 3.73 (s, 3H), 3.59 (virt. td, J = 11.3, 4.0 Hz, 1H), 3.30 (s, 3H), 2.41 (dd, J = 15.5, 
10.9 Hz, 1H), 2.13 (dd, J = 15.5, 4.0 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ (ppm): 
173.2, 171.6, 157.9, 137.6, 133.8, 129.2, 128.7, 128.4, 127.6, 113.4, 56.7, 54.9, 51.1, 44.2, 
38.4. HRMS-ESI (m/z): [M+Na]+ calcd for C19H20O5Na, 351.1208; found, 351.1198. 











OMe OMe  
(2R,3R)-Dimethyl 3-(4-methoxyphenyl)-2-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (7.2 mg, 21.9 µmol), TMSCHN2 in hexane (0.10 mL, 
1.76 M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(9% ethyl acetate in hexanes) to afford the product (7.1 mg, 20.7 µmol, 95% yield). Ee: 97% 
(Chiralcel® AD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=59.8 min; t2=74.5 min). [α]D
23 +27.2o (c 0.34, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.49-7.44 (m, 2H), 7.39-7.34 (m, 2H), 7.33-7.28 (m, 0H), 7.23 (d, J=8.7 Hz, 2H), 
6.84 (d, J=8.7 Hz, 2H), 3.89-3.78 (m, 2H), 3.79 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H), 2.43-2.31 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ (ppm):  172.7, 172.1, 158.5, 136.6, 133.1, 128.9, 
128.9, 128.7, 127.9, 113.8, 58.0, 55.1, 51.8, 51.4, 44.4, 38.8. LRMS-ESI (m/z): [M+Na]+ 
calcd for C20H22O5Na, 365; found, 365. 
OH
O
n-BuLi, THF, -78 oC, 0.5 h
+











(2S,3R)-5-Methoxy-3-(3-nitrophenyl)-5-oxo-2-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 M in 
hexanes, 2.01 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
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methyl (E)-methyl 3-(3-nitrophenyl)acrylate (0.114 g, 0.552 mmol, 1.1 equiv) in THF (0.50 
mL) at -78 °C. The reaction was quenched after 0.5 h and product (46.1 mg, 0.114 mmol, 
27%) was obtained after purification by column chromatography on silica gel (35% diethyl 
ether in hexanes with 0.5% AcOH). [α]D
23 +35.0° (c 0.60, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ (ppm): 8.16 (t, J=1.8 Hz, 1H), 8.08-8.05 (m, 1H), 7.65-7.62 (m, 1H), 7.42-7.33 
(m, 6H), 3.93 (dt, J=11.8, 7.2 Hz, 1H), 3.85 (d, J=11.8 Hz, 1H), 3.41 (s, 3H), 2.42 (d, J=7.2 
Hz, 2H). 13C NMR (151 MHz, CDCl3) δ (ppm): 176.4, 171.6, 148.5, 143.6, 135.5, 135.0, 
129.6, 129.4, 128.8, 128.7, 123.0, 122.6, 57.2, 51.9, 44.5, 38.3. HRMS-ESI (m/z): [M+Na]+ 












(3R, 4S)-Methyl 5-hydroxy-3-(3-nitrophenyl)-4-phenylpentanoate. Methyl 
chloroformate (9 µL, 0.114 mol, 1.4 equiv) was added dropwise to a solution of carboxylic 
acid (28.0 mg, 0.0816 mmol) in THF (0.82 mL) and Et3N (34 µL, 0.244 mmol, 3.0 equiv) at 
0 °C. The resultant mixture was stirred at the same temperature for 0.5 h. NaBH4 (15.0 mg, 
0.408 mmol, 5.0 equiv) was added to the crude reaction followed by MeOH (1.0 mL) at 0 
˚C. The reaction was stirred at the same temperature for 20 min. The solvent was removed 
by rotary evaporation and the crude reaction mixture was quenched with saturate aqueous 
NH4Cl and extracted with ethyl acetate. The combined organic phase was washed with 
brine, dried over Na2SO4, concentrated, and the residue was purified by column 
chromatography on silica gel (70% diethyl ether in hexanes) to afford the product (8.0 mg, 
24.3 µmol, 42% yield). Ee: 75% (Chiralcel® OD-H; 10% i-PrOH in hexanes; flow rate = 1.0 
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mL/min; detection at 215 nm; t1=25.1 min; t2=32.9 min). [α]D
19 -0.59° (c 0.60, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ (ppm): 8.18 (s, 1H), 8.13 (d, J=8.2Hz, 1H), 7.66 (d, J=7.8 Hz, 
1H), 7.52 (t, J=7.9 Hz, 1H), 7.44-7.38 (m, 2H), 7.36-7.30 (m, 3H), 3.66 (virt. dt, J=11.0, 7.5 
Hz, 1H), 3.57 (dd, J=11.1, 7.8 Hz, 1H), 3.47 (dd, J=11.1, 4.1 Hz, 1H), 3.42 (s, 3H), 3.04 
(ddd, J=11.5, 7.8, 4.1 Hz, 1H), 2.54-2.47 (m, 2H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
171.9, 144.5, 139.5, 134.6, 129.6, 129.2, 128.6, 127.8, 122.6, 122.2, 64.9, 53.5, 51.6, 43.6, 
39.2. LRMS-ESI (m/z): [M+Na]+ calcd for C18H19NO5Na, 352; found, 352. 
OH
O
n-BuLi, THF, -78 oC, 6 h
+












(2S,3R)-5-Methoxy-3-(1-methyl-1H-pyrrol-2-yl)-5-oxo-2-phenylpentanoic acid. The 
title compound was prepared according to general procedure I using phenylacetic acid (68.1 
mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl 3-(1-methyl-1H-pyrrol-2-yl)acrylate (86.7 mg, 0.525 mmol, 1.05 equiv) 
in THF (0.50 mL) at -78 °C. The reaction was quenched after 6 h and product (86.9 mg, 
0.288 mmol, 58%) was obtained after purification by column chromatography on silica gel 
(25% ethyl acetate in hexanes then 4% methanol in dichloromethane). [α]D
23 +48.4° (c 1.2, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.46-7.26 (m, 5H), 6.41 (dd, J=2.7, 1.6 Hz, 
1H), 6.03 (dd, J=3.6, 2.7 Hz, 1H), 5.99 (dd, J=3.6, 1.6 Hz, 1H), 3.86 (ddd, J=11.2, 7.8, 5.9 
Hz, 1H), 3.80 (d, J=11.2 Hz, 1H), 3.63 (s, 3H), 3.43 (s, 3H), 2.41-2.28 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ (ppm): 177.8, 172.2, 136.2, 133.0, 128.9, 128.5, 128.0, 121.4, 106.7, 
  72 
104.9, 57.8, 51.5, 39.0, 35.2, 33.6. HRMS-ESI (m/z): [M+Na]+ calcd for C17H19NO4Na, 














(2S,3R)-Dimethyl 3-(1-methyl-1H-pyrrol-2-yl)-2-phenylpentanedioate. The title 
compound was prepared using carboxylic acid 5d (18.0 mg, 59.7 µmol), TMSCHN2 in 
hexane (0.15 mL, 1.76 M, 0.264 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 
°C for 0.5 h. The solvent was removed and the residue was purified by column 
chromatography on silica gel (9% ethyl acetate in hexanes) to afford product (15.9 mg, 50.4 
µmol, 95% yield). Ee: 86% (Chiralcel® AD-H; 1% i-PrOH in hexanes; flow rate = 1.0 
mL/min; detection at 215 nm; t1=13.9 min; t2=16.1 min). [α]D
23 +53.0o (c 0.76, CHCl3). 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.42 (d, J = 6.9 Hz, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.30 (t, 
J = 7.2 Hz, 1H), 6.46 (dd, J = 2.7, 1.8 Hz, 1H), 6.04 (virt. t, J = 3.1 Hz, 1H), 6.00 (dd, J = 
3.6, 1.8 Hz, 1H), 3.91 (ddd, J = 11.5, 8.5, 5.6 Hz, 1H), 3.81 (d, J = 11.5 Hz, 1H), 3.74 (s, 
3H), 3.44 (s, 3H), 3.44 (s, 3H), 2.42-2.32 (m, 2H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
173.0, 172.2, 136.7, 133.3, 128.9, 128.5, 128.0, 121.3, 106.7, 104.8, 57.9, 52.0, 51.5, 39.0, 
35.7, 33.8. LRMS-ESI (m/z): [M+Na]+ calcd for C18H21NO4Na, 338; found, 338. 
OH
O
n-BuLi, THF, -90 oC, 1 h
+
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(2S,3R)-3-(Benzofuran-2-yl)-5-methoxy-5-oxo-2-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl 3-(benzofuran-2-yl)acrylate (0.106 g, 0.525 mmol, 1.05 equiv) in THF 
(0.50 mL) at -90 °C. The reaction was quenched after 1 h and product (0.150 g, 0.443 mmol, 
89%) was obtained after purification by column chromatography on silica gel (25% ethyl 
acetate in hexanes then 4% methanol in dichloromethane). [α]D
23 +54.9° (c 0.50, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ (ppm): 8.70 (brs, 1 H), 7.42 (d, J=7.3 Hz, 1H), 7.38-7.09 (m, 
8H), 6.50 (s, 1H), 4.20-4.00 (m, 2H), 3.45 (s, 3H), 2.56-2.37 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 177.7, 171.9, 157.2, 154.6, 135.3, 128.9, 128.8, 128.3, 128.1, 123.7, 122.6, 
120.8, 111.0, 103.9, 54.6, 51.7, 38.4, 35.5. HRMS-ESI (m/z): [M+Na]+ calcd for 











(2S,3R)-3-(Benzofuran-2-yl)-2-phenylpentane-1,5-diol. To a solution of carboxylic 
acid (13.9 mg, 39.4 µmol) in THF (2 mL) was added lithium aluminum hydride (LAH, 20.1 
mg, 0.529 mmol) at 0 ˚C. After stirring for 1 h at the same temperature, the reaction was 
carefully quenched by adding 20 µL of water. After stirring for 5 min, 20 µL of aqueous 
NaOH (15% w/w) solution was added and the mixture was stirred for 5 min. Water (60 µL) 
was added and the mixture was stirred for additional 5 min. The white solid was filtered off, 
the filtrate was concentrated and the residue was purified by column chromatography on 
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silica gel (50% of ethyl acetate in hexanes) to afford product (10.7 mg, 36.1 µmol, 92%). 
Ee: 73% (Chiralcel® OD-H; 10% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 
215 nm; t1=19.0 min; t2=34.0 min). [α]D
23 +15.7o (c 0.51, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ (ppm): 7.55-7.49 (m, 1H), 7.49-7.43 (m, 1H), 7.42-7.34 (m, 2H), 7.34-7.27 (m, 
3H), 7.30-7.18 (m, 2H), 6.57 (d, J=0.9 Hz, 1H), 3.68 (dd, J=11.2, 7.7 Hz, 1H), 3.63 (dd, 
J=11.2, 4.3 Hz, 1H), 3.49 (ddd, J=10.8, 6.6, 4.2 Hz, 1H), 3.45-3.31 (m, 2H), 3.23 (ddd, 
J=10.7, 7.7, 4.3 Hz, 1H), 1.85 (dddd, J=13.9, 11.3, 5.6, 4.3 Hz, 1H), 1.70 (dddd, J=13.9, 8.9, 
6.6, 3.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 158.7, 154.8, 140.6, 129.0, 128.6, 
128.3, 127.3, 123.6, 122.8, 120.5, 111.0, 104.4, 65.6, 60.6, 52.1, 38.2, 34.7. LRMS-ESI 
(m/z): [M+Na]+ calcd for C19H20O3Na, 319; found, 319. 
OH
O
n-BuLi, THF, -90 oC, 0.5 h
+














phenylpentanoic acid. The title compound was prepared according to general procedure I 
using phenylacetic acid (68.1 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), 
n-BuLi (0.82 mL, 2.44 M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by 
addition of a solution of methyl (E)-tert-butyl 3-(3-methoxy-3-oxoprop-1-enyl)-1H-indole-
1-carboxylate (0.158 g, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -90 °C. The reaction 
was quenched after 0.5 h and product (0.180 g, 0.411 mmol, 82%) was obtained after 
purification by column chromatography on silica gel (25% ethyl acetate in hexanes then 4% 
methanol in dichloromethane). [α]D
23 +41.2° (c 1.3, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 8.10 (brs, 1H), 7.65 (d, J=7.8 Hz, 1H), 7.46 (s, 1H), 7.42-7.36 (m, 2H), 7.38-7.25 (m, 
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4H), 7.25-7.18 (m, 1H), 4.16 (ddd, J=10.9, 8.7, 4.8 Hz, 1H), 4.06 (d, J=10.9 Hz, 1H), 3.36 
(s, 3H), 2.50 (dd, J=15.7, 4.8 Hz, 1H), 2.43 (dd, J=15.7, 8.7 Hz, 1H), 1.65 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 177.5, 171.9, 149.5, 135.8, 129.4, 128.9, 128.8, 128.1, 124.4, 
123.1, 122.4, 121.0, 119.3, 115.2, 83.6, 56.1, 51.4, 37.8, 35.3, 28.2. HRMS-ESI (m/z): 

















The title compound was prepared using carboxylic acid (15.9 mg, 36.3 µmol), TMSCHN2 in 
hexane (0.1 mL, 1.76 M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C 
for 0.5 h. The solvent was removed and the residue was purified by column chromatography 
on silica gel (9% ethyl acetate in hexanes) to afford product (14.2 mg, 31.5 µmol, 87% 
yield). Ee: 97% (Chiralcel® AD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; 
detection at 215 nm; t1=24.4 min; t2=28.6 min). [α]D
23 +41.3° (c 0.71, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 8.11 (brs, 1H), 7.71 (d, J=7.8 Hz, 1H), 7.53-7.45 (m, 3H), 7.40-7.35 
(m, 2H), 7.35-7.29 (m, 2H), 7.28-7.25 (m, 1H), 4.21 (ddd, J=11.4, 8.1, 5.5 Hz, 1H), 4.09 (d, 
J=11.4 Hz, 1H), 3.41 (s, 3H), 3.38 (s, 3H), 2.51 (dd, J=15.9, 5.5 Hz, 1H), 2.47 (dd, J=15.9, 
8.1 Hz, 1H), 1.68 (s, 9H). LRMS-ESI (m/z): [M+Na]+ calcd for C26H29NO6Na, 474; found, 
474. 
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n-BuLi, THF, -90 oC, 0.5 h
+














(2S,3R)-3-(Furan-2-yl)-5-methoxy-5-oxo-2-phenylpentanoic acid. The title compound 
was prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 
mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.81 mL, 2.47 M in hexanes, 
2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of methyl (E)-
methyl 3-(furan-2-yl)acrylate (79.9 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -90 
°C. The reaction was quenched after 0.5 h and product (0.120 g, 0.415 mmol, 83%) was 
obtained after purification by column chromatography on silica gel (2-5% methanol in 
dichloromethane). [α]D
23 +41.4o (c 0.96, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.38-
7.28 (m, 6H), 6.23 (dd, J=3.2, 1.8 Hz, 1H), 6.13 (d, J=3.2 Hz, 1H), 4.01 (ddd, J=11.1, 9.2, 
4.3 Hz, 1H), 3.95 (d, J=11.1 Hz, 1H), 3.49 (s, 3H), 2.44 (dd, J=15.8, 9.2 Hz, 1H), 2.37 (dd, 
J=15.8, 4.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 178.0, 171.8, 153.9, 141.7, 
135.3, 128.9, 128.7, 128.2, 110.2, 106.9, 55.0, 51.6, 38.2, 35.9. HRMS-ESI (m/z): [M+Na]+ 













0 oC, 0.5 h
86% yield
 
(2S,3R)-Dimethyl 3-(furan-2-yl)-2-phenylpentanedioate. The title compound was 
prepared using carboxylic acid (26.7 mg, 92.7 µmol), TMSCHN2 in hexane (0.2 mL, 1.76 
M, 0.352 mmol) in a mixture of benzene-MeOH (4:1, 2.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
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ethyl acetate in hexanes) to afford product (24.2 mg, 80.0 µmol, 86% yield). Ee: 85% 
(Chiralcel® OJ-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=22.9 min; t2=30.0 min). [α]D
23 +41.7o (c 1.2, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.40-7.37 (m, 2H), 7.37-7.32 (m, 3H), 7.32-7.27 (m, 1H), 6.27 (dd, J=3.2, 1.8 Hz, 1H), 6.15 
(d, J=3.2 Hz, 1H), 4.04 (ddd, J=11.3, 9.6, 4.4 Hz, 1H), 3.96 (d, J=11.3 Hz, 1H), 3.54 (s, 
3H), 3.49 (s, 3H), 2.46 (dd, J=15.7, 9.6 Hz, 1H), 2.37 (dd, J=15.7, 4.4 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 172.7, 171.8, 154.3, 141.7, 135.9, 128.9, 128.7, 128.0, 110.2, 




n-BuLi, THF, -90 oC, 0.5 h











(2S,3R)-3-(3,5-Dimethylisoxazol-4-yl)-5-methoxy-5-oxo-2-phenylpentanoic acid. The 
title compound was prepared according to general procedure I using phenylacetic acid (68.1 
mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 M in 
hexanes, 2.01 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl 3-(3,5-dimethylisoxazol-4-yl)acrylate (0.100 g, 0.552 mmol, 1.1 equiv) 
in THF (0.50 mL) at -90 °C. The reaction was quenched after 0.5 h and product (86.0 mg, 
0.271 mmol, 54%) was obtained after purification by column chromatography on silica gel 
(50% diethyl ether in hexanes with 0.5% AcOH). [α]D
23 +2.2° (c 1.0, CHCl3). 1H NMR (400 
MHz, CDCl3) δ (ppm):  7.43 (m, 5H), 3.78 (d, J=11.8 Hz, 1H), 3.71 (dt, J=11.8, 3.7 Hz, 
1H), 3.46 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H), 2.42-2.24 (m, 2H). 13C NMR (100 MHz, 
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CDCl3) δ (ppm): 176.0, 171.8, 171.7, 171.6, 135.5, 129.2, 128.5, 128.4, 112.8, 55.2, 51.7, 













(2S,3R)-Methyl 3-(3,5-dimethylisoxazol-4-yl)-5-hydoxy-4-phenylpentanoate. Methyl 
chloroformate (15 µL, 0.176 mmol, 1.4 equiv) was added dropwise to a solution of 
carboxylic acid (40.0 mg, 0.126 mmol) in THF (0.42 mL) and Et3N (53 µL, 0.378 mmol, 3.0 
equiv) at 0 °C. The resultant mixture was stirred at the same temperature for 0.5 h. Then 
NaBH4 (24.0 mg, 0.630 mmol, 5.0 equiv) was added followed by MeOH (1.0 mL) at 0 °C. 
The reaction was stirred at the same temperature for 20 min. The reaction mixture was 
quenched with saturate aqueous NH4Cl and extracted with ethyl acetate. The combined 
organic phase was washed with brine, dried over Na2SO4, concentrated, and the residue was 
purified by column chromatography on silica gel (70% diethyl ether in hexanes) to afford 
the product (23.0 mg, 75.6 µmol, 60% yield). Ee: 86% (Chiralcel® OD-H; 10% i-PrOH in 
hexanes; flow rate = 1.0 mL/min; detection at 215 nm; t1=21.2 min; t2=27.1 min). [α]D
24 
+30.2° (c 0.5, CHCl3). 1H NMR (600 MHz, DMSO) δ (ppm): 7.39-7.27 (m, 5H), 3.52-3.46 
(m, 2H), 3.43 (s, 3H), 3.35-3.32 (m, 1H), 2.98-2.93 (m, 1H), 2.47 (dd, J = 15.6, 11.8 Hz, 
1H), 2.31 (s, 3H), 2.30-2.26 (m, 1H), 2.21 (s, 3H). 13C NMR (126 MHz, DMSO) δ (ppm): 
172.8, 165.9, 159.6, 142.8, 129.6, 129.1, 127.5, 113.8, 63.8, 52.1, 51.3, 37.3, 33.6, 12.0, 
11.4.  LRMS-ESI (m/z): [M+Na]+ calcd for C17H21NO4Na, 326.14; found, 326.14. 
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(2S,3R)-5-Methoxy-5-oxo-2-phenyl-3-(thiazol-2-yl)pentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 M in 
hexanes, 2.01 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
methyl (E)-methyl 3-(thiazol-2-yl)acrylate (93.0 mg, 0.552 mmol, 1.1 equiv) in THF (0.50 
mL) at -90 °C. The reaction was quenched after 0.5 h and product (0.111 g, 0.361 mmol, 
72% yield) was obtained after purification by column chromatography on silica gel (50% 
ethyl acetate in hexanes with 0.5% AcOH). [α]D
21 +33.5° (c 1.0, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ (ppm): 7.66 (d, J=3.3 Hz, 1H), 7.37-7.30 (m, 5H), 7.16 (d, J=3.3 Hz, 1H), 4.32 
(virt. dt, J=10.9, 3.8 Hz, 1H), 4.20 (d, J=11.0 Hz, 1H), 3.48 (s, 3H), 2.63 (dd, J=16.5, 10.1 
Hz, 1H), 2.43 (dd, J=16.5, 3.8 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ (ppm): 176.0, 171.7, 
171.0, 142.1, 135.8, 129.3, 128.9, 128.5, 119.2, 56.2, 51.9, 42.0, 37.9. HRMS-ESI (m/z): 







0 oC, 0.5 h
 
(2S,3R)-Dimethyl 2-phenyl-3-(thiazol-2-yl)pentanedioate. The title compound was 
prepared using carboxylic acid (10.0 mg, 32.7 µmol), TMSCHN2 in hexane (0.1 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (30-40% 
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diethyl ether in hexanes) to afford product (10.3 mg, 32.4 µmol, 99% yield). Ee: 69% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=24.6 min; t2=28.3 min). [α]D
22 +63.4° (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ 
(ppm): 7.72 (d, J=2.8 Hz, 1H), 7.44-7.30 (M, 5H), 7.23 (d, J=2.8 Hz, 1H), 4.38 (virt. dt, 
J=10.9, 3.6 Hz, 1H), 4.20 (d, J=11.5 Hz, 1H), 3.52 (s, 3H), 3.50 (s, 3H), 2.67 (dd, J = 16.4, 
10.2 Hz, 1H), 2.44 (dd, J=16.4, 3.6 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ (ppm): 172.8, 
171.8, 170.5, 142.4, 136.2, 129.3, 128.8, 128.4, 119.0, 56.3, 52.4, 51.9, 42.3, 37.9. LRMS-
ESI (m/z): [M+Na]+ calcd for C16H17NO4SNa, 342; found, 342. 
OH
O
n-BuLi, THF, -90 oC, 0.5 h
+












(2R,3S)-5-Methoxy-3-methyl-5-oxo-2-phenylpentanoic acid. The title compound was 
prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 mmol), 
(R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 M in hexanes, 2.01 
mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-methyl 
crotonate (53 µL, 50.0 mg, 0.500 mmol, 1.0 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 0.5 h and product (0.101 g, 0.429 mmol, 86% yield) was 
obtained after purification by column chromatography on silica gel (5% methanol in 
dichloromethane). [α]D
23 -23.1° (c 1.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.36-
7.27 (m, 5H), 3.58 (s, 3H), 3.39 (d, J=10.7 Hz, 1H), 2.79-2.66 (m, 1H), 2.17 (dd, J=15.5, 4.0 
Hz, 1H), 1.92 (dd, J=15.5, 9.3 Hz, 1H), 1.13 (d, J=6.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 179.1, 172.8, 136.6, 128.8, 128.7, 127.9, 57.7, 51.4, 38.3, 33.4, 18.5. 
HRMS-ESI (m/z): [M+Na]+ calcd for C13H16O4Na, 259.0946; found, 259.0939. 














(2R,3S)-Dimethyl 3-methyl-2-phenylpentanedioate. The title compound was prepared 
using carboxylic acid (9.1 mg, 38.6 µmol), TMSCHN2 in hexane (0.1 mL, 1.76 M, 0.176 
mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent was 
removed and the residue was purified by column chromatography on silica gel (9% ethyl 
acetate in hexanes) to afford product (8.0 mg, 32.0 µmol, 83% yield). Ee: 52% (Chiralcel® 
OJ-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 210 nm; anti: t1=18.9 
min; t2=22.7 min; syn: t1=29.4 min; t2=61.1 min). [α]D
23 -26.9° (c 0.24, CHCl3). 1H NMR 
(500 MHz, CDCl3) δ (ppm): 7.38-7.30 (m, 4H), 7.28-7.23 (m, 1H), 3.66 (s, 3H), 3.58 (s, 
3H), 3.39 (d, J=10.8 Hz, 1H), 2.77-2.68 (m, 1H), 2.17 (dd, J=15.5, 4.0 Hz, 1H), 1.91 (dd, 
J=15.5, 9.4 Hz, 1H), 1.08 (d, J=6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.7, 
172.8, 137.2, 128.7, 128.6, 127.7, 57.7, 51.9, 51.4, 38.4, 33.8, 18.6. LRMS-ESI (m/z): 
[M+Na]+ calcd for C14H18O4Na, 273; found, 273. 
OH
O
n-BuLi, THF, -90 oC, 0.5 h
+












(2R,3S)-5-tert-Butoxy-3-methyl-5-oxo-2-phenylpentanoic acid. The title compound 
was prepared according to general procedure I using phenylacetic acid (0.136 g, 0.999 
mmol), (R)-1TA (0.462 g, 1.03 mmol, 1.03 equiv), n-BuLi (1.64 mL, 2.44 M in hexanes, 
2.00 mmol, 4.0 equiv) in THF (10 mL) followed by addition of a solution of (E)-tert-butyl 
crotonate (0.171 g, 1.20 mmol, 1.2 equiv) in THF (1.0 mL) at -90 °C. The reaction was 
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quenched after 0.5 h and product (0.203 g, 0.730 mmol, 73% yield) was obtained after 
recrystallization from ethyl acetate and hexanes. [α]D
23 -31.7o (c 1.1, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 7.38-7.24 (m, 5H), 3.38 (d, J=10.8 Hz, 1H), 2.72-2.61 (m, 1H), 2.09 
(dd, J=15.1, 3.4 Hz, 1H), 1.80 (dd, J=15.1, 9.7 Hz, 1H), 1.40 (s, 3H), 1.13 (d, J=6.4 Hz, 
9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 179.4, 171.8, 136.7, 128.7, 128.6, 127.7, 80.4, 















(2R,3S)-5-tert-Butyl 1-methyl-3-methyl-2-phenylpentanedioate. The title compound 
was prepared using carboxylic acid 5k (23.5 mg, 84.4 µmol), TMSCHN2 in hexane (0.1 mL, 
1.76 M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(9% ethyl acetate in hexanes) to afford product (22.8 mg, 78.0 µmol, 92% yield). Ee: 78% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 0.5 mL/min; detection at 215 nm; 
t1=9.8 min; t2=10.4 min). [α]D
23 -41.8o (c 1.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.35-7.29 (m, 4H), 7.28-7.24 (m, 1H), 3.65 (s, 3H), 3.39 (d, J=10.7 Hz, 1H), 2.72-2.62 (m, 
1H), 2.08 (dd, J=15.1, 3.8 Hz, 1H), 1.79 (dd, J=15.1, 9.6 Hz, 1H), 1.40 (s, 9H), 1.08 (d, 
J=6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.8, 171.8, 137.4, 128.7, 128.6, 
127.5, 80.3, 57.6, 51.9, 39.8, 33.9, 28.1, 18.2. LRMS-ESI (m/z): [M+Na]+ calcd for 
C17H24O4Na, 315; found, 315. 
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(2S,3R)-5-tert-Butoxy-3-ethyl-5-oxo-2-phenylpentanoic acid. The title compound was 
prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 mmol), 
(S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in hexanes, 2.00 
mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-tert-butyl pent-
2-enoate (82.0 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -78 °C. The reaction was 
quenched after 5 h and product (0.105 g, 0.359 mmol, 72% yield) was obtained after 
purification by column chromatography on silica gel (20% ethyl acetate in hexanes, then 5% 
methanol in dichloromethane). [α]D
23 +29.1° (c 1.6, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.37-7.22 (m, 5H), 3.59 (d, J=10.7 Hz, 1H), 2.61-2.50 (m, 1H), 2.10 (dd, J=15.6, 4.2 
Hz, 1H), 1.90 (dd, J=15.6, 7.9 Hz, 1H), 1.64-1.54 (m, 1H), 1.53-1.46 (m, 1H), 1.38 (s, 9H), 
0.95 (t, J=7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 179.6, 171.9, 137.0, 128.9, 
128.7, 127.6, 80.3, 55.4, 39.2, 35.8, 28.0, 24.7, 10.4. HRMS-ESI (m/z): [M+Na]+ calcd for 








(2S,3R)-3-Ethyl-2-phenylpentane-1,5-diol. The title compound was prepared using 
carboxylic acid (11.2 mg, 36.6 µmol), and lithium aluminum hydride (20.0 mg, 0.526 mmol) 
in THF (2.0 mL) at 0 °C. The reaction was quenched after 1 h, and product (6.8 mg, 32.6 
µmol, 89% yield) was obtained after purification by column chromatography on silica gel 
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(66% ethyl acetate in hexanes). Ee: 84% (Chiralcel® OJ-H; 10% i-PrOH in hexanes; flow 
rate = 1.0 mL/min; detection at 215 nm; t1=11.7 min; t2=14.0 min). [α]D
23 +9.9° (c 0.28, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.36-7.29 (m, 2H), 7.28-7.18 (m, 3H), 3.94 
(dd, J=11.0, 5.9 Hz, 1H), 3.83 (dd, J=11.0, 8.4 Hz, 1H), 3.62 (ddd, J=10.3, 7.4, 5.0 Hz, 1H), 
3.51 (ddd, J=10.3, 7.8, 6.7 Hz, 1H), 2.87 (virt. td, J=8.2, 5.8 Hz, 1H), 1.92-1.80 (m, 1H), 
1.61-1.28 (m, 6H), 0.95 (t, J=7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 141.1, 
128.8, 128.6, 126.8, 64.7, 61.3, 50.6, 37.3, 33.3, 23.5, 10.4. LRMS-ESI (m/z): [M+Na]+ 






n-BuLi, THF, -78 oC, 5 h
+









(2R,3R)-3-Isopropyl-5-methoxy-5-oxo-2-phenylpentanoic acid. The title compound 
was prepared according to general procedure I using phenylacetic acid (68.1 mg, 0.500 
mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in hexanes, 
2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-methyl-4-
methylpent-2-enoate (67.3 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -78 °C. The 
reaction was quenched after 5 h and product (0.107 g, 0.400 mmol, 81% yield) was obtained 
after purification by column chromatography on silica gel (10% ethyl acetate in hexanes, 
then 5% methanol in dichloromethane). [α]D
23 +8.2° (c 1.0, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ (ppm): 7.40-7.35 (m, 2H), 7.32-7.23 (m, 3H), 3.52 (d, J=11.7 Hz, 1H), 3.36 (s, 
3H), 2.91-2.77 (m, 1H), 2.13 (dd, J=15.9, 5.8 Hz, 1H), 2.00- 1.93 (m, 1H), 1.89 (dd, J = 
15.9, 6.0 Hz, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.90 (d, J=7.0 Hz, 3H). 13C NMR (126 MHz, 
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CDCl3) δ (ppm): 178.9, 173.6, 136.3, 129.3, 128.6, 127.9, 55.5, 51.4, 43.1, 31.9, 29.7, 21.2, 














(2R,3R)-Dimethyl 3-isopropyl-2-phenylpentanedioate. The title compound was 
prepared using carboxylic acid (14.3 mg, 54.1 µmol), TMSCHN2 in hexane (0.1 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford product (12.2 mg, 43.8 µmol, 81% yield). Ee: 90% 
(Chiralcel® AD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=10.3 min; t2=13.2 min). [α]D
23 +7.9 (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.40-7.34 (m, 2H), 7.33-7.25 (m, 2H), 7.28-7.21 (m, 1H), 3.65 (s, 3H), 3.53 (d, J=11.6 Hz, 
1H), 3.37 (s, 3H), 2.90-2.82 (m, 1H), 2.12 (dd, J=15.9, 6.0 Hz, 1H), 1.90 (dd, J=15.9, 5.9 
Hz, 1H), 1.88-1.83 (m, 1H), 0.98 (d, J=6.9 Hz, 3H), 0.89 (d, J=7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ (ppm): 173.9, 173.6, 136.9, 129.2, 128.5, 127.7, 55.4, 52.0, 51.4, 43.4, 32.2, 






n-BuLi, THF, -78 oC, 5 h
+









(2S,3R)-3-(2-tert-Butoxy-2-oxoethyl)-5-methyl-2-phenylhexanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
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hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-
tert-butyl 5-methylhex-2-enoate (96.7 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -78 
°C. The reaction was quenched after 5 h and product (0.116 g, 0.362 mmol, 72% yield) was 
obtained after purification by column chromatography on silica gel (10% ethyl acetate in 
hexanes, then 4% methanol in dichloromethane). [α]D
23 +26.8° (c 1.5, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 7.37-7.34 (m, 2H), 7.33-7.29 (m, 2H), 7.30-7.23 (m, 1H), 3.69 (d, 
J=10.1 Hz, 1H), 2.67-2.56 (m, 1H), 2.21 (dd, J=15.7, 4.6 Hz, 1H), 1.89 (dd, J=15.7, 5.8 Hz, 
1H), 1.75-1.65 (m, 1H), 1.45-1.36 (m, 1 H), 1.39 (s, 9H), 1.28-1.17 (m, 1H), 0.92 (d, J=6.6 
Hz, 3H), 0.90 (d, J=6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm):  179.6, 171.7, 136.8, 
129.1, 128.6, 127.6, 80.3, 55.8, 41.8, 36.3, 36.1, 28.0, 25.4, 23.7, 21.5. HRMS-ESI (m/z): 














(2S,3R)-5-tert-Butyl 1-methyl-3-isobutyl-2-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (14.7 mg, 45.9 µmol), TMSCHN2 in hexane (0.14 mL, 
1.76 M, 0.246 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(9% ethyl acetate in hexanes) to afford product (14.1 mg, 42.2 µmol, 92% yield). Ee: 90% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 0.5 mL/min; detection at 210 nm; 
t1=7.6 min; t2=8.8 min). [α]D
23 +7.9 (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.37-7.34 (m, 2H), 7.34-7.27 (m, 2H), 7.28-7.23 (m, 1H), 3.69 (d, J=10.2 Hz, 1H), 3.65 (s, 
3H), 2.67-2.54 (m, 1H), 2.19 (dd, J=15.6, 4.7 Hz, 1H), 1.88 (dd, J=15.6, 5.8 Hz, 1H), 1.72-
1.63 (m, 1H), 1.43-1.35 (m, 1 H), 1.39 (s, 9H), 1.15 (ddd, J=13.6, 9.4, 4.1 Hz, 1H), 0.91 (d, 
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J=6.3 Hz, 3H), 0.90 (d, J=6.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 174.2, 171.7, 
137.4, 128.9, 128.5, 127.4, 80.2, 55.8, 51.8, 41.9, 36.4, 36.4, 28.1, 25.4, 23.8, 21.6. LRMS-






n-BuLi, THF, -78 oC, 0.5 h
+









(2S,3S)-5-tert-Butoxy-3-cyclopropyl-5-oxo-2-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-
tert-butyl-3-cyclopropylacrylate (84.1 mg, 0.500 mmol, 1.0 equiv) in THF (0.50 mL) at -78 
°C. The reaction was quenched after 0.5 h and product (0.119 g, 0.391 mmol, 78% yield) 
was obtained after purification by column chromatography on silica gel (4% methanol in 
dichloromethane). [α]D
23 +4.1° (c 0.60, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.39-
7.31 (m, 2H), 7.34-7.22 (m, 3H), 3.73 (d, J=10.1 Hz, 1H), 2.22 (dd, J=15.0, 3.9 Hz, 1H), 
2.01 (dd, J=15.0, 8.1 Hz, 1H), 1.96-1.82 (m, 1H), 1.40 (s, 9H), 0.87-0.77 (m, 1H), 0.53-0.44 
(m, 2H), 0.37-0.32 (m, 1H), 0.31-0.22 (m, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
179.7, 171.9, 136.7, 128.9, 128.5, 127.6, 80.3, 56.6, 43.4, 38.9, 28.0, 15.2, 5.1, 3.5. HRMS-









  88 
(2S,3S)-3-Cyclopropyl-2-phenylpentane diol. The title compound was prepared using 
carboxylic acid (29.1 mg, 95.7 µmol), and lithium aluminum hydride (36.4 mg, 0.957 mmol) 
in THF (3.0 mL) at 0 °C. The reaction was quenched after 1 h, and product (11.9 mg, 54.0 
µmol, 56% yield) was obtained after purification by column chromatography on silica gel 
(55% ethyl acetate in hexanes). Ee: 85% (Chiralcel® OJ-H; 5% i-PrOH in hexanes; flow 
rate = 1.0 mL/min; detection at 215 nm; t1=15.8 min; t2=22.4 min). [α]D
23 +7.7° (c 0.55, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.35-7.28 (m, 2H), 7.27-7.20 (m, 3H), 4.11 
(dd, J=11.0, 6.0 Hz, 1H), 3.91 (dd, J=11.0, 8.3 Hz, 1H), 3.78-3.58 (m, 2H), 2.96 (td, J=8.0, 
6.0 Hz, 1H), 1.72-1.65 (m, 1H), 1.60-1.40 (m, 3H), 1.19-1.10 (m, 1H), 0.60-0.48 (m, 3H), 
0.28-0.16 (m, 2H). 13C NMR (126 MHz, CDCl3) δ (ppm): 141.0, 128.8, 128.5, 126.8, 65.0, 




n-BuLi, THF, -90 oC, 1 h
+












(2R,3S)-5-tert-Butoxy-5-oxo-2-phenyl-3-(trifluoromethyl)pentanoic acid. The title 
compound was prepared according to general procedure I using phenylacetic acid (68.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.82 mL, 2.44 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-
tert-butyl-3-trifluoromethylacrylate (0.103 g, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at 
-90 °C. The reaction was quenched after 1 h and product (0.144 g, 0.433 mmol, 87% yield) 
was obtained after purification by column chromatography on silica gel (4-6% methanol in 
dichloromethane). [α]D
23 +12.0 (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.37-
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7.29 (m, 5H), 3.82-3.69 (m, 2H), 2.25 (dd, J=17.0, 6.9 Hz, 1H), 2.09 (dd, J=17.0, 3.7 Hz, 
1H), 1.33 (s, 9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 176.8, 169.4, 133.75, 129.2, 129.1, 
128.6, 127.1 (q, J = 280.8 Hz), 81.4, 50.2, 42.0 (q, J=26.0 Hz), 32.5 (q, J = 2.2 Hz), 27.8. 
19F NMR (376 MHz, CDCl3) δ (ppm): -69.9 (d, J=7.2 Hz). HRMS-ESI (m/z): [M+Na]+ 














(2R,3S)-5-tert-Butyl 1-methyl-2-phenyl-3-(trifluoromethyl)pentanedioate. The title 
compound was prepared using carboxylic acid (15.4 mg, 46.3 µmol), TMSCHN2 in hexane 
(0.15 mL, 1.76 M, 0.264 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 
h. The solvent was removed and the residue was purified by column chromatography on 
silica gel (9% ethyl acetate in hexanes) to afford product (15.4 mg, 44.5 µmol, 96% yield). 
Ee: 58% (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 0.5 mL/min; detection at 
215 nm; t1=8.7 min; t2=9.5 min). [α]D
23 +7.4o (c 0.52, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.37-7.28 (m, 5H), 3.80-3.73 (m, 2H), 3.68 (s, 3H), 2.29-2.20 (m, 1H), 2.13-2.01 (m, 
1H), 1.33 (s, 9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 172.2, 169.4, 134.4, 129.1, 129.0, 
127.2 (q, J=281.0 Hz), 81.3, 52.5, 50.3 (q, J=2.2 Hz), 42.2 (q, J=25.8 Hz), 32.7 (q, J=2.2 
Hz), 27.9. 19F NMR (376 MHz, CDCl3) δ (ppm): -70.0 (d, J=7.0 Hz). LRMS-ESI (m/z): 
[M+Na]+ calcd for C17H21F3O4Na, 369; found, 369. 
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n-BuLi, THF, -90 oC, 1 h
+
















The title compound was prepared according to general procedure I using phenylacetic acid 
(68.1 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-ethyl 4-(4-methoxyphenyloxy)but-2-enoate (0.124 g, 0.525 mmol, 1.05 equiv) in THF 
(0.50 mL) at -90 °C. The reaction was quenched after 1 h and product (0.168 g, 0.452 mmol, 
90% yield) was obtained after purification by column chromatography on silica gel (20% 
ethyl acetate in hexanes, then 4% methanol in dichloromethane). [α]D
23 +29.8 (c 1.6, CHCl3). 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.41-7.28 (m, 5H), 6.83 (d, J=9.1 Hz, 2H), 6.78 (d, 
J=9.1 Hz, 2H), 4.10 (dd, J=9.6, 4.9 Hz, 1H), 4.06-3.96 (m, 3H), 3.90 (d, J=10.4 Hz, 1H), 
3.75 (s, 3H), 3.20-3.08 (m, 1H), 2.28 (d, J=6.4 Hz, 2H), 1.15 (t, J=7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 178.6, 172.2, 153.9, 152.7, 135.9, 128.9, 128.8, 127.9, 115.4, 
114.6, 68.9, 60.4, 55.6, 52.3, 37.8, 33.3, 14.0. HRMS-ESI (m/z): [M+Na]+ calcd for 
C21H24O6Na, 395.1471; found, 395.1454. 
TMSCHN2
benzene-MeOH
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(2R,3S)-5-Ethyl 1-methyl-3-((4-methoxyphenoxy)methyl)-2-phenylpentanedioate. 
The title compound was prepared using carboxylic acid (14.9 mg, 40.1 µmol), TMSCHN2 in 
hexane (0.15 mL, 1.76 M, 0.264 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 
°C for 0.5 h. The solvent was removed and the residue was purified by column 
chromatography on silica gel (9% ethyl acetate in hexanes) to afford product (13.1 mg, 33.9 
µmol, 85% yield). Ee: 60% (Chiralcel® OJ-H; 1% i-PrOH in hexanes; flow rate = 1 
mL/min; detection at 215 nm; t1=77.7 min; t2=95.4 min). [α]D
23 +36.4o (c 0.62, CHCl3). 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.39-7.30 (m, 4H), 7.32-7.26 (m, 1H), 6.88-6.79 (m, 4H), 
4.08-3.95 (m, 4H), 3.89 (d, J=10.4 Hz, 1H), 3.77 (s, 3H), 3.62 (s, 3H), 3.17-3.06 (m, 1H), 
2.34-2.20 (m, 2H), 1.15 (t, J=7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm):  173.5, 
172.2, 154.0, 152.9, 136.5, 128.8, 128.8, 127.8, 115.5, 114.6, 68.9, 60.4, 55.7, 52.1, 52.1, 
38.2, 33.4, 14.1. LRMS-ESI (m/z): [M+Na]+ calcd for C22H26O6Na, 409; found, 409. 
n-BuLi, THF, -90 oC, 0.5 h
CO2MeHO2C
+









(2S,3R)-2-(4-Chlorophenyl)-5-methoxy-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 4-chlorophenylacetic acid 
(85.3 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (83.5 mg, 0.515 mmol, 1.03 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 1 h and product (0.130 g, 0.392 mmol, 78% yield) was obtained 
after purification by column chromatography on silica gel (4% methanol in dichloromethane 
with 0.5% HOAc). [α]D
23 +39.3° (c 0.25, MeOH). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.37 
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(d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 7.26-7.23 (m, 4H), 7.22-7.17 (m, 1H), 3.84 (d, 
J=11.4 Hz, 1H), 3.77 (ddd, J=11.4, 8.8, 5.3 Hz, 1H), 3.39 (s, 3H), 2.41 (dd, J=15.6, 8.8 Hz, 
1H), 2.41 (dd, J=15.6, 5.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 177.1, 171.7, 
140.6, 134.5, 134.2, 130.1, 129.1, 128.5, 127.9, 127.3, 56.7, 51.5, 44.8, 38.4. HRMS-ESI 







0 oC, 0.5 h
97% yield
 
(2S,3R)-Dimethyl 2-(4-chlorophenyl)-3-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (14.7 mg, 44.1 µmol), TMSCHN2 in hexane (0.10 mL, 
1.76 M, 0.176 mmol) in a mixture of toluene-MeOH (3:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(8% ethyl acetate in hexanes) to afford product (14.7 mg, 42.5 µmol, 97% yield). Ee: 93% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=11.6 min; t2=14.8 min). [α]D
23 +25.5° (c 0.25, MeOH). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.44-7.40 (m, 2H), 7.36-7.32 (m, 2H), 7.32-7.27 (m, 2H), 7.25-7.20 (m, 1H), 3.89-
3.80 (m, 2H), 3.41 (s, 3H), 3.37 (s, 3H), 2.46-2.41 (m, 1H), 2.38 (dd, J=15.6, 4.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ (ppm): 172.3, 171.8, 140.8, 135.0, 134.0, 130.1, 129.0, 
128.5, 127.9, 127.2, 57.0, 51.9, 51.4, 45.2, 38.5. LRMS-ESI (m/z): [M+Na]+ calcd for 
C19H19ClO4Na, 369; found, 369. 
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n-BuLi, THF, -90 oC, 0.5 h
CO2MeHO2C
+










(2S,3R)-2-(3-Chlorophenyl)-5-methoxy-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 3-chlorophenylacetic acid 
(85.3 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (83.5 mg, 0.515 mmol, 1.03 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 0.5 h and product (0.160 g, 0.487 mmol, 97% yield) was 
obtained after purification by column chromatography on silica gel (5% methanol in 
dichloromethane with 0.5% HOAc). [α]D
23 +26.9° (c 0.47, MeOH). 1H NMR (500 MHz, 
CDCl3) δ (ppm): 7.48-7.45 (m, 1H), 7.37-7.27 (m, 7H), 7.24-7.19 (m, 1H), 3.87 (d, J=11.6 
Hz, 1H), 3.86-3.75 (m, 1H), 3.41 (s, 3H), 2.43 (dd, J=15.0, 8.1 Hz, 1H), 2.38 (dd, J=15.0, 
4.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 176.7, 171.7, 140.4, 137.9, 134.8, 130.2, 
128.9, 128.5, 128.5, 127.9, 127.4, 127.0, 57.0, 51.5, 44.8, 38.5. HRMS-ESI (m/z): [M+Na]+ 








(2S,3R)-Dimethyl 2-(3-chlorophenyl)-3-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (14.0 mg, 42.1 µmol), TMSCHN2 in hexane (0.10 mL, 
1.31 M, 0.131 mmol) in a mixture of toluene-MeOH (3:1, 1.0 mL) at 0 °C for 0.5 h. The 
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solvent was removed and the residue was purified by column chromatography on silica gel 
(8% ethyl acetate in hexanes) to afford product (13.5 mg, 39.0 µmol, 93% yield). Ee: 86% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes flow rate = 1.0 mL/min; detection at 215 nm; 
t1=12.3 min; t2=16.8 min). [α]D
23 +13.6° (c 0.50, CHCl3). 1H NMR (600 MHz, CDCl3) δ 
(ppm): 7.50-7.47 (m, 1H), 7.39-7.35 (m, 1H), 7.33-7.28 (m, 6H), 7.23 (d, J=6.1 Hz, 1H), 
3.88-3.81 (m, 2H), 3.41 (s, 3H), 3.38 (s, 3H), 2.48-2.37 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 172.2, 171.8, 140.9, 138.6, 134.8, 130.2, 128.9, 128.6, 128.4, 128.0, 127.4, 
127.0, 57.4, 52.0, 51.6, 45.3, 38.6. LRMS-ESI (m/z): [M+Na]+ calcd for C19H19ClO4Na, 
369; found, 369. 
n-BuLi, THF, -78 oC, 3 h
CO2MeHO2C
+









(2S,3R)-2-(2-Chlorophenyl)-5-methoxy-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 3-chlorophenylacetic acid 
(85.3 mg, 0.500 mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (83.5 mg, 0.515 mmol, 1.03 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 3 h and products (0.143 g, 0.431 mmol, dr 5:1, 86% yield) 
together with inseparable 3-chlorophenylacetic acid (11.0 mg, 64.5 µmol, 13% yield) were 
obtained after purification by column chromatography on silica gel (4% methanol in 
dichloromethane). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.64 (dd, J=7.8, 1.8 Hz, 1H), 7.43 
(dd, J=7.9, 1.5 Hz, 1H), 7.34-7.14 (m, 7H), 4.61 (d, J=11.5 Hz, 1H), 3.82 (virt. td, J=11.2, 
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4.4 Hz, 1H), 3.37 (s, 3H), 2.53 (dd, J=15.6, 10.9 Hz, 1H), 2.31 (dd, J=15.6, 4.4 Hz, 1H). 








(2S,3R)-Dimethyl 2-(2-chlorophenyl)-3-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (10.0 mg, 30.0 µmol), TMSCHN2 in hexane (0.10 mL, 
1.31 M, 0.131 mmol) in a mixture of toluene-MeOH (3:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(6% ethyl acetate in hexanes) to afford product (9.0 mg, 26.0 µmol, 86% yield). Ee: 70% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=9.6 min; t2=12.8 min). [α]D
23 +44.3° (c 0.33, CHCl3). 1H NMR (400 MHz, CDCl3) δ 
(ppm): 7.72 (dd, J=7.8, 1.7 Hz, 1H), 7.42 (dd, J=8.0, 1.4 Hz, 1H), 7.39-7.28 (m, 5H), 7.25-
7.19 (m, 2H), 4.61 (d, J=11.6 Hz, 1H), 3.86 (virt. td, J=11.3, 4.4 Hz, 1H), 3.38 (s, 3H), 3.37 
(s, 3H), 2.56 (dd, J=15.6, 11.0 Hz, 1H), 2.32 (dd, J=15.6, 4.4 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 172.2, 172.0, 141.2, 135.0, 134.4, 129.9, 129.14, 129.09, 128.6, 128.2, 
127.7, 127.3, 52.3, 52.0, 51.5, 45.9, 38.1. LRMS-ESI (m/z): [M+Na]+ calcd for 










n-BuLi, THF, -90 oC, 0.5 h
+
70% yield over 2 steps









ii) TMSCHN2 in hexanes
toluene / MeOH (3:1)
0 ºC, 30 min
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(2S,3R)-2-(1,3-Benzodioxol-5-yl)-5-methoxy-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 2-(1,3-benzodioxol-5-yl)-
acetic acid (90.1 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi 
(0.80 mL, 2.51 M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition 
of a solution of (E)-methyl cinnamate (83.5 mg, 0.515 mmol, 1.03 equiv) in THF (0.50 mL) 
at -90 °C. The reaction was quenched after 0.5 h and the crude product (0.168 g) was 
obtained after work up. Due to its extremely low solubility, no effort was attempted to purify 
by column chromatography, and the crude product was directly submitted to the next step. 
(2S,3R)-Dimethyl 2-(1,3-benzodioxol-5-yl)-3-phenylpentanedioate. The title 
compound was prepared using above crude acid (0.168 g), TMSCHN2 in hexane (1.30 mL, 
1.13 M, 1.47 mmol) in a mixture of toluene-MeOH (3:1, 16 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(6% ethyl acetate in hexanes) to afford product (0.124 mg, 0.348 mmol, 70% yield over 
steps). Ee: 88 % (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; 
detection at 215 nm; t1=30.1 min; t2=37.9 min). [α]D
23 +21.6° (c 0.50, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 7.32-7.27 (m, 4H), 7.24-7.18 (m, 1H), 7.03 (d, J= 1.8Hz, 1H), 6.88 
(dd, J=7.9, 1.8 Hz, 1H), 6.78 (d, J=7.9 Hz, 1H), 5.97 (d, J=1.5 Hz, 1H), 5.96 (d, J=1.5 Hz, 
1H), 3.83-3.75 (m, 2H), 3.42 (s, 3H), 3.37 (s, 3H), 2.48-2.39 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 172.6, 172.0, 148.1, 147.4, 141.1, 130.2, 128.4, 127.9, 127.1, 122.4, 108.5, 
108.4, 101.2, 57.3, 51.8, 51.4, 45.4, 38.6. HRMS-ESI (m/z): [M+Na]+ calcd for C20H20O6Na, 
379.1158; found, 379.1146. 
  97 
OH
O
n-BuLi, THF, -90 oC, 0.5 h
+












(2S,3R)-5-Methoxy-2-(naphthalen-2-yl)-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 2-naphthaleneacetic acid 
(93.1 mg, 0.500 mmol), (S)-2TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (85.1 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 0.5 h and product (0.143 g, 0.410 mmol, 82% yield) was 
obtained after purification by column chromatography on silica gel (4% methanol in 
dichloromethane). [α]D
23 +33.9o (c 0.38, CHCl3). 1H NMR (500 MHz CDCl3) δ (ppm): 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.87 (d, J=1.8 Hz, 1H), 7.86-7.76 (m, 3H), 7.56 (dd, 
J=8.6, 1.8 Hz, 1H), 7.53-7.44 (m, 2H), 7.34-7.27 (m, 2H), 7.24 (t, J=7.5 Hz, 2H), 7.20-7.11 
(m, 1H), 4.02 (d, J=11.6 Hz, 1H), 3.94 (ddd, J=11.6, 9.5, 5.0 Hz, 1H), 3.32 (s, 3H), 2.41 (dd, 
J=15.5, 9.5 Hz, 1H), 2.38 (dd, J=15.5, 5.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
176.6, 171.9, 140.8, 133.36, 133.35, 133.0, 128.8, 128.5, 128.2, 127.9, 127.6, 127.2, 126.4, 
126.3, 125.9, 57.4, 51.4, 44.7, 38.6, 29.7. HRMS-ESI (m/z): [M+Na]+ calcd for C22H20O4Na, 











0 oC, 0.5 h
93% yield
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(2S,3R)-Dimethyl 2-(naphthalen-2-yl)-3-phenylpentanedioate. The title compound 
was prepared using carboxylic acid (18.6 mg, 53.4 µmol), TMSCHN2 in hexane (0.15 mL, 
1.76 M, 0.264 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The 
solvent was removed and the residue was purified by column chromatography on silica gel 
(9% ethyl acetate in hexanes) to afford product (18.0 mg, 49.7 µmol, 93% yield). Ee: 87% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=19.3 min; t2=24.6 min). [α]D
23 +33.7o (c 0.86, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.92 (d, J=1.7 Hz, 1H), 7.90-7.82 (m, 3H), 7.65 (dd, J=8.5, 1.8 Hz, 1H), 7.53-7.46 
(m, 2H), 7.40-7.36 (m, 2H), 7.35-7.31 (m, 2H), 7.27-7.22 (m, 1H), 4.06 (d, J=11.6 Hz, 1H), 
4.01 (ddd, J=11.6, 9.4, 4.3 Hz, 1H), 3.39 (s, 3H), 3.34 (s, 3H), 2.47 (dd, J=15.6, 9.4 Hz, 1H), 
2.41 (dd, J=15.6, 4.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 172.6, 171.9, 141.2, 
134.0, 133.4, 133.0, 128.7, 128.5, 128.1, 128.0, 127.9, 127.6, 127.1, 126.4, 126.2, 126.0, 




n-BuLi, THF, -78 oC, 0.5 h
+












(2S,3R)-5-Methoxy-2-(naphthalen-1-yl)-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 1-naphthaleneacetic acid 
(93.1 mg, 0.500 mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (85.1 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -78 °C. The 
reaction was quenched after 0.5 h and product (0.167 g, 0.478 mmol, dr 5:1, 88% yield) was 
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obtained after purification by column chromatography on silica gel (6% methanol in 
dichloromethane). Pure major diastereomer could be separated partially by column 
chromatography on silica gel (6% methanol in dichloromethane). [α]D
23 +71.4o (c 1.2, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 8.24 (d, J=8.5 Hz, 1H), 7.89 (d, J=8.1 Hz, 
1H), 7.81 (d, J=8.0 Hz, 1H), 7.76 (d, J=7.4 Hz, 1H), 7.58 (t, J=7.4 Hz, 1H), 7.56-7.49 (m, 
1H), 7.48 (t, J=7.7 Hz, 1H), 7.35 (d, J=7.3 Hz, 2H), 7.23 (t, J=7.5 Hz, 2H), 7.16 (t, J=7.3 
Hz, 1H), 4.77 (d, J=9.9 Hz, 1H), 4.10-3.98 (m, 1H), 3.32 (s, 3H), 2.41 (dd, J=15.6, 10.7 Hz, 
1H), 2.30 (dd, J=15.6, 4.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 177.1, 172.0, 
141.0, 134.0, 132.2, 129.1, 128.5, 128.4, 128.1, 127.2, 126.7, 125.8, 125.7, 122.8, 51.3, 
45.0, 38.3. HRMS-ESI (m/z): [M+Na]+ calcd for C22H20O4Na, 371.1259; found, 371.1244. 
TMSCHN2
benzene-MeOH









(2S,3R)-Dimethyl 2-(naphthalen-1-yl)-3-phenylpentanedioate. The title compound 
was prepared using the (18.2 mg, 52.3 µmol, dr 5:1), TMSCHN2 in hexane (0.10 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford pure diastereomer product (11.4 mg, 31.5 mol, 60% 
yield). Ee: 79% (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; 
detection at 215 nm; t1=18.7 min; t2=27.3 min). [α]D
23 +89.3o (c 1.9, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 8.34 (d, J=8.5 Hz, 1H), 7.94-7.87 (m, 2H), 7.85 (d, J=8.1 Hz, 1H), 
7.63 (ddd, J=8.4, 6.8, 1.4 Hz, 1H), 7.58-7.51 (m, 2H), 7.51-7.45 (m, 2H), 7.41-7.33 (m, 2H), 
7.31-7.24 (m, 1H), 5.00-4.69 (m, 1H), 4.22-4.13 (m, 1H), 3.37 (s, 3H), 3.35 (s, 3H), 2.49 
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(dd, J=15.6, 10.8 Hz, 1H), 2.36 (dd, J=15.6, 4.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
(ppm): 172.6, 171.9, 141.4, 134.0, 132.7, 132.2, 129.1, 128.4, 128.3, 128.1, 127.1, 126.7, 
125.74, 125.71, 122.8, 51.8, 51.3, 45.5, 38.3. HRMS-ESI (m/z): [M+Na]+ calcd for 






n-BuLi, THF, -90 oC, 0.5 h
+











(2R,3R)-5-Methoxy-5-oxo-3-phenyl-2-(thiophen-2-yl)pentanoic acid. The title 
compound was prepared according to general procedure I using 2-thiopheneacetic  acid 
(71.1 mg, 0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 
M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of 
(E)-methyl cinnamate (85.1 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 1 h and product (0.126 g, 0.414 mmol, 93% yield) was obtained 
after purification by column chromatography on silica gel (16% ethyl acetate in hexanes, 
then 4-6% methanol in dichloromethane). [α]D
23 +14.9 (c 0.35, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ (ppm): 7.23 (d, J=5.1 Hz, 1H), 7.22-7.14 (m, 5H), 7.01 (d, J=3.5 Hz, 1H), 6.95 
(dd, J=5.1, 3.5 Hz, 1H), 4.10 (d, J=11.0 Hz, 1H), 3.74 (virt. td, J=10.4, 4.4 Hz, 1H), 3.42 (s, 
3H), 2.54 (dd, J=15.6, 4.4 Hz, 1H), 2.46 (dd, J=15.6, 10.1 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 176.9, 172.1, 140.5, 138.2, 128.4, 127.9, 127.20, 127.17, 126.8, 125.5, 
52.9, 51.5, 46.1, 38.3. HRMS-ESI (m/z): [M+Na]+ calcd for C16H16O4NaS, 327.0667; found, 
327.0653. 














(2R,3R)-Dimethyl 3-phenyl-2-(thiophen-2-yl)pentanedioate. The title compound was 
prepared using carboxylic acid (10.3 mg, 33.8 µmol), TMSCHN2 in hexane (0.10 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford product (9.1 mg, 28.6 µmol, 84% yield). Ee: 94% 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1 mL/min; detection at 215 nm; 
t1=22.2 min; t2=23.1 min). [α]D
23 +6.3 (c 0.43, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.33-7.25 (m, 5H), 7.26-7.18 (m, 1H), 7.09 (dd, J=3.5, 1.2 Hz, 1H), 6.99 (dd, J=5.2, 3.5 Hz, 
1H), 4.17 (d, J=11.3 Hz, 1H), 3.80 (ddd, J=11.3, 10.0, 4.6 Hz, 1H), 3.44 (s, 3H), 3.40 (s, 
3H), 2.57 (dd, J=15.7, 4.6 Hz, 1H), 2.51 (dd, J=15.7, 10.0 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ (ppm): 171.9, 171.9, 140.6, 138.6, 128.5, 127.9, 127.3, 127.0, 126.8, 125.6, 52.9, 
52.0, 51.5, 46.7, 38.5. LRMS-ESI (m/z): [M+Na]+ calcd for C17H18O4NaS, 341; found, 341. 
n-BuLi, THF, -90 oC, 0.5 h
CO2MeHO2C
+










(2S,3R)-2-(Furan-3-yl)-5-Methoxy-5-oxo-3-phenylpentanoic acid. The title 
compound was prepared according to general procedure I using 3-furanacetic acid (63.1 mg, 
0.500 mmol), (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv), n-BuLi (0.80 mL, 2.51 M in 
hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by addition of a solution of (E)-
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methyl cinnamate (85.1 mg, 0.525 mmol, 1.05 equiv) in THF (0.50 mL) at -90 °C. The 
reaction was quenched after 0.5 h and product (0.113 g, 0.442 mmol, 99% yield) was 
obtained after purification by column chromatography on silica gel (20% ethylacetate in 
hexanes with 1% AcOH). [α]D
23 +31.1° (c 0.25, MeOH). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.44-7.39 (m, 2H), 7.25-7.18 (m, 5H), 6.51-6.43 (m, 1H), 3.81 (d, J = 10.0 Hz, 1H), 
3.69 (virt. td, J = 10.0, 5.0 Hz, 1H), 3.45 (s, 3H), 2.62 (dd, J=15.7, 5.0 Hz, 1H), 2.49 (dd, 
J=15.7, 9.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 176.9, 172.0, 143.5, 141.2, 
140.5, 128.5, 127.8, 127.3, 120.2, 110.2, 51.5, 48.0, 44.4, 38.3. HRMS-ESI (m/z): [M+Na]+ 








(2S,3R)-Dimethyl 2-(furan-3-yl)-3-phenylpentanedioate. The title compound was 
prepared using carboxylic acid (18.6 mg, 64.6 µmol), TMSCHN2 in hexane (0.10 mL, 1.31 
M, 0.131 mmol) in a mixture of toluene-MeOH (3:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (8% 
ethyl acetate in hexanes) to afford product (18.5 mg, 61.2 µmol, 95% yield). Ee: 92 % 
(Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 215 nm; 
t1=17.0 min; t2=21.7 min). [α]D
23 +9.6° (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ (ppm): 
7.44-7.38 (m, 2H), 7.30-7.15 (m, 5H), 6.50 (m, 1H), 3.83 (d, J=10.9 Hz, 1H), 3.69 (virt. td, 
J=10.4, 4.5 Hz, 1H), 3.44 (s, 3H), 3.39 (s, 3H), 2.61 (dd, J=15.6, 4.5 Hz, 1H), 2.48 (dd, 
J=15.6, 9.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 172.5, 172.1, 143.5, 141.0, 
141,0, 128.5, 127.9, 127.3, 120.9, 110.3, 51.9, 51.6, 48.5, 45.0, 38.5. LRMS-ESI (m/z): 
[M+Na]+ calcd for C17H18O5Na, 325; found, 325. 
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CO2MeHO2C
+











(2S,3R)-2-(1-benzyl-1H-indol-3-yl)-5-methoxy-5-oxo-3-phenylpentanoic acid. The 
title compound was prepared according to general procedure I using N-benzyl-3-
indolylacetic acid (0.133 g, 0.500 mmol), (S)-2TA (0.217 g, 0.515 mmol, 1.03 equiv), n-
BuLi (0.80 mL, 2.51 M in hexanes, 2.00 mmol, 4.0 equiv) in THF (5.0 mL) followed by 
addition of a solution of (E)-methyl cinnamate (85.1 mg, 0.525 mmol, 1.05 equiv) in THF 
(0.50 mL) at -78 °C. The reaction was quenched after 5 h and product (0.189 g, 0.442 mmol, 
88% yield) was obtained after purification by column chromatography on silica gel (8% 
methanol in dichloromethane with 1% AcOH). [α]D
23 +5.7° (c 0.5, CHCl3). 1H NMR (500 
MHz, CDCl3) δ (ppm): 7.81-7.77 (m, 1H), 7.35-7.14 (m, 12H), 7.14-7.09 (m, 2H), 5.29 (s, 
2H), 4.18 (d, J=11.2 Hz, 1H), 3.97 (virt. td, J=10.5, 4.4 Hz, 1H), 3.33 (s, 2H), 2.62 (dd, 
J=15.7, 4.5 Hz, 1H), 2.52 (dd, J=15.6, 10.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ (ppm): 
177.5, 172.3, 141.3, 137.1, 136.6, 128.8, 128.4, 127.9, 127.7, 127.7, 127.1, 126.8, 122.2, 
119.9, 119.6, 110.0, 109.9, 51.3, 50.2, 48.8, 44.9, 38.8. HRMS-ESI (m/z): [M+Na]+ calcd 
for C27H25NO4Na, 450.1681; found, 450.1664. 
TMSCHN2 in hexanes
toluene-MeOH (3:1)
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(2S,3R)-Diemthyl 2-(1-benzyl-1H-indol-3yl)-3-phenylpentanedioate. The title 
compound was prepared using carboxylic acid (10.0 mg, 23.4 µmol), TMSCHN2 in hexane 
(0.10 mL, 1.31 M, 0.131 mmol) in a mixture of toluene-MeOH (3:1, 1.0 mL) at 0 °C for 0.5 
h. The solvent was removed and the residue was purified by column chromatography on 
silica gel (6% ethyl acetate in hexanes) to afford product (7.9 mg, 17.9 µmol, 77% yield). 
Ee: 81% (Chiralcel® OD-H; 2% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 
215 nm; t1=37.6 min; t2=68.9 min). [α]D
23 +12.2° (c 0.33, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ (ppm): 7.84-7.77 (m, 1H), 7.36-7.25 (m, 9H), 7.24-7.16 (m, 3H), 7.15-7.11 (m, 
2H), 5.30 (s, 2H), 4.18 (d, J=11.3 Hz, 1H), 3.99 (ddd, J=11.3, 10.1, 4.6 Hz, 1H), 3.36 (s, 
3H), 3.32 (s, 3H), 2.61 (dd, J=15.7, 4.6 Hz, 1H), 2.52 (dd, J=15.6, 10.1 Hz, 1H). 13C 
NMR(126 MHz, CDCl3) δ (ppm): 173.2, 172.3, 141.6, 137.2, 136.5, 128.8, 128.4, 127.9, 
127.7, 127.5, 127.0, 126.8, 122.1, 119.8, 119.5, 110.5, 110.0, 51.7, 51.3, 50.2, 49.1, 45.4, 
38.9. LRMS-ESI (m/z): [M+Na]+ calcd for C28H27NO4Na, 464; found, 464. 
OH
O
n-BuLi, THF, 0 oC, 1 min
+












(2R,3R)-5-Methoxy-5-oxo-2-phenylethyl-3-phenylpentanoic acid. A solution of n-
BuLi (0.80 mL, 2.51 M in hexanes, 2.01 mmol, 4.0 equiv) was added dropwise to a solution 
of i-Pr2NH (0.14 mL, 0.101 g, 1.00 mmol) and (R)-1TA (0.231 g, 0.515 mmol, 1.03 equiv) 
in THF (3.5 mL) at 0 °C and the reaction mixture was stirred at this temperature for 30 min. 
Then 4-phenylbutyric acid (82.1 mg, 0.500 mmol) in THF (1.0 mL + (0.2 + 0.3) mL rinses) 
was added dropwise. After additional 30 min, a solution of methyl cinnamate (81.1 mg, 
0.500 mmol, 1.0 equiv) in THF (0.30 mL + 2×0.10 mL rinses) was added to the reaction 
  105 
mixture dropwise over 1 min, immediately followed by a mixture of THF-MeOH (3:1, 0.64 
mL). After 5 min, the reaction mixture was acidified with 1 M aqueous solution of HCl and 
extracted with ethyl acetate. The combined organic phase was sequentially washed with 1 M 
aqueous solution of HCl and brine, dried over Na2SO4, concentrated, and the residue was 
purified by column chromatography on silica gel (20-66% ethyl acetate in hexanes then 6% 
methanol in dichloromethane) to afford the pure major diastereomer product (65.3 mg, 0.200 
mmol, 40% yield) together with minor diastereomer (15.1 mg, 46.3 mmol, 9% yield). [α]D
23 
+9.9° (c 1.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.30-7.23 (m, 4H), 7.22-7.11 
(m, 6H), 3.53 (s, 3H), 3.49 (ddd, J = 9.4, 7.4, 5.8 Hz, 1H), 2.86 (dd, J=15.8, 5.6 Hz, 1H), 
2.78-2.64 (m, 3H), 2.58-2.48 (m, 1H), 2.03-1.91 (m, 1H), 1.90 – 1.78 (m, 1H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 179.4, 172.2, 141.1, 140.6, 128.40, 128.37, 128.35, 128.0, 
127.1, 126.0, 51.6, 50.3, 43.7, 37.4, 33.7, 31.2. HRMS-ESI (m/z): [M+Na]+ calcd for 
C20H22O4Na, 349.1416; found, 349.1406. Absolute configuration of this compound 









(2R,3R)-2-phenylethyl-3-phenylpentane diol. The title compound was prepared using 
carboxylic acid (31.4 mg, 96.3 µmol), and lithium aluminum hydride (40.1 mg, 1.06 mmol) 
in THF (2.0 mL) at 23 °C. The reaction was quenched after 2 h, and product (22.5 mg, 79.1 
µmol, 82% yield) was obtained after purification by column chromatography on silica gel 
(50% ethyl acetate in hexanes). Ee: 80% (Chiralcel® OJ-H; 10% i-PrOH in hexanes; flow 
rate = 1.0 mL/min; detection at 215 nm; t1=20.0 min; t2=30.7 min). [α]D
23 +17.8° (c 1.2, 
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CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.34-7.24 (m, 4H), 7.25-7.15 (m, 6H), 3.58 
(dd, J=11.1, 4.9 Hz, 1H), 3.55-3.46 (m, 1H), 3.46-3.33 (m, 2H), 2.91 (ddd, J=11.0, 7.0, 3.9 
Hz, 1H), 2.73 (ddd, J=13.8, 10.1, 5.5 Hz, 1H), 2.60 (ddd, J=13.8, 9.9, 5.6 Hz, 1H), 2.08 
(dddd, J=14.3, 8.8, 7.0, 4.0 Hz, 1H), 1.92-1.62 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 
(ppm): 143.0, 142.4, 128.5, 128.3, 128.3, 126.4, 125.7, 62.9, 61.2, 45.6, 42.9, 34.9, 33.5, 
30.2. HRMS-ESI (m/z): [M+Na]+ calcd for C19H24O2Na, 307.1674; found, 307.1670. 










n-BuLi, THF, -90 oC, 0.5 h
then MeI, 0 oC, 1 h+





(2S,3R,4R)-5-Methoxy-4-methyl-5-oxo-2,3-diphenylpentanoic acid. A solution of n-
BuLi (1.6 mL, 2.51 M in hexanes, 4.02 mmol, 4.0 equiv) was added dropwise to a solution 
of phenylacetic acid (136 mg, 1.00 mmol) and (R)-1TA (0.462 g, 1.03 mmol, 1.03 equiv) in 
THF (10 mL) at 0 °C and the reaction mixture was stirred at this temperature for 30 min. 
The reaction mixture was then cooled to -90 °C and stirred for an additional 5 min. A 
solution of methyl cinnamate (162 mg, 1.00 mmol, 1.0 equiv) in THF (0.60 mL + 2×0.20 
mL rinses) was added to the reaction mixture dropwise over 10 min. The resultant mixture 
was stirred for additional 20 min before a quench with a mixture of THF-MeOH (3:1, 1.3 
mL) at -90 °C. After 5 min, the reaction mixture was acidified with 1 M aqueous solution of 
HCl and extracted with ethyl acetate. The combined organic phase was sequentially washed 
with 1 M aqueous solution of HCl and brine, dried over Na2SO4, concentrated, and the 
residue was purified by column chromatography on silica gel (15% ethyl acetate in hexanes 
with 0.5% HOAc) to afford the pure product (0.230 g, 0.736 mmol, 74% yield). [α]D
23 +31.7 
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(c 1.2, CHCl3). 1H NMR (500 MHz, DMSO-d6) δ (ppm): 7.54 (d, J=6.7 Hz, 2H), 7.41 (t, 
J=7.6 Hz, 2H), 7.36-7.27 (m, 3H), 7.28-7.21 (m, 3H), 4.21 (d, J=12.3 Hz, 1H), 3.92 (dd, 
J=12.3, 4.3 Hz, 1H), 3.41 (s, 3H), 2.33 (qd, J=7.0, 4.3 Hz, 1H), 0.78 (d, J=7.0 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ (ppm): 174.4, 173.3, 138.9, 137.3, 128.8, 128.7, 128.5, 
127.9, 127.7, 126.8, 53.4, 51.2, 49.1, 40.2, 10.7. HRMS-ESI (m/z): [M+Na]+ calcd for 













(2R,3R,4S)-Dimethyl-2-methyl-3,4-diphenylpentanedioate. The title compound was 
prepared using carboxylic acid (12.7 mg, 40.7 µmol), TMSCHN2 in hexane (0.1 mL, 1.76 
M, 0.176 mmol) in a mixture of benzene-MeOH (4:1, 1.0 mL) at 0 °C for 0.5 h. The solvent 
was removed and the residue was purified by column chromatography on silica gel (9% 
ethyl acetate in hexanes) to afford product (10.0 mg, 30.6 µmol, 75% yield). Ee: 96% 
(Chiralcel® AD-H; 1% i-PrOH in hexanes; flow rate = 1.0 ml/min; detection at 215 nm; 
t1=20.5 min; t2=26.8 min). [α]D
23 +40.9o (c 0.48, CHCl3). 1H NMR (400 MHz, CDCl3) δ 
(ppm): 7.51 (d, J=6.9 Hz, 2H), 7.37 (t, J=7.4 Hz, 2H), 7.34-7.26 (m, 3H), 7.25-7.19 (m, 3H), 
4.10 (d, J=12.1 Hz, 1H), 4.04 (dd, J=12.1, 4.9 Hz, 1H), 3.42 (s, 3H), 3.34 (s, 3H), 2.52 (qd, 
J=7.0, 4.9 Hz, 1H), 0.89 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 175.1, 
172.7, 138.6, 136.3, 128.9, 128.8, 128.7, 128.2, 128.0, 127.2, 55.1, 51.8, 51.4, 49.6, 41.3, 
11.9. LRMS-ESI (m/z): [M+Na]+ calcd for C20H22O4Na, 349; found, 349. 






benzene, reflux, 12 h









(2R,3S,4S)-Methyl 4-(benzyloxycarbonylamino)-2-methyl-3,4-diphenylbutanoate. A 
solution of acid (78.1 mg, 0.250 mmol), diphenylphosphoryl azide (DPPA, 80 µL, 0.102 g, 
0.372 mmol) and i-Pr2NEt (90 µL, 66.8 mg, 0.517 mmol) in benzene was heated to reflux 
for 12 h. Then benzyl alcohol (80 µL, 83.2 mg, 0.769 mmol) was added, and the reaction 
mixture was stirred at reflux for additional 5 h. After cooling, the reaction mixture was 
diluted with CH2Cl2, washed with 1 M aqueous solution of NaOH, extracted with CH2Cl2. 
The combined organic phase was washed with 10% aqueous solution of H2SO4 and brine, 
dried over Na2SO4, concentrated, and the residue was purified by column chromatography 
on silica gel (15% ethyl acetate in hexanes) to afford product (55.5 mg, 0.133 mmol, 53% 
yield). [α]D
23 -0.67o (c 1.4, CHCl3). 1H NMR (500 MHz, DMSO-d6) δ (ppm): 7.71 (d, J=9.4 
Hz, 1H), 7.50-7.45 (m, 2H), 7.41-7.33 (m, 2H), 7.32-7.22 (m, 7H), 7.20-7.16 (m, 2H), 7.08-
7.02 (m, 2H), 5.03 (dd, J=11.4, 9.4 Hz, 1H), 4.92 (d, J=12.8 Hz, 1H), 4.76 (d, J=12.8 Hz, 
1H), 3.66 (dd, J=11.4, 5.0 Hz, 1H), 3.39 (s, 3H), 2.35 (qd, J=7.0, 5.0 Hz, 1H), 0.82 (d, J=7.0 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 174.3, 155.2, 141.7, 138.1, 137.1, 129.0, 
128.3, 128.2, 127.8, 127.5, 127.1, 126.6, 64.8, 56.3, 51.7, 51.2, 40.6, 11.5. HRMS-ESI 
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n-BuLi, THF, -90 oC, 1 h
then 3-phenyl-2-propyn-1-ol, 3 h
ii) TMSCHN2 in hexanes
benzene / MeOH (4/1)
+
83% yield over 2 steps










Alcohol. A solution of n-BuLi (0.80 mL, 2.51 M in hexanes, 2.01 mmol, 4.0 equiv) was 
added dropwise to a solution of phenylacetic acid (68.1 mg, 0.500 mmol) and (R)-1TA 
(0.231 g, 0.515 mmol, 1.03 equiv) in THF (5.0 mL) at 0 °C and the reaction mixture was 
stirred at this temperature for 30 min. The reaction mixture was then cooled to -78 °C and 
stirred for an additional 5 min. A solution of (E)-2-(trimethylsilyl)ethyl 3-phenyl-2-
butenoate (0.149 g, 0.600 mmol, 1.2 equiv) in THF (0.30 mL + 2×0.10 mL rinses) was 
added to the reaction mixture dropwise over 10 min. After stirring for additional 50 min, a 
solution of 3-phenyl-2-propynal (0.325 g, 2.50 mmol) was added. The reaction mixture was 
stirred for additional 3 h before a quench with a mixture of THF-MeOH (3:1, 0.64 mL) at -
78 °C. After 5 min, the reaction mixture was acidified with 1 M aqueous solution of HCl and 
extracted with ethyl acetate. The combined organic phase was sequentially washed with 1 M 
aqueous solution of HCl and brine, dried over Na2SO4, concentrated, and the residue was 
directly used for the next step.  
The above crude acid was dissolved in a mixture of benzene-MeOH (4:1, 5.0 mL) and 
TMSCHN2 in hexane (2.6 mL, 0.57 M in hexanes, 1.48 mmol) was added at 0 °C. The 
resultant mixture was stirred at the same temperature for 1 h. The solvent was removed on a 
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rotary evaporator and the residue was purified by column chromatography on silica gel (9-
11% ethyl acetate in hexanes) to afford the product (0.221 g, 0.418 mol, dr 2:1, 83% yield).  
Major diastereomer: Ee: 87% (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 
1.0 mL/min; detection at 215 nm; major diasteremoer t1=18.0 min; t2=54.5 min). [α]D
23 -5.2o 
(c 0.5, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.52-7.46 (m, 2H), 7.43-7.37 (m, 2H), 
7.38-7.28 (m, 6H), 7.29–7.23 (m, 5H), 4.21 (d, J=11.2 Hz, 1H), 4.15-4.05 (m, 1H), 3.78-
3.66 (m, 1H), 3.51 (d, J=10.5 Hz, 1H), 3.44-3.33 (m, 1H), 3.28 (s, 3H), 2.97 (dd, J=9.8, 3.9 
Hz, 1H), 0.88-0.75 (m, 2H), -0.04 (s, 9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.6, 
172.4, 139.0, 135.6, 131.6, 129.8, 128.9, 128.54, 128.46, 128.3, 128.2, 128.0, 127.5, 122.3, 
88.1, 85.4, 63.3, 61.6, 57.2, 55.3, 51.7, 47.1, 17.2, -1.7. HRMS-ESI (m/z): [M+Na]+ calcd 
for C32H36O5NaSi, 551.2230; found, 551.2217. 
Ee: 86% ee. (Chiralcel® OD-H; 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; 





















over 2 steps  
Lactone. To a solution of ester (51.8 mg, 98.0 µmol) in THF (2 mL) was added TBAF 
(1.0 M in THF, 0.25 mL, 0.250 mmol) at 23 °C. After stirring for 2 h, the reaction mixture 
was diluted with ethyl ether, quenched with water, and extracted with ethyl ether. The 
combined organic phase was washed with brine, dried over Na2SO4, concentrated, and the 
crude acid was directly used for the next step.  
To a solution of above crude acid in MeOH (2 mL) was added AgNO3 (16.6 mg, 97.7 
µmol) at 23 °C. Additional AgNO3 (16.6 mg, 97.7 µmol) was added after 14 h, followed by 
third portion of AgNO3 (33.2 mg, 0.195 mmol) after 10 h. The resultant mixture was stirred 
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for further 14 h. The solvent was removed on a rotary evaporator and the residue was 
purified by column chromatography on silica gel (25% ethyl acetate in hexanes) to afford 
the product (36.6 mg, 85.4 mmol, dr 2:1, 87% yield over two steps.). The two diastereomers 
could be partially separated by column chromatography. 
Major diastereomer:  [α]D
23 +56.1 (c 0.71, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 7.49-7.44 (m, 2H), 7.34-7.27 (m, 4H), 7.27-7.18 (m, 9H), 5.62 (s, 1H, H-6), 4.99 (d, 
J=7.9 Hz, 1H, H-8), 4.66 (virt. t, J=5.7 Hz, 1H, H-4), 3.87 (virt. t, J=8.1 Hz, 1H, H-7), 3.55 
(s, 3H), 3.54 (dd, J=8.0, 6.5 Hz, 1 H, H-3), 1.88 (d, J=5.3 Hz, 1H, H-OH). 13C NMR (126 
MHz, CDCl3) δ (ppm): 174.1, 172.8, 149.1, 138.0, 136.8, 132.9, 129.6, 129.2, 128.8, 128.6, 
128.4, 128.2, 127.7, 127.6, 127.5, 106.8, 52.6, 51.9, 46.6, 46.1. LRMS-ESI (m/z): [M+Na]+ 
calcd for C27H24O5Na, 451; found, 451. 
Minor diastereomer: [α]D
23 -89.7 (c 0.75, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 
7.71-7.65 (m, 2H), 7.48-7.38 (m, 4H), 7.39-7.32 (m, 1H), 7.29-7.12 (m, 7H), 7.11-7.03 (m, 
1H), 5.40 (d, J=1.8 Hz, 1H, H-6), 4.87 (virt. td, J=9.0, 1.8 Hz, 1H, H-4), 4.63 (d, J=12.2 Hz, 
1H, H-8), 4.06 (dd, J=12.2, 3.6 Hz, 1H, H-7), 3.33 (s, 3H), 2.82 (dd, J=8.9, 3.5 Hz, 1H, H-
3), 2.06 (d, J=9.1 Hz, 1H, H-OH). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.0, 172.5, 
149.9, 138.1, 136.6, 132.9, 129.1, 129.0, 128.9, 128.8, 128.4, 128.19, 128.15, 128.10, 127.0, 



















J = 0-1.8 Hz J = 6.6 Hz
S612  
Scheme 1. Comparison of J-coupling constant 
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The regioselectivity of the Ag-mediated cyclization reaction was confirmed by J-
coupling constant as shown in Scheme 1. Dihydro-2-pyrone S6 was prepared using 




















diphenyl-propanoate.68 Trifluoroacetic anhydride (TFAA, 40 µL, 0.283 mmol) was added 
to a solution of DMSO (40 µL, 0.563 mmol) in CH2Cl2 (1.5 mL) at -78 °C. After stirring for 
0.5 h, alcohol (36.6 mg, dr 2:1, 85.5 µmol) in CH2Cl2 (1.5 mL) was added dropwise. The 
reaction mixture was stirred at the same temperature for 2.5 h before NEt3 (0.15 mL, 1.08 
mmol) was added. After stirring for 2 h, the reaction mixture was quenched with water and 
extracted with CH2Cl2. The combined organic phase was washed brine, dried over Na2SO4, 
concentrated, and the residue was purified by column chromatography on silica gel (20% 
ethyl acetate in hexanes then 5% methanol in dichloromethane) to afford the pure product 
(19.7 mg, 46.2 µmol, 54% yield). [α]D
23
 +51.2o (c 0.14, CHCl3). 1H NMR (500 MHz, 
Acetone-d6) δ (ppm): 7.67-7.60 (m, 4H), 7.52-7.46 (m, 2H), 7.39-7.26 (m, 7H), 7.28-7.18 
(m, 2H), 6.22 (s, 1H), 4.94 (d, J=12.2 Hz, 1H), 4.88 (d, J=12.2 Hz, 1H), 3.41 (s, 3H). 13C 
NMR (126 MHz, Acetone-d6) δ (ppm): 206.2, 173.4, 169.2, 164.0, 143.3, 142.0, 138.4, 
133.7, 131.0, 129.6, 129.5, 129.4, 129.3, 129.1, 129.0, 128.6, 127.9, 107.1, 104.5, 53.9, 
52.1, 43.7, 30.2, 30.0, 29.8, 29.7, 29.5. HRMS-ESI (m/z): [M+Na]+ calcd for C27H22O5Na, 
449.1365; found, 449.1346. 
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Table 1. Comparison of 1H NMR Data of Synthetic and Reported Structures for 









proposed structure  
synthetic (500 MHz) reported for natural pulveraven B 
(500 MHz)69 
7.67-7.60 (m, 4H)  7.70 (d, J=7.2 Hz, 2H) 
7.52-7.46 (m, 2H) 7.45-7.30 (m, 6H) 
7.39-7.26 (m, 7H) 7.13-7.04 (m, 4H) 
7.28-7.18 (m, 2H)  6.95-6.85 (m, 3H) 
6.22 (s, 1H) 5.95 (s, 1H) 
4.94 (d, J=12.2 Hz, 1H)  5.20 (d, J=12.2 Hz, 1H)  
4.88 (d, J=12.2 Hz, 1H) 4.46 (d, J=12.2 Hz, 1H) 




THF, -78 °C, 10 min









(S)-2-Methyl-2-phenyl-butanoic acid. A solution of n-BuLi (0.55 mL, 2.46 M in 
hexanes, 1.35 mmol, 4.0 equiv) was added dropwise to a solution of 2-phenylpropanoic acid 
(51 mg, 0.338 mmol) and (R)-1TA (0.155 g, 0.346 mmol, 1.03 equiv) in THF (2.3 mL) at 0 
°C. The reaction mixture was warmed to room temperature and stirred for 1 hour. The 
reaction mixture was then cooled to -78 °C and stirred for an additional 10 min. Iodoethane 
(0.11 ml, 1.35 mmol, 4.0 equiv) was added to the reaction mixture dropwise over 10 min. 
The resultant mixture was immediately quenched with a mixture of THF-MeOH (3:1, 1.0 
mL) at -78 °C. After 5 min, the reaction mixture was acidified with 1 M aqueous solution of 
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HCl and extracted with ethyl acetate. The combined organic phase was sequentially washed 
with 1 M aqueous solution of HCl and brine, dried over Na2SO4, concentrated, and the 
residue was purified by column chromatography on silica gel (40% diethyl ether in hexanes 
with 0.5% acetic acid) to afford the pure product as a white crystalline solid (46 mg, 0.257 
mmol, 76% yield). Ee: 90% (Chiralcel® OD-H; 1% i-PrOH in hexanes with 0.1% TFA; 
flow rate = 1.0 mL/min; detection at 215 nm; t1=19.9 min; t2=22.6 min). [a]D
20 +24.2° (c 1.0, 
PhH). 1H NMR (500 MHz, C6D6) δ (ppm): 7.23-7.20 (m, 2H), 7.05-7.01 (m, 2H), 6.98-6.94 
(m, 1H), 2.00-1.92 (m, 1H), 1.83-1.75 (m, 1H), 1.36 (s, 3H), 0.64 (t, J = 7.4 Hz, 3H). 13C 
NMR (125 MHz, C6D6) δ (ppm): 183.4, 143.3, 128.7, 127.0, 126.6, 50.8, 32.0, 21.8, 9.2. 
LRMS-ESI (m/z): [M+Na]+ calcd for C11H14O2Na, 201; found, 201.  
(R)-1TA
n-BuLi, allylBr
THF, -78 °C, 10 min









(S)-2-Methyl-2-phenyl-pent-4-enoic acid. A solution of n-BuLi (0.55 mL, 2.46 M in 
hexanes, 1.35 mmol, 4.0 equiv) was added dropwise to a solution of 2-phenylpropanoic acid 
(51 mg, 0.338 mmol) and (R)-1TA (0.155 g, 0.346 mmol, 1.03 equiv) in THF (2.3 mL) at 0 
°C. The reaction mixture was warmed to room temperature and stirred for 1 hour. The 
reaction mixture was then cooled to -78 °C and stirred for an additional 10 min. 
Allylbromide (0.12 ml, 1.35 mmol, 4.0 equiv) was added to the reaction mixture dropwise 
over 10 min. The resultant mixture was immediately quenched with a mixture of THF-
MeOH (3:1, 1.0 mL) at -78 °C. After 5 min, the reaction mixture was acidified with 1 M 
aqueous solution of HCl and extracted with ethyl acetate. The combined organic phase was 
sequentially washed with 1 M aqueous solution of HCl and brine, dried over Na2SO4, 
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concentrated, and the residue was purified by column chromatography on silica gel (40% 
diethyl ether in hexanes with 0.5% acetic acid) to afford the pure product as a colorless film 
(51 mg, 0.270 mmol, 80% yield). Ee: 85% (Chiralcel® AD-H; 1% i-PrOH in hexanes with 
0.1% TFA; flow rate = 1.0 mL/min; detection at 215 nm; t1=32.4 min; t2=34.1 min). [a]D
20 
+50.5° (c 1.0, EtOH). 1H NMR (500 MHz, C6D6) δ (ppm): 7.23-7.18 (m, 2H), 7.05-7.00 (m, 
2H), 6.98-6.93 (m, 1H), 5.52 (ddt, J = 17.2, 10.1, 7.2 Hz, 1H), 5.09 (m, 2H), 2.73 (ddt, J = 
13.8, 7.4, 1.2 Hz, 1H), 2.52 (ddt, J = 13.8, 17.1, 1.2, 1H), 1.40 (s, 3H). 13C NMR (125 MHz, 
C6D6) δ (ppm): 182.8, 142.8, 134.1, 128.7, 127.2, 126.5, 118.6, 50.0, 43.8, 22.2. LRMS-ESI 










then CH3I (0.9 equiv)









(S)-2-(2-bromo-4-methoxyphenyl)propanoic acid. A freshly titrated solution of n-
BuLi (29.5 mL, 2.60 M in hexanes, 76.7 mmol, 4.0 eq) was added dropwise over 5 min to a 
solution of (R)-1TA (8.82 g, 19.7 mmol, 1.025eq) and N-(trimethylsilyl)-tert-butylamine70 
(7.35 mL, 38.4 mmol, 2.0 eq) in THF (100 mL) at -78 °C and stirred 20 min. A solution of 
2-bromo-4-methoxy phenylacetic acid (4.70 g, 19.2 mmol) in THF (22 mL) was added 
dropwise over 5 min and the reaction was stirred at -78 °C for 20 min. The bright yellow 
solution was warmed to 0 °C and stirred for 10 min. The resultant orange solution was 
cooled to -90 °C and MeI (1.11 mL, 17.8 mmol, 0.9 eq) in THF (5 mL) was added dropwise 
over 1 min. The reaction was immediately quenched with a mixture of MeOH:THF (1:3, 25 
mL) over 1 min at -90 °C. After 5 min, the reaction mixture was warmed to room 
temperature, acidified with 1 M aqueous HCl to pH = 1, and extracted with EtOAc. The 
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combined organic phase was sequentially washed with 1 M aqueous HCl and brine solution, 
dried over Na2SO4, concentrated, and the residue was purified by normal-phase column 
chromatography on silica gel (30% diethyl ether in hexanes with 0.5% AcOH) to afford the 
product as a light-orange solid (3.23 g, 12.5 mmol, 65% yield). [a]D
24 +40.7° (c 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.25 (d, J = 8.6 Hz, 1H), 7.12 (d, J = 2.7 Hz, 1H), 
6.86 (dd, J = 8.6, 2.7 Hz, 1H), 4.21 (q, J = 7.2 Hz, 1H), 3.79 (s, 3H), 1.49 (d, J = 7.2 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ (ppm): 179.5, 159.3, 131.6, 129.0, 124.9, 118.3, 114.3, 









0 °C, 30 min
71% yield
 
Methyl ester. A solution of TMSCHN2 in hexanes (0.10 mL, 1.76 M in hexanes, 0.176 
mmol, 4.6 eq) was added dropwise over 30 sec to a solution of acid (10.0 mg, 38.6 µmol) in 
a mixture of MeOH:PhMe (1:3, 1.0 mL) at 0 °C. The resultant mixture was stirred for 30 
min at this temperature and after concentrating, the residue was purified by normal-phase 
column chromatography on silica gel (10% EtOAc in hexanes) to afford methyl ester as a 
colorless oil (7.5 mg, 27.5 µmol, 71% yield). Ee: 81% (Chiralcel® OD-H; 250mmx4.6mm, 
1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 210 nm; t1 = 8.4 min; t2 = 10.4 
min). [a]D
21 +69.9° (c 0.5, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.21 (d, J = 8.7 Hz, 
1H), 7.11 (d, J = 2.6 Hz, 1H), 6.85 (dd, J = 8.7, 2.7 Hz, 1H), 4.15 (q, J = 7.2 Hz, 1H), 3.78 
(s, 3H), 3.68 (s, 3H), 1.46 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ (ppm): 174.9, 
159.2, 132.5, 128.9, 124.7, 118.4, 114.3, 55.8, 52.3, 44.0, 18.3. HRMS-EI+ (m/z): [M]+ calcd 
for C10H11BrO3, 272.0048; found, 272.0058.  







pyridine, DMAP (10 mol%)
2-(trimethylsilyl)ethanol






2-(Trimethylsilyl)ethyl ester. 2,4,6-trichlorobenzoyl chloride (3.86 mL, 24.7 mmol, 2.0 
eq) was added to a solution of (S)-2-(2-bromo-4-methoxypheneyl)propanoic acid (3.20 g, 
12.4 mmol) and pyridine (3.75 mL, 46.3 mmol, 3.75 eq) in PhMe (52 mL) at 0 °C. The 
solution was stirred for 1 h. Additional 2,4,6-trichlorobenzoyl chloride (1.35 mL, 8.65 
mmol, 0.7 eq) and pyridine (3.75 mL, 46.3 mmol, 3.75 eq) were added and stirred another 1 
h. A solution of DMAP (0.151 g, 1.24 mmol, 10 mol%) and 2-(trimethylsilyl)ethanol (8.85 
mL, 61.8 mmol, 5.0 eq) in PhMe (10 mL) were added dropwise over 3 min and the solution 
was stirred at 0 °C for 15 min. The reaction was warmed up to room temperature and stirred 
for 3 h then it was diluted with brine solution and extracted with EtOAc. The combined 
organic phase was washed with brine, dried over Na2SO4, concentrated, and purified by 
normal-phase column chromatography on silica gel (5-10% EtOAc in hexanes) to afford the 
product as a colorless oil (3.95 g, 9.99 mmol, 89% yield). Ee: 81% (Chiralcel® OD-H; 
250mmx4.6mm, 1% i-PrOH in hexanes; flow rate = 1.0 mL/min; detection at 210 nm; t1 = 
6.2 min; t2 = 6.7 min). [a]D
20 +41.5° (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ (ppm): 
7.22 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 2.6 Hz, 1H), 6.84 (dd, J = 8.7, 2.6 Hz, 1H), 4.23-4.05 
(m, 3H), 3.78 (s, 3H), 1.44 (d, J = 7.2 Hz, 3H), 1.00-0.90 (m, 2H), -0.01 (s, 9H). 13C NMR 
(151 MHz, CDCl3) δ (ppm): 174.6, 159.1, 132.6, 128.9, 124.7, 118.2, 114.2, 63.4, 55.7, 
44.2, 18.3, 17.4, -1.32. HRMS-EI+ (m/z): [M]+ calcd for C15H23BrO3Si, 358.0600; found, 
358.0609. 






Cu(NO3)2 • 5 H2O











30% yield67% yield  
Ortho-nitrobromide. Cu(NO3)2 ! 5 H2O (1.13 g, 4.84 mmol, 1.2 eq) was added to Ac2O 
(8.5 mL) under air atmosphere at 0 °C and warmed up to RT. After 45 min, dissolution was 
complete and the bright blue mixture was cooled to -10 °C. A solution of 2-
(trimethylsilyl)ethyl ether (1.41 g, 4.04 mmol) in Ac2O (5.0 mL) was added dropwise over 
10 min, maintaining the reaction temperature below -5 °C. The reaction mixture was stirred 
at -10 °C for 2 h, quenched with H2O and then extracted with EtOAc. The combined organic 
phase was dried over Na2SO4 and concentrated. The crude product was cooled to -10 °C, 
dissolved in MeOH (50 mL), and stirred for 1 h at -10 °C in order to remove the excess 
Ac2O. After concentrating, the material was purified by normal-phase column 
chromatography on silica gel (5-15% EtOAc in hexanes) to afford the products. 
Para-nitrobromide: Isolated as a yellow oil that solidified upon standing (1.09 g, 2.70 
mmol, 67% yield). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.87 (s, 1H), 7.30 (s, 1H), 4.24-
4.15 (m, 2H), 4.11 (q, J = 7.2 Hz, 1H), 3.96 (s, 3H), 1.51 (d, J = 7.3 Hz, 3H), 1.04-0.88 (m, 
2H), 0.01 (s, 9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.4, 152.1, 138.9, 133.1, 130.5, 
125.6, 118.3, 63.9, 57.1, 44.3, 18.0, 17.5, -1.3. HRMS-EI+ (m/z): [M]+ calcd for 
C15H22BrNO5Si, 403.0451; found, 403.0449. 
Ortho-nitrobromide: Isolated as a yellow oil that solidified upon standing (0.489 g, 
1.21 mmol, 30% yield). Ee: 80% (Chiralcel® AD-H; 250mmx4.6mm, 1% i-PrOH in 
hexanes; flow rate = 1.0 mL/min; detection at 210 nm; t1 = 12.1 min; t2 = 16.7 min). [a]D
20 
+33.6° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 7.40 (d, J = 8.9 Hz, 1H), 7.00 
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(d, J = 8.9 Hz, 1H), 4.24-4.03 (m, 3H), 3.89 (s, 3H), 1.47 (d, J = 7.2 Hz, 3H), 1.02-0.89 (m, 
2H), 0.00 (s, 9H). 13C NMR (126 MHz, CDCl3) δ (ppm): 173.7, 150.7, 143.0, 133.9, 129.8, 
115.6, 112.2, 63.8, 57.0, 44.3, 18.2, 17.5, -1.3. HRMS-EI+ (m/z): [M]+ calcd for 


















67% yield 27% yield2.X  
Ortho-bromoaniline.  A suspension of ortho-nitrobromide (0.233 g, 0.576 mmol) and 
10 wt% Pd/C (31 mg, 28.8 µmol, 5 mol%) was prepared in MeOH (5.8 mL), then hydrazine 
monohydrate (0.30 mL, 5.76 mmol, 10 eq, Reagent Grade, 60% N2H2) was added and the 
reaction mixture was placed in a pre-heated oil bath at 50 °C for 25 min. The reaction was 
immediately cooled in an ice-water bath to 0 °C in order to halt the reaction as quickly as 
possible and it was filtered through a 1 cm silica gel plug with EtOAc then concentrated. 
The residue was purified by normal-phase column chromatography on silica gel (10% 
EtOAc in hexanes) to deliver the products. 
Ortho-bromoaniline: Isolated as a colorless oil that solidified upon standing (0.144 g, 
0.386 mmol, 67% yield). Ee: 80% (Chiralcel® OD-H; 250mmx4.6mm, 1% i-PrOH in 
hexanes; flow rate = 1.0 mL/min; detection at 210 nm; t1 = 15.2 min; t2 = 19.1 min). [a]D
19 
+48.8° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3); δ (ppm): 6.72 (d, J = 8.4 Hz, 1H), 6.67 
(d, J = 8.4 Hz, 1H), 4.29 (s, 2H), 4.23-4.05 (m, 3H), 3.84 (s, 3H), 1.44 (d, J = 7.1 Hz, 3H), 
1.06-0.85 (m, 2H), -0.01 (s, 9H). 13C NMR (126 MHz, CDCl3); δ (ppm): 174.8, 146.4, 
135.3, 133.0, 116.3, 111.1, 109.2, 63.2, 56.1, 44.9, 18.2, 17.5, -1.3. HRMS-EI+ (m/z): [M]+ 
calcd for C15H24BrNO3Si, 373.0709; found, 373.0700.  
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Aniline: Isolated as a light-brown oil (46 mg, 0.267 mmol, 27% yield). 1H NMR (500 
MHz, CDCl3); δ (ppm): 6.72 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 6.65 (dd, J = 8.2, 
2.2 Hz, 1H), 4.23-4.04 (m, 2H), 3.82 (s, 3H), 3.72 (bs, 2H), 3.54 (q, J = 7.1 Hz, 1H), 1.43 (d, 
J = 7.1 Hz, 3H), 0.96-0.94 (m, 2H), 0.0 (s, 9H). 13C NMR (126 MHz, CDCl3); δ (ppm): 
175.2, 146.6, 136.2, 133.6, 117.5, 114.3, 110.5, 63.0, 55.7, 45.2, 18.9, 17.4, -1.4. HRMS-EI+ 







100 °C, 1 h
89% yield  
2,6-diiodopyrazine. Aqueous hydroiodic acid (15 mL, 47+%, ACS Reagent, stabilized 
with hypophosphorous acid) was added to 2,6-dichloropyrazine (3.0 g, 20.1 mmol) and 
sodium iodide (3.91 g, 26.1 mmol, 1.3 eq) in a 50 mL thick-walled Schlenk tube. The tube 
was sealed and it was heated at 100 °C for 1 h. After cooling, the reaction mixture was 
diluted with Et2O and washed sequentially with water, sat. aq. NaHCO3, sat. aq. Na2S2O3, 
and brine solutions. The organic phase was filtered through Na2SO4 and concentrated to 
yield 2,6-diiodopyrazine as a white solid (5.95 g, 17.9 mmol, 89% yield) that was used 
without further purification. 1H NMR (500 MHz, CDCl3) δ (ppm): 8.73 (s, 2H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 151.3, 116.8. HRMS-EI+ (m/z): [M]+ calcd for C4H2I2N2, 









85 °C, 1 h
I  
6-iodopyrazin-2-one. Potassium hydroxide (1.28 g, 22.9 mmol, 4.0 eq) was added to a 
solution of 2,6-diiodopyrazine (1.9 g, 5.72 mmol) in tBuOH (19 mL) place in a 50 mL thick-
walled Schlenk tube at room temperature. The tube was sealed and heated at 85 °C for 1 h. 
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After cooling, the reaction mixture was acidified with 1M HCl and extracted with EtOAc 
(200 mL x 3). The combined organic phase was washed with brine, filtered through Na2SO4, 
and concentrated to yield an orange solid (~1.3 g). The crude pyrazinone was used in the 
subsequent reaction without further purification. 1H NMR (500 MHz, DMSO-d6) δ (ppm): 
12.4 (bs, 1H), 8.33 (s, 1H), 8.10 (s, 1H). 13C NMR (126 MHz, DMSO-d6) δ (ppm): 159.6, 














Iodopyrazine. Triethylamine (3.3 mL, 23.4 mmol, 4.0 eq) and TBSCl (2.20 g, 14.6 
mmol, 2.5 eq) were added sequentially to a solution of crude pyrazinone (1.3 g, 5.86 mmol) 
in CH2Cl2 (19.5 mL) at room temperature. The reaction mixture was stirred for 5 h at room 
temperature then diluted with water and extracted with CH2Cl2. The combined organic phase 
was washed with brine, filtered through Na2SO4, concentrated, and the residue was purified 
by normal-phase column chromatography on silica gel (5-10% EtOAc in hexanes) to afford 
the product as a colorless oil (1.28 g, 3.81 mmol, 67% yield). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 8.37 (s, 1H), 8.04 (s, 1H), 0.97 (s, 9H), 0.32 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 
(ppm): 158.4, 144.5, 135.0, 112.6, 25.9, 18.3, 4.5. HRMS-EI+ (m/z): [M-C4H9]+ calcd for 








CuI (4 mol%), Et3N
PPh3 (4 mol%)
trimethylsilyl acetylene
THF, RT, 2 h
86% yield  
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(Pyrazinyl)acetylene. Ethynyltrimethylsilane (0.58 mL, 4.10 mmol, 2.0 eq) was added 
to a solution of S2.6 (2.30 g, 6.84 mmol), CuI (52 mg, 0.274 mmol, 4 mol%), PPh3 (72 mg, 
0.274 mmol, 4 mol%), PdCl2(PPh3)2 (96 mg, 0.137 mmol, 2 mol%), and Et3N (2.86 mL, 
20.5 mmol, 3.0 eq) in THF (14 mL) at room temperature. The reaction was stirred for 2 h at 
room temperature and filtered through a 1 cm SiO2 plug with EtOAc. After concentrating, 
the residue was purified by normal-phase column chromatography on silica gel (5% EtOAc 
in hexanes) to afford the product as a colorless oil (1.81 g, 5.89 mmol, 86% yield). Note: 
Store in freezer, decomposes slowly at room temperature on benchtop. 1H NMR (500 MHz, 
CDCl3) δ (ppm): 8.22 (s, 1H), 8.03 (s, 1H), 0.98 (s, 9H), 0.34 (s, 6H), 0.27 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ (ppm): 158.4, 140.4, 136.5, 136.0, 101.3, 98.1, 25.9, 18.2, 0.13, -4.2. 

























(Pyrazinyl)indole. A 1-dram vial was charged with freshly purified ortho-bromoaniline 
(45 mg, 0.120 mmol) and freshly purified (pyrazinyl)acetylene (90 mg, 0.295 mmol, 2.5 eq) 
without a stir bar. The 1-dram vial was placed in a glove-box and charged with 
PdCl2(dtBPF) (23 mg, 35.3 µmol, 30 mol%) and n-tetrabutylammonium bromide (38 mg, 
0.120 mmol, 1.0 eq). After removing from the glove-box, the reaction vial was charged with 
MeCN (1.2 mL) and Et3N (84 µL, 0.60 mmol, 5.0 eq) through a Teflon-lined septa. The 
reaction was then sealed with a Teflon-lined cap and heated at 100 °C for 48 h. After 
cooling, the crude reaction mixture was filtered through a 1 cm silica gel plug with EtOAc, 
concentrated, and the residue was purified by normal-phase column chromatography on 
silica gel (7-12% EtOAc in hexanes) to deliver (pyrazinyl)indole as a light-brown foam (43 
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mg, 71.7 µmol, 60% yield). Ee: 81% (Chiralcel® AD-H; 250mmx4.6mm, 1% i-PrOH in 
hexanes; flow rate = 1.0 mL/min; detection at 210 nm; t1 = 8.6 min; t2 = 12.2 min). [a]D
21 
+94.9° (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ (ppm): 8.45 (s, 1H), 8.23 (s, 1H), 8.14 
(s, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 4.06-3.87 (m, 2H), 3.98 (s, 3H), 
3.78 (q, J = 7.1 Hz, 1H), 1.31 (d, J = 7.1 Hz, 3H), 1.00 (s, 9H), 0.84 (ddd, J = 9.7, 6.7, 2.4 
Hz, 2H), 0.29 (s, 3H), 0.27 (s, 3H), 0.12 (s, 9H), -0.05 (s, 9H). 13C NMR (126 MHz, CDCl3) 
δ (ppm): 175.5, 158.2, 149.9, 145.1, 139.6, 136.9, 135.3, 129.0, 127.6, 126.3, 123.2, 118.5, 
102.5, 62.8, 55.6, 40.5, 25.9, 18.8, 18.2, 17.3, -0.5, -1.4, -4.0, -4.2. HRMS-EI+ (m/z): [M]+ 











N OBBr3 (1.0 M in CH2Cl2)








(Indolyl)pyrazinone. To a solution of (pyrazinyl)indole (190 mg, 0.317 mmol) in 
CH2Cl2 (3.2 mL) cooled to -10 °C, was added BBr3 (4.75 mL, 1.0 M in CH2Cl2, 4.75 mmol, 
15 eq) dropwise over 2 min. The deep purple reaction mixture was stirred at -10 °C. After 1 
h the reaction was quenched with H2O (5 mL) and warmed to room temperature. After 
stirring approximately 30 min the solution color changed to dark red-orange. The CH2Cl2 
was carefully removed via rotary evaporation and then the crude mixture was purified by 
reverse-phase column chromatography on silica gel (20% MeCN in H2O with 0.1% TFA) to 
yield (indolyl)pyrazinone as a dark red solid (95 mg, 0.317 mmol, 99% yield). [a]D
23 +79.9° 
(c 1.0, CH3OH). 1H NMR (500 MHz, CD3OD) δ (ppm): 7.99 (s, 1H), 7.58 (s, 1H), 7.46 (s, 
1H), 6.90 (d, J = 7.9 Hz, 1H), 6.60 (d, J = 8.0 Hz, 1H), 4.04 (q, J = 7.1 Hz, 1H), 1.42 (d, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ (ppm): 179.0, 144.9, 144.4, 139.5, 128.6, 
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128.2, 127.0, 126.8, 125.1, 120.3, 108.5, 107.9, 107.6, 41.7, 18.6. HRMS-ESI+ (m/z): 






















Bis-(indolyl)pyrazinone. A solution of TfOH in DMF (6.7 mL, 0.5 M in DMF, 3.34 
mmol, 5.0 eq) was added to (indolyl)pyrazinone (95 mg, 0.317 mmol) and 6-bromoindole 
(0.262 g, 1.34 mmol, 2.0 eq) in a 25 mL round-bottom flask protected from light. The 
reaction mixture was placed under an atmosphere of O2 and heated in the dark at 100 °C for 
4 h. After cooling the crude reaction mixture was diluted with EtOAc, washed sequentially 
with water and brine, dried over Na2SO4, concentrated and purified by reverse-phase column 
chromatography on silica gel (50-60% MeCN in H2O with 0.1% TFA) to deliver bis-
(indolyl)pyrazinone as a orange-red solid (65 mg, 0.132 mmol, 42% yield). [a]D
20 +83.4° (c 
1.0, CH3OH). 1H NMR (500 MHz, CD3OD) δ (ppm): 8.73 (s, 1H), 8.55 (d, J = 8.6 Hz, 1H), 
7.62 (s, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.45 (s, 1H), 7.28 (dd, J = 8.6, 1.8 Hz, 1H), 6.90 (d, J 
= 7.9 Hz, 1H), 6.60 (d, J = 7.9 Hz, 1H), 4.13 (q, J = 7.1 Hz, 1H), 1.44 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CD3OD) δ (ppm): 179.1, 157.2, 149.7, 144.3, 138.9, 132.8, 132.6, 
128.5, 127.9, 127.2, 126.4, 125.3, 125.2, 125.1, 124.8, 120.0, 117.0, 115.4, 113.1, 108.6, 
107.5, 41.6, 18.7. HRMS-ESI+ (m/z): [M+Na]+ calcd for C23H17BrN4O4Na, 515.0331; found, 
515.0336. 























Thioester. 1,1ʹ′-Carbonyldiimidazole (89 mg, 0.549 mmol, 5.0 eq) was added to a 
solution of bis-(indolyl)pyrazinone (54 mg, 0.110 mmol) in THF (3.6 mL) at room 
temperature. The reaction mixture was stirred 1 h at room temperature then 4-
methylbenzenethiol (0.204 g, 1.64 mmol, 15 eq) was added and stirred was continued for an 
additional 2 h. The crude reaction mixture was diluted with water then extracted with 
EtOAc. The combined organic phase was washed with brine, dried over Na2SO4, 
concentrated and purified by reverse-phase column chromatography on silica gel (60% 
MeCN in H2O with 0.1% TFA) to deliver thioester as a dark red solid (62 mg, 0.104 mmol, 
95% yield). [a]D
24 +297.8° (c 0.5, CH3OH). 1H NMR (500 MHz, CD3OD) δ (ppm): 8.71 (s, 
1H), 8.56 (d, J = 8.6 Hz, 1H), 7.61 (s, 1H), 7.59 (d, J = 1.8 Hz, 1H), 7.46 (s, 1H), 7.25 (dd, J 
= 8.6, 1.8 Hz, 1H), 7.08 (s, 4H), 6.91 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 7.9 Hz, 1H), 4.40 (q, J 
= 7.0 Hz, 1H), 2.27 (s, 3H), 1.56 (d, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 
(ppm): 202.2, 144.8, 140.4, 138.9, 135.5, 132.4, 132.0, 130.7, 128.4, 127.8, 127.7, 126.5, 
126.4, 126.3, 126.1, 125.4, 124.7, 123.2, 121.1, 116.9, 115.3, 113.4, 108.7, 107.4, 106.4, 
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N,Nʹ′ ,Nʹ′ ʹ′-tri-Boc-(tributylstannylmethyl)guanidine. Di-tert-butyl azodicarboxylate 
(0.282 g, 1.22 mmol, 1.0 eq) was added portion wise to a mixture of tri-n-
butylstannylmethanol (0.393 g, 1.22 mmol), tri-Boc-guanidine (0.440 g, 1.22 mmol, 1.0 eq), 
and PPh3 (0.321 g, 1.22 mmol, 1.0 eq) in THF (5.0 mL) at room temperature. After stirring 
for 2 h, the reaction was quenched with water and extracted with EtOAc. The combined 
organic phase was washed with brine, filtered through Na2SO4, concentrated, and the residue 
was purified by normal-phase column chromatography on silica gel (2% EtOAc in hexanes) 
to afford the pure product as a colorless oil (0.623 g, 0.941 mmol, 77% yield). 1H NMR (500 
MHz, CDCl3) δ (ppm): 10.64 (s, 1H), 3.42 (s, 2H), 1.56-1.39 (m, 33H), 1.33-1.22 (m, 6H), 
0.96-0.79 (m, 15H). 13C NMR (126 MHz, CDCl3) δ (ppm): 154.42, 151.4, 83.5, 82.2, 80.0, 
34.5, 29.2, 28.3, 28.2, 27.6, 13.9, 10.4. HRMS-ESI+ (m/z): [M+Na]+ calcd for 












































(+)-Dragmacidin D. A 25 mL round-bottomed flask, charged with N,Nʹ′,Nʹ′ʹ′-tri-Boc-
(tributylstannylmethyl)guanidine (0.205 g, 0.309 mmol, 5.0 eq) was placed in a glove box 
and charged with CuOAc (38 mg, 0.309 mmol, 5.0 eq). The flask was removed from the 
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glove box and charged with a solution of thioester (37 mg, 61.9 µmol) in THF (6.2 mL) 
through a rubber septa. The orange heterogeneous solution was stirred at room temperature 
for 1.5 h. The reaction was quenched with saturated aqueous NH4Cl and stirred for an 
additional 30 min at room temperature. The crude mixture was extracted with EtOAc, 
washed with brine, dried over Na2SO4, concentrated and purified by normal-phase column 
chromatography on silica gel (3-4% MeOH in CH2Cl2) to deliver tri-Boc-guanidinyl ketone 
as a bright yellow solid (39 mg), which also contained inseparable tin by-products and was 
used without further purification. Note: tri-Boc-guanidinyl ketone begins to decompose 
rapidly at room temperature on benchtop after ~12 h. To a solution of crude tri-Boc-
guanidinyl ketone (34 mg) in CH2Cl2 (2.0 mL) was added TFA (0.40 mL) at room 
temperature. The dark-red solution was stirred at room temperature for 3 h then concentrated 
and purified by reverse-phase HPLC (YMC-ODS-AM column, 250mmx20mm, 210 nm, 
40% MeCN in H2O with 0.1% TFA, 7 mL/min, t = 15 min) to deliver dragmacidin D as a 
bright red film (15 mg, 23.3 µmol, 44% yield). Ee: 61% (Lux® 5u Amylose-2; 
250mmx4.6mm, 15% EtOH in hexanes with 0.1% TFA; flow rate = 1.0 mL/min; detection 
at 210 nm; t1 = 7.3 min; t2 = 9.1 min). [a]D
21 +69.1° (c 1.0, CH3OH), +106.3° (c 0.95, EtOH). 
1H NMR (500 MHz, CD3OD) δ (ppm): 8.72 (s, 1H), 8.58 (d, J = 8.6 Hz, 1H), 7.60 (d, J = 
1.8 Hz, 1H), 7.47 (s, 1H), 7.44 (s, 1H), 7.26 (dd, J = 8.6, 1.8 Hz, 1H), 6.83 (d, J = 7.9 Hz, 
1H), 6.63 (d, J = 7.9 Hz, 1H), 5.97 (s, 1H), 4.34 (q, J = 6.9 Hz, 1H), 1.52 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CD3OD) δ (ppm): 157.0, 150.1, 148.6, 144.7, 138.9, 134.0, 
132.4, 132.1, 128.6, 127.8, 127.1, 126.5, 126.0, 125.5, 125.4, 124.7, 120.0, 116.9, 115.3, 
113.5, 110.0, 108.8, 107.2, 33.0, 20.6. HRMS-ESI+ (m/z): [M+H]+ calcd for C25H21BrN7O2, 
530.0935; found, 530.0941.  













Alcohol.71 A solution of (S)-2-(2-bromo-4-methoxypheneyl)propanoic acid  (0.167 g, 
0.644 mmol) in THF (3.0 mL) was added dropwise over 1 min to a mixture of LiAlH4 (49 
mg, 1.29 mmol, 2.0 eq) in THF (3.4 mL) cooled to 0 °C. A reflux condenser was attached 
and the reaction was refluxed for 18 h. After cooling to 0 °C, 50 µL of H2O was added, then 
50 µL of 3M NaOH was added, followed by 0.150 mL H2O. The solution was warmed to 
room temperature and filtered. After concentrating, the residue was purified by normal-
phase column chromatography on silica gel (40% EtOAc in hexanes) to afford the pure 
product as a colorless oil (0.103 g, 0.620 mmol, 96% yield). [a]D
21 -13.1° (c 2.1, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ (ppm): 7.17 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 3.80 
(s, 3H), 3.70-3.63 (m, 2H), 2.96-2.87 (m, 1H), 1.25 (d, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ (ppm): 158.5, 135.8, 128.5, 114.2, 68.9, 55.4, 41.7, 17.9. HRMS-ESI+ (m/z): 
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Position Synthetic dragmacidin D (600 
MHz) 
Reported for natural dragmacidin 
D72 
5 7.47 (s, 1H) 7.51 (s, 1H) 
2ʹ′ 8.72 (s, 1H) 8.67 (s, 1H) 
4ʹ′ 8.58 (d, J = 8.6 Hz, 1H) 8.55 (d, J = 8.6 Hz, 1H) 
5ʹ′ 7.26 (dd, J = 8.6, 1.8 Hz, 1H) 7.34 (dd, J = 8.6, 1.8 Hz, 1H) 
7ʹ′ 7.60 (d, J = 1.8 Hz, 1H) 7.68 (d, J = 1.8 Hz, 1H) 
2ʹ′ʹ′ 7.44 (s, 1H) 7.43 (s, 1H) 
5ʹ′ʹ′ 6.83 (d, J = 7.9 Hz, 1H) 6.85 (d, J = 7.9 Hz, 1H)  
6ʹ′ʹ′ 6.63 (d, J = 7.9 Hz, 1H) 6.65 (d, J = 7.9 Hz, 1H)  
4ʹ′ʹ′ʹ′ 5.97 (s, 1H) 6.05 (s, 1H) 
6ʹ′ʹ′ʹ′ 4.34 (q, J = 6.9 Hz, 1H) 4.35 (q, J = 6.9 Hz, 1H)  
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Position Synthetic dragmacidin D 
(201 MHz) 
Reported for natural 
dragmacidin D3 
2 157.0 157.0 
3 150.1 149.8 
5 125.5 125.4 
6 132.1 132.2 
2ʹ′ 132.4 133.6 
3ʹ′ 113.5 113.1 
3aʹ′ 126.5 126.3 
4ʹ′ 125.4 125.3 
5ʹ′ 124.7 124.8 
6ʹ′ 116.9 116.9 
7ʹ′ 115.3 115.3 
7aʹ′ 138.9 138.8 
2ʹ′ʹ′ 127.8 127.8 
3ʹ′ʹ′ 108.7 108.5 
3aʹ′ʹ′ 127.1 126.9 
4ʹ′ʹ′ 126.0 125.6 
5ʹ′ʹ′ 120.0 120.0 
6ʹ′ʹ′ 107.2 107.4 
7ʹ′ʹ′ 144.7 144.4 
7aʹ′ʹ′ 128.6 128.5 
2ʹ′ʹ′ʹ′ 148.6 148.5 
4ʹ′ʹ′ʹ′ 110.0 109.9 
5ʹ′ʹ′ʹ′ 134.0 133.8 
6ʹ′ʹ′ʹ′ 33.0 33.0 
7ʹ′ʹ′ʹ′ 20.6 20.6 
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5 Number of Scans 144
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-05-13T08:35:23










































5 Number of Scans 12
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-05-14T08:51:29

























































5 Number of Scans 160
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-05-14T08:53:33




























5 Number of Scans 52
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-20T16:32:46



















































5 Number of Scans 10000
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-06T03:28:39










































5 Number of Scans 8
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-19T08:57:53
8 Spectrometer Frequency (599.63, 150.79)





























5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-11-17T10:08:21













































5 Number of Scans 30000
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-16T11:22:37





































5 Number of Scans 8
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-18T15:10:14
8 Spectrometer Frequency (599.64, 150.79)
































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-28T16:55:08



















































5 Number of Scans 1432
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-28T16:55:34




































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-29T13:18:26

























































5 Number of Scans 1832
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-29T13:19:07


























5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-03-10T09:47:09













































5 Number of Scans 64
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-03-10T09:47:24




































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-04-21T09:05:41













































5 Number of Scans 1108
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-15T14:15:23
































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-07-07T09:31:28



















































5 Number of Scans 80
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-07-07T09:31:41




































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-24T11:37:53



















































5 Number of Scans 92
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-24T11:40:39




































5 Number of Scans 8
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-09-03T10:25:47



















































5 Number of Scans 80
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-03T10:27:52








































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-02T09:03:59













































5 Number of Scans 124
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-02T09:06:45
































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-06-20T09:02:34



















































5 Number of Scans 292
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-06-20T17:08:15








































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-06-20T09:09:33






















































5 Number of Scans 220
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-06-20T09:09:45









































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-06-21T09:23:55

























































5 Number of Scans 96
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-06-21T09:24:15










































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-06-12T08:35:16

























































5 Number of Scans 264
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-06-12T08:35:57








































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-07-30T09:15:51




















































5 Number of Scans 52
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-07-31T10:57:41








































5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-08-08T18:57:57














































5 Number of Scans 112
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-08T18:45:43






















5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-06T18:11:51































































5 Number of Scans 912
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-06T18:14:09


























5 Number of Scans 12
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-11-15T11:04:00





















5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-01T09:37:12
















































































5 Number of Scans 1104
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-02T18:09:15












5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-09-01T10:06:08








































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-09-03T10:34:30































































5 Number of Scans 120
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-03T10:34:39










































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-07-14T12:52:38


































































5 Number of Scans 88
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-07-14T12:51:04




































5 Number of Scans 8
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-07-19T14:43:17



















































5 Number of Scans 892
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-26T10:25:05






























5 Number of Scans 12
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-11-08T15:53:23

























































5 Number of Scans 1112
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-08T15:55:46






























5 Number of Scans 12
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-08-07T11:08:40




























































5 Number of Scans 688
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-07T17:03:07






























5 Number of Scans 12
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-11-12T23:13:23


































































5 Number of Scans 528
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-12T23:15:24


































5 Number of Scans 24
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-10-10T10:51:34































































5 Number of Scans 444
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-10T12:00:32


































5 Number of Scans 16
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-10-02T13:01:31


































































5 Number of Scans 400
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-02T13:03:56












































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-23T15:58:03











































































5 Number of Scans 388
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-23T16:00:11












































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-08-02T17:27:45


































































5 Number of Scans 104
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-02T17:29:54












































5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-01T09:25:02































































5 Number of Scans 280
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-01T09:25:14












































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-02T08:56:25


































































5 Number of Scans 104
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-02T08:58:52




































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-08T09:08:48

























































5 Number of Scans 104
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-20T18:50:59








































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-08-25T09:41:48






















































5 Number of Scans 200
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-25T09:42:09




































5 Number of Scans 24
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-09-24T15:26:44






















































5 Number of Scans 136
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-10T19:24:12


































5 Number of Scans 12
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-11-13T14:02:02

























































5 Number of Scans 136
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-13T13:54:24

































5 Number of Scans 16
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-09-19T13:36:35


































































5 Number of Scans 416
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-19T13:39:26





































5 Number of Scans 24
6 Relaxation Delay 4.0000
7 Acquisition Date 2014-10-20T10:20:37





































































5 Number of Scans 396
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-20T10:24:06






























5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-28T15:21:45






















































5 Number of Scans 156
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-29T10:03:48






































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-08-28T19:20:40






















































5 Number of Scans 44
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-08-29T13:41:42
































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-12-31T09:39:09































































5 Number of Scans 152
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-31T09:42:04








































5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-09-20T17:37:01



















































5 Number of Scans 900
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-09-20T17:37:22




































5 Number of Scans 16
6 Relaxation Delay 4.8000
7 Acquisition Date 2014-06-07T10:11:44




























































5 Number of Scans 256
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-06-07T13:11:07












































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-10-23T14:31:18































































5 Number of Scans 436
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-10-23T14:33:22
















































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-11-14T19:24:07




















































































5 Number of Scans 252
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-14T19:26:11





































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-11-15T09:27:25











































































5 Number of Scans 60
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-14T19:06:21


















































5 Number of Scans 16
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-11-15T09:34:00











































































5 Number of Scans 184
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-14T19:14:51










































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2014-11-15T13:27:35

















































































5 Number of Scans 1044
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-11-15T13:30:35
















  201 
8/9/2014 17:30:13 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-35a.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-35a.lcd
Acquired by   : Admin
Sample Name : PLu-05-35
Sample ID : PLu-05-35
Vail # : 
Injection Volume : 20 uL
Data File Name : PLu-05-35a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/3/2014 6:54:56 PM
Data Processed : 4/3/2014 7:37:17 PM
PeakTable

























8/9/2014 17:28:53 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-46a.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-46a.lcd
Acquired by   : Admin
Sample Name : PLu-05-46
Sample ID : PLu-05-46
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-46a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/12/2014 1:18:40 PM
Data Processed : 4/12/2014 1:51:24 PM
PeakTable

































  202 
11/18/2014 09:41:52 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-39.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-39.lcd
Acquired by   : Admin
Sample Name : PLu-05-39
Sample ID : PLu-05-39
Vail # : 
Injection Volume : 20 uL
Data File Name : PLu-05-39.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/4/2014 5:38:28 PM
Data Processed : 4/4/2014 6:53:25 PM
PeakTable
























11/18/2014 09:44:26 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-51b.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-51b.lcd
Acquired by   : Admin
Sample Name : PLu-05-51
Sample ID : PLu-05-51
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-51b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/15/2014 5:42:42 PM
Data Processed : 4/15/2014 6:19:20 PM
PeakTable
































  203 
7/9/2014 10:35:36 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-37a.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-37a.lcd
Acquired by   : Admin
Sample Name : PLu-05-37
Sample ID : PLu-05-37
Vail # : 
Injection Volume : 20 uL
Data File Name : PLu-05-37a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/4/2014 1:30:29 PM
Data Processed : 7/8/2014 5:23:52 PM
PeakTable

























4/7/2016 15:00:24 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-49a.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-49a.lcd
Acquired by   : Admin
Sample Name : PLu-05-49
Sample ID : PLu-05-49
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-49a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/14/2014 5:29:47 PM
Data Processed : 4/14/2014 6:37:38 PM
PeakTable

































  204 
11/18/2014 09:46:16 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-66Me-a.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-66Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-66Me
Sample ID : PLu-05-66Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-66Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/29/2014 8:55:50 AM
Data Processed : 5/6/2014 2:01:20 PM
PeakTable

























11/18/2014 09:48:38 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-106-Me-a.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-106-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-106-Me
Sample ID : PLu-05-106-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-106-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/24/2014 5:26:08 PM
Data Processed : 5/24/2014 5:49:54 PM
PeakTable

































  205 
11/18/2014 09:53:52 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-123Me-testa.lcd.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-123Me-testa.lcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-123Me
Sample ID : PLu-05-123Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-123Me-testa.lcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/11/2014 11:02:53 AM
Data Processed : 6/11/2014 12:02:25 PM
PeakTable

























11/18/2014 09:55:31 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-128Me-bb.lcd.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-128Me-bb.lcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-128Me
Sample ID : PLu-05-128Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-128Me-bb.lcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/11/2014 12:09:43 PM
Data Processed : 6/11/2014 12:58:54 PM
PeakTable































  206 
11/18/2014 10:04:17 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-125Me-dd lcd.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-125Me-dd lcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-125Me
Sample ID : PLu-05-125Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-125Me-dd lcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/10/2014 2:49:33 PM
Data Processed : 6/10/2014 4:38:55 PM
PeakTable

























11/18/2014 09:59:45 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-127Me-dd lcd.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-127Me-dd lcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-127Me
Sample ID : PLu-05-127Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-127Me-dd lcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/10/2014 4:42:45 PM
Data Processed : 6/10/2014 6:12:28 PM
PeakTable


































  207 
11/18/2014 19:00:10 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-242-a.lcd 



















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-242-a.lcd
Acquired by   : Admin
Sample Name : jjj-5-242-a
Sample ID : jjj-5-242-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-242-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 11/18/2014 8:42:39 AM
Data Processed : 11/18/2014 9:27:17 AM
PeakTable

























11/18/2014 19:00:10 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-242-a.lcd 



















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-242-a.lcd
Acquired by   : Admin
Sample Name : jjj-5-242-a
Sample ID : jjj-5-242-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-242-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 11/18/2014 8:42:39 AM
Data Processed : 11/18/2014 9:27:17 AM
PeakTable































  208 
11/18/2014 10:05:59 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-101Me-aaa.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-101Me-aaa.lcd
Acquired by   : Admin
Sample Name : PLu-05-101Me
Sample ID : PLu-05-101Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-101Me-aaa.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/7/2014 5:22:57 PM
Data Processed : 6/7/2014 5:42:58 PM
PeakTable

























11/18/2014 10:08:13 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-126Me-a.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-126Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-126Me
Sample ID : PLu-05-126Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-126Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/7/2014 4:40:34 PM
Data Processed : 6/7/2014 5:15:05 PM
PeakTable

































  209 
11/18/2014 10:12:32 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-226-01.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-226-01.lcd
Acquired by   : Admin
Sample Name : PLu-05-226
Sample ID : PLu-05-226
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-226-01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/27/2014 9:51:57 AM
Data Processed : 8/27/2014 10:44:07 AM
PeakTable

























11/18/2014 10:14:16 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-227-a.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-227-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-227
Sample ID : PLu-05-227
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-227-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/28/2014 9:57:50 AM
Data Processed : 11/17/2014 2:52:48 PM
PeakTable































  210 
11/18/2014 10:17:40 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-100-Me-d.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-100-Me-d.lcd
Acquired by   : Admin
Sample Name : PLu-05-100-Me
Sample ID : PLu-05-100-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-100-Me-d.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/20/2014 2:24:11 PM
Data Processed : 5/20/2014 3:15:04 PM
PeakTable

























11/18/2014 10:16:40 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-99-Me-b.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-99-Me-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-99-Me
Sample ID : PLu-05-99-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-99-Me-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/20/2014 12:28:10 PM
Data Processed : 5/20/2014 1:26:01 PM
PeakTable



































  211 
11/18/2014 10:20:51 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-73Me-b.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-73Me-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-73Me
Sample ID : PLu-05-73Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-73Me-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/2/2014 11:57:39 AM
Data Processed : 5/2/2014 1:19:50 PM
PeakTable

























11/18/2014 10:19:44 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-90c.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-90c.lcd
Acquired by   : Admin
Sample Name : PLu-05-90Me
Sample ID : PLu-05-90Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-90c.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/13/2014 3:44:13 PM
Data Processed : 5/13/2014 4:35:00 PM
PeakTable



































  212 
11/18/2014 10:24:42 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-101-c02.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-101-c02.lcd
Acquired by   : Admin
Sample Name : jjj-5-101-c
Sample ID : jjj-5-101-c
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-101-c02.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/27/2014 5:28:47 PM
Data Processed : 8/27/2014 6:03:17 PM
PeakTable

























11/18/2014 10:23:26 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-107-a01.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-107-a01.lcd
Acquired by   : Admin
Sample Name : jjj-5-107-a
Sample ID : jjj-5-107-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-107-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/29/2014 4:13:52 PM
Data Processed : 11/3/2014 4:10:10 PM
PeakTable































  213 
11/18/2014 10:25:42 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-092-a01.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-092-a01.lcd
Acquired by   : Admin
Sample Name : jjj-5-092-a
Sample ID : jjj-5-092-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-092-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/25/2014 9:14:31 AM
Data Processed : 8/25/2014 10:33:45 AM
PeakTable

























11/18/2014 10:37:37 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-116-a01.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-116-a01.lcd
Acquired by   : Admin
Sample Name : jjj-5-116-a
Sample ID : jjj-5-116-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-116-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/5/2014 5:18:49 PM
Data Processed : 11/3/2014 4:11:24 PM
PeakTable





























  214 
11/18/2014 10:35:09 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-9Me-c.lcd 


























PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-9Me-c.lcd
Acquired by   : Admin
Sample Name : PLu-05-9Me
Sample ID : PLu-05-9Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-9Me-c.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/20/2014 2:07:11 PM
Data Processed : 4/20/2014 3:30:23 PM
PeakTable





































11/18/2014 10:36:26 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-55Me-a.lcd 

























PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-55Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-55Me
Sample ID : PLu-05-55Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-55Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/20/2014 3:34:28 PM
Data Processed : 4/20/2014 4:50:43 PM
PeakTable













































  215 
11/18/2014 10:39:57 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-104-Me-h.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-104-Me-h.lcd
Acquired by   : Admin
Sample Name : PLu-05-104-Me
Sample ID : PLu-05-104-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-104-Me-h.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 5/23/2014 3:08:15 PM
Data Processed : 5/23/2014 3:46:43 PM
PeakTable

























11/18/2014 10:41:34 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-155-Me-aa.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-155-Me-aa.lcd
Acquired by   : Admin
Sample Name : PLu-05-155-Me
Sample ID : PLu-05-155-Me
Vail # : 
Injection Volume : 5 uL
Data File Name : PLu-05-155-Me-aa.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/14/2014 1:50:51 PM
Data Processed : 7/14/2014 5:29:30 PM
PeakTable

































  216 
11/18/2014 10:44:06 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-228-b.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-228-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-228
Sample ID : PLu-05-228
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-228-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/29/2014 10:42:30 AM
Data Processed : 8/29/2014 11:07:24 AM
PeakTable

























11/18/2014 10:45:31 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-229-a.lcd 



























PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-229-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-229
Sample ID : PLu-05-229
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-229-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/2/2014 11:10:52 AM
Data Processed : 9/2/2014 11:40:52 AM
PeakTable







































  217 
11/18/2014 10:48:50 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-136-Me-g.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-136-Me-g.lcd
Acquired by   : Admin
Sample Name : PLu-05-136-Me
Sample ID : PLu-05-136-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-136-Me-g.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/17/2014 2:48:35 PM
Data Processed : 6/17/2014 3:39:16 PM
PeakTable

























11/18/2014 10:47:37 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-137-Me-g.lcd 

















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-137-Me-g.lcd
Acquired by   : Admin
Sample Name : PLu-05-137-Me
Sample ID : PLu-05-137-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-137-Me-g.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/17/2014 3:41:01 PM
Data Processed : 6/17/2014 4:10:32 PM
PeakTable

































  218 
11/18/2014 10:54:50 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-131Me-a.lcd.lcd 


















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-131Me-a.lcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-131Me
Sample ID : PLu-05-131Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-131Me-a.lcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/11/2014 1:40:54 PM
Data Processed : 6/11/2014 2:07:40 PM
PeakTable

























11/18/2014 10:55:44 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-142-Me-a.lcd 



















PDA Multi 1/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-142-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-142-Me
Sample ID : PLu-05-142-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-142-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 6/23/2014 2:46:39 PM
Data Processed : 6/23/2014 3:18:55 PM
PeakTable

































  219 
11/18/2014 11:02:38 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-197-cc.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-197-cc.lcd
Acquired by   : Admin
Sample Name : PLu-05-197
Sample ID : PLu-05-197
Vail # : 
Injection Volume : 20 uL
Data File Name : PLu-05-197-cc.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/7/2014 5:44:51 PM
Data Processed : 8/7/2014 6:14:25 PM
PeakTable

























11/18/2014 10:58:24 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-201-blcd.lcd 


























PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-201-blcd.lcd
Acquired by   : Admin
Sample Name : PLu-05-201
Sample ID : PLu-05-201
Vail # : 
Injection Volume : 20 uL
Data File Name : PLu-05-201-blcd.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/7/2014 4:52:59 PM
Data Processed : 8/7/2014 5:42:58 PM
PeakTable







































  220 
11/18/2014 11:05:27 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-217-Me-b.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-217-Me-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-217-Me
Sample ID : PLu-05-217-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-217-Me-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/20/2014 11:57:53 AM
Data Processed : 8/20/2014 1:15:14 PM
PeakTable

























11/18/2014 11:10:11 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-230-Me-b.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-230-Me-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-230-Me
Sample ID : PLu-05-230-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-230-Me-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/4/2014 3:00:45 PM
Data Processed : 11/17/2014 2:52:44 PM
PeakTable



































  221 
11/18/2014 11:12:25 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-152-Me-c.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-152-Me-c.lcd
Acquired by   : Admin
Sample Name : PLu-05-152-Me
Sample ID : PLu-05-152-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-152-Me-c.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/5/2014 11:43:37 AM
Data Processed : 9/4/2014 11:50:40 AM
PeakTable

























11/18/2014 11:10:11 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-230-Me-b.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-230-Me-b.lcd
Acquired by   : Admin
Sample Name : PLu-05-230-Me
Sample ID : PLu-05-230-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-230-Me-b.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/4/2014 3:00:45 PM
Data Processed : 11/17/2014 2:52:44 PM
PeakTable




































  222 
11/18/2014 11:56:11 1 / 1 
C:\LabSolutions\Data\Project1\je2-167-colmB.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-167-colmB.lcd
Acquired by   : Admin
Sample Name : je2-167-colmB
Sample ID : je2-167-colmB
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-167-colmB.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/15/2014 10:15:53 AM
Data Processed : 7/15/2014 11:26:46 AM
PeakTable

























11/18/2014 11:55:36 1 / 1 
C:\LabSolutions\Data\Project1\je2-173-plug001.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-173-plug001.lcd
Acquired by   : Admin
Sample Name : je2-173-plug
Sample ID : je2-173-plug
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-173-plug001.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/20/2014 8:18:26 PM
Data Processed : 7/20/2014 10:14:43 PM
PeakTable





























  223 
11/19/2014 11:13:09 1 / 1 
C:\LabSolutions\Data\Project1\je-2-227-01.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je-2-227-01.lcd
Acquired by   : Admin
Sample Name : je-2-227
Sample ID : je-2-227
Vail # : 
Injection Volume : 10 uL
Data File Name : je-2-227-01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 11/19/2014 10:31:32 AM
Data Processed : 11/19/2014 11:12:30 AM
PeakTable

























11/18/2014 11:59:10 1 / 1 
C:\LabSolutions\Data\Project1\je2-184-plug01.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-184-plug01.lcd
Acquired by   : Admin
Sample Name : je2-184-plug
Sample ID : je2-184-plug
Vail # : 
Injection Volume : 20 uL
Data File Name : je2-184-plug01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/8/2014 4:09:44 PM
Data Processed : 8/8/2014 5:15:38 PM
PeakTable





























  224 
11/18/2014 12:11:53 1 / 1 
C:\LabSolutions\Data\Project1\je2-172-colm01.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-172-colm01.lcd
Acquired by   : Admin
Sample Name : je2-172-colm
Sample ID : je2-172-colm
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-172-colm01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/22/2014 7:35:08 AM
Data Processed : 7/22/2014 8:29:40 AM
PeakTable

























11/18/2014 12:11:02 1 / 1 
C:\LabSolutions\Data\Project1\je2-223.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-223.lcd
Acquired by   : Admin
Sample Name : je2-223
Sample ID : je2-223
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-223.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/8/2014 5:30:25 PM
Data Processed : 10/8/2014 6:42:07 PM
PeakTable





























  225 
11/18/2014 12:19:17 1 / 1 
C:\LabSolutions\Data\Project1\je2-216-colm-rac01.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-216-colm-rac01.lcd
Acquired by   : Admin
Sample Name : je2-214-colm-rac
Sample ID : je2-214-colm-rac
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-216-colm-rac01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/4/2014 10:50:40 AM
Data Processed : 10/4/2014 12:08:44 PM
PeakTable

























11/18/2014 12:14:22 1 / 1 
C:\LabSolutions\Data\Project1\je2-219-colm-ent01.lcd 




















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-219-colm-ent01.lcd
Acquired by   : Admin
Sample Name : je2-219-colm-ent
Sample ID : jjj-5-156-a
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-219-colm-ent01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/2/2014 2:00:17 PM
Data Processed : 10/2/2014 3:55:36 PM
PeakTable





































  226 
11/18/2014 11:37:25 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-187-Me.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-187-Me.lcd
Acquired by   : Admin
Sample Name : PLu-05-187-Me
Sample ID : PLu-05-187-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-187-Me.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 7/29/2014 11:38:41 AM
Data Processed : 7/30/2014 8:52:58 AM
PeakTable

























11/18/2014 11:36:41 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-193-Me-a.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-193-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-193-Me
Sample ID : PLu-05-193-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-193-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/2/2014 1:29:00 PM
Data Processed : 8/2/2014 2:06:55 PM
PeakTable

































  227 
11/18/2014 11:35:35 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-198Me-a.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-198Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-198Me
Sample ID : PLu-05-198Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-198Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/6/2014 8:41:55 AM
Data Processed : 8/6/2014 9:15:26 AM
PeakTable

























11/18/2014 11:33:19 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-224-Me-2-a.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-224-Me-2-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-224-Me-2
Sample ID : PLu-05-224-Me-2
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-224-Me-2-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/2/2014 10:01:31 AM
Data Processed : 9/2/2014 10:35:39 AM
PeakTable

































  228 
11/18/2014 11:38:21 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-216-Me-a.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-216-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-216-Me
Sample ID : PLu-05-216-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-216-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/20/2014 10:03:49 AM
Data Processed : 8/20/2014 10:51:11 AM
PeakTable

























11/18/2014 11:39:27 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-219-c.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-219-c.lcd
Acquired by   : Admin
Sample Name : PLu-05-219
Sample ID : PLu-05-219
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-219-c.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/23/2014 1:13:41 PM
Data Processed : 8/23/2014 2:05:16 PM
PeakTable



































  229 
11/18/2014 12:03:15 1 / 1 
C:\LabSolutions\Data\Project1\je2-204-colm_rac01.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-204-colm_rac01.lcd
Acquired by   : Admin
Sample Name : je2-204-colm_rac
Sample ID : je2-204-colm_rac
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-204-colm_rac01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/15/2014 3:49:28 PM
Data Processed : 9/15/2014 5:13:13 PM
PeakTable

























11/18/2014 12:06:04 1 / 1 
C:\LabSolutions\Data\Project1\je2-233-ent02.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-233-ent02.lcd
Acquired by   : Admin
Sample Name : je2-233-ent
Sample ID : je2-233-ent
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-233-ent02.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 11/12/2014 9:06:25 PM
Data Processed : 11/12/2014 10:11:43 PM
PeakTable





























  230 
11/18/2014 12:08:30 1 / 1 
C:\LabSolutions\Data\Project1\je2-207-colm_rac01.lcd 



















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-207-colm_rac01.lcd
Acquired by   : Admin
Sample Name : je2-207-colm_rac
Sample ID : je2-207-colm_rac
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-207-colm_rac01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 9/15/2014 9:16:57 AM
Data Processed : 9/15/2014 10:58:15 AM
PeakTable

























11/18/2014 12:07:33 1 / 1 
C:\LabSolutions\Data\Project1\je2-229-ent03.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\je2-229-ent03.lcd
Acquired by   : Admin
Sample Name : je2-229-ent
Sample ID : je2-229-ent
Vail # : 
Injection Volume : 10 uL
Data File Name : je2-229-ent03.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/20/2014 5:52:17 PM
Data Processed : 10/20/2014 7:40:58 PM
PeakTable





























  231 
11/18/2014 11:42:33 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-176L.lcd 

















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-176L.lcd
Acquired by   : Admin
Sample Name : PLu-05-176
Sample ID : PLu-05-176
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-176L.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/29/2014 11:09:42 AM
Data Processed : 8/29/2014 11:49:29 AM
PeakTable

























11/18/2014 11:41:34 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-225-a.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-225-a.lcd
Acquired by   : Admin
Sample Name : PLu-05-225
Sample ID : PLu-05-225
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-225-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 8/29/2014 9:59:29 AM
Data Processed : 8/29/2014 12:51:14 PM
PeakTable



























  232 
1/2/2015 13:20:44 1 / 1 
C:\LabSolutions\Data\Project1\PLu-06-72-Me-a.lcd 



















PDA Multi 2/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu-06-72-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-06-72-Me
Sample ID : PLu-06-72-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-06-72-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 1/2/2015 11:53:36 AM
Data Processed : 1/2/2015 1:18:53 PM
PeakTable

























1/2/2015 13:21:07 1 / 1 
C:\LabSolutions\Data\Project1\PLu-06-71-Me-a.lcd 

















PDA Multi 2/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu-06-71-Me-a.lcd
Acquired by   : Admin
Sample Name : PLu-06-71-Me
Sample ID : PLu-06-71-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-06-71-Me-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 1/2/2015 10:43:14 AM
Data Processed : 1/2/2015 11:51:25 AM
PeakTable





































  233 
11/18/2014 11:52:42 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-06-12-Me-03.lcd 


























PDA Multi 2/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-06-12-Me-03.lcd
Acquired by   : Admin
Sample Name : PLu-06-12-Me
Sample ID : PLu-06-12-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-06-12-Me-03.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/31/2014 9:54:08 AM
Data Processed : 10/31/2014 11:43:52 AM
PeakTable





































11/18/2014 11:44:40 1 / 1 
C:\LabSolutions\Data\Project1\PLu\PLu-05-297-Me-01.lcd 


















PDA Multi 2/215nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\PLu\PLu-05-297-Me-01.lcd
Acquired by   : Admin
Sample Name : PLu-05-297-Me
Sample ID : PLu-05-297-Me
Vail # : 
Injection Volume : 10 uL
Data File Name : PLu-05-297-Me-01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 10/31/2014 1:20:42 PM
Data Processed : 10/31/2014 2:25:04 PM
PeakTable


























































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2016-04-02T11:26:56






































5 Number of Scans 96
6 Relaxation Delay 1.0000
7 Acquisition Date 2016-04-02T11:27:17






























5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2016-04-02T14:07:53










































5 Number of Scans 76
6 Relaxation Delay 1.0000
7 Acquisition Date 2016-04-02T14:08:09






  236 
4/6/2016 12:27:41 1 / 1 
C:\LabSolutions\Data\Project1\jjj-4-020-a.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-4-020-a.lcd
Acquired by   : Admin
Sample Name : jjj-4-020-a
Sample ID : jjj-4-020-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-4-020-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/6/2016 11:20:43 AM
Data Processed : 4/6/2016 12:22:48 PM
PeakTable

























4/4/2016 11:11:45 1 / 1 
C:\LabSolutions\Data\Project1\jjj-3-294-a01.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-3-294-a01.lcd
Acquired by   : Admin
Sample Name : jjj-3-294-a
Sample ID : jjj-3-294-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-3-294-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/4/2016 9:23:39 AM
Data Processed : 4/4/2016 11:09:54 AM
PeakTable





























  237 
4/6/2016 16:14:46 1 / 1 
C:\LabSolutions\Data\Project1\jjj-3-280-a01.lcd 



















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-3-280-a01.lcd
Acquired by   : Admin
Sample Name : jjj-3-280-a
Sample ID : jjj-3-280-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-3-280-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/6/2016 2:53:56 PM
Data Processed : 4/6/2016 3:51:38 PM
PeakTable

























4/6/2016 15:52:34 1 / 1 
C:\LabSolutions\Data\Project1\jjj-3-300-a-01.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-3-300-a-01.lcd
Acquired by   : Admin
Sample Name : jjj-3-300-a-
Sample ID : jjj-3-300-a-
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-3-300-a-01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/6/2016 1:57:34 PM
Data Processed : 4/6/2016 2:53:08 PM
PeakTable
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5 Number of Scans 604
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-20T14:33:01
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5 Number of Scans 1276
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-10T18:02:48
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5 Number of Scans 256
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-20T16:24:58
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5 Number of Scans 1136
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-21T10:08:24
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5 Number of Scans 536
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-16T17:47:05
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5 Number of Scans 524
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-22T08:39:52
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5 Number of Scans 136
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-16T18:29:34
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5 Number of Scans 104
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-22T09:52:58
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5 Number of Scans 564
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-22T17:46:41
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5 Number of Scans 80
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-22T10:13:24
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5 Number of Scans 40
6 Relaxation Delay 1.0000
7 Acquisition Date 2014-12-22T11:45:09
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5 Number of Scans 336
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-01-13T08:32:22
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5 Number of Scans 10000
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-13T03:21:38
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5 Number of Scans 19836
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-13T19:53:20
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5 Number of Scans 24640
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-14T17:09:17






































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2015-02-23T15:28:25













































5 Number of Scans 448
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-02-23T15:29:08










































5 Number of Scans 8
6 Relaxation Delay 8.0000
7 Acquisition Date 2015-04-10T19:38:03




















































































5 Number of Scans 21932
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-04-10T19:42:42
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5 Number of Scans 76
6 Relaxation Delay 1.0000
7 Acquisition Date 2015-04-23T13:06:06






  256 
2/3/2015 16:43:00 1 / 1 
C:\Documents and Settings\User\Desktop\Zakarian Group\sds-3-119.lcd 
==== Shimadzu LCsolution Analysis Report ====
C:\Documents and Settings\User\Desktop\Zakarian Group\sds-3-119.lcd
min
mAU














PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\Documents and Settings\User\Desktop\Zakarian Group\sds-3-119.lcd
Acquired by   : Admin
Sample Name : sds-3-119
Sample ID : sds-3-119
Vail # : 
Injection Volume : 10 uL
Data File Name : sds-3-119.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 11/5/2014 5:31:35 PM
Data Processed : 12/11/2014 11:49:51 AM
PeakTable

























2/3/2015 16:46:32 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-031-a-MeOR.lcd 


















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-031-a-MeOR.lcd
Acquired by   : Admin
Sample Name : jjj-6-031-a-MeOR
Sample ID : jjj-6-031-a-MeOR
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-031-a-MeOR.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 2/2/2015 3:55:25 PM
Data Processed : 2/2/2015 4:18:38 PM
PeakTable































  257 
2/3/2015 16:29:15 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-249a-02.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-249a-02.lcd
Acquired by   : Admin
Sample Name : jjj-5-249a-02
Sample ID : jjj-5-249a-02
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-249a-02.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 12/2/2014 3:40:48 PM
Data Processed : 12/2/2014 4:18:38 PM
PeakTable

























2/3/2015 16:33:56 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-281-a01.lcd 


















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-281-a01.lcd
Acquired by   : Admin
Sample Name : jjj-5-281-a
Sample ID : jjj-5-281-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-281-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 12/21/2014 4:20:16 PM
Data Processed : 12/21/2014 5:20:17 PM
PeakTable



































  258 
2/3/2015 16:35:33 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-254-a01.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-254-a01.lcd
Acquired by   : Admin
Sample Name : jjj-5-254-a
Sample ID : jjj-5-254-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-254-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 12/21/2014 10:21:27 AM
Data Processed : 12/21/2014 11:14:12 AM
PeakTable

























2/16/2015 13:23:53 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-034-b01.lcd 



















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-034-b01.lcd
Acquired by   : Admin
Sample Name : jjj-6-033-b
Sample ID : jjj-6-033-b
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-034-b01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 2/5/2015 1:39:42 PM
Data Processed : 2/5/2015 2:12:49 PM
PeakTable
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5/2/2015 13:01:50 1 / 1 
C:\LabSolutions\Data\Project1\jjj-5-260-b01.lcd 


















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-5-260-b01.lcd
Acquired by   : Admin
Sample Name : jjj-5-260-b
Sample ID : jjj-5-260-b
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-5-260-b01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 12/11/2014 12:30:14 PM
Data Processed : 5/2/2015 1:00:05 PM
PeakTable

























5/2/2015 13:00:38 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-036-a01.lcd 


















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-036-a01.lcd
Acquired by   : Admin
Sample Name : jjj-6-036-a
Sample ID : jjj-6-036-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-036-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 2/6/2015 10:42:25 AM
Data Processed : 2/6/2015 12:00:21 PM
PeakTable
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2/20/2015 10:44:01 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-021-a01.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-021-a01.lcd
Acquired by   : Admin
Sample Name : jjj-6-021-a
Sample ID : jjj-6-021-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-021-a01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 2/4/2015 9:25:51 AM
Data Processed : 2/4/2015 10:26:18 AM
PeakTable
























2/9/2015 11:28:32 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-037-b01.lcd 


















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-037-b01.lcd
Acquired by   : Admin
Sample Name : jjj-6-037-b
Sample ID : jjj-6-037-b
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-037-b01.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 2/9/2015 10:50:52 AM
Data Processed : 2/9/2015 11:27:37 AM
PeakTable
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4/13/2015 16:30:38 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-104-a.lcd 




















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-104-a.lcd
Acquired by   : Admin
Sample Name : jjj-6-104-a
Sample ID : jjj-6-104-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-104-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/13/2015 3:18:27 PM
Data Processed : 4/13/2015 4:30:11 PM
PeakTable
























4/13/2015 16:31:32 1 / 1 
C:\LabSolutions\Data\Project1\jjj-6-100-a.lcd 

















PDA Multi 1/210nm 4nm1
<Chromatogram>
C:\LabSolutions\Data\Project1\jjj-6-100-a.lcd
Acquired by   : Admin
Sample Name : jjj-6-100-a
Sample ID : jjj-6-100-a
Vail # : 
Injection Volume : 10 uL
Data File Name : jjj-6-100-a.lcd
Method File Name : ATH-OD-J-analytical-hplc.lcm
Batch File Name : 
Report File Name : Default.lcr
Data Acquired : 4/10/2015 12:01:52 PM
Data Processed : 4/10/2015 6:13:46 PM
PeakTable
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